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GENERAL INTRODUCTION
AND AIMS OF THIS THESIS
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General Introduction
CANCER
Cancer is a significant and leading public health burden and a major cause of 
morbidity and mortality among men and women worldwide. Especially due 
to growth, aging and adaptation of deleterious behavior and lifestyle of the 
worldwide population, this burden is expected to grow in the coming years.1 
Although treatment options such as cytotoxic chemotherapy, (anti)hormone 
therapy and the more recent targeted agents are rapidly evolving, anticancer 
treatment is still associated with many challenges. Since most anticancer 
drugs have narrow therapeutic windows it is important to “get the dose right” 
in order to optimize drug exposure and effect and minimalize side effects.2 
To accomplish this goal there is a shifting paradigm towards individualized 
dosing rather than flat-fixed dosing in order to optimize cancer therapy. Along 
with other factors, such as life style, genetic factors and organ (dys)function, 
the use of comedication and the subsequent risk for drug-drug-interactions 
(DDIs) is one of the key factors influencing systemic drug exposure in cancer 
patients (figure 1).2
Figure 1: Key factors influencing the systemic exposure to an anticancer drugs
Abbreviations: BMI: body-mass index; BSA: body-surface area; CAM: complementary 
and alternative medicine; PPI: proton-pump inhibitor; SNPs: single-nucleotide poly-
morphisms.
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DRUG-DRUG INTERACTIONS IN CANCER PATIENTS
DDIs in vivo, defined as a modification of the effect of a drug when administered 
with another drug in a given patient, can be divided into two main groups: i) 
pharmacokinetic and ii) pharmacodynamic DDIs.3
Pharmacokinetic DDIs can be further subdivided into DDIs concerning the 
pharmacokinetic properties Absorption, Distribution, Metabolism or Excretion 
(ADME principle; see also figure 2). When any of these parameters is modified 
by comedication, systemic exposure of the anticancer drug might be affected 
and the patient may be deprived from optimal therapy.
The process by which a drug proceeds from
the site of administration to the site of
measurement
The process of reversible transfer of drug to
and from the site of measurement
The process of a conversion of one chemical
species to another chemical species
The irreversible loss of drug from the site of
measurement. It may occur by metabolism
or exretion
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Figure 2: The ADME-principles
Abbreviations : ADME (Absorption, Distribution, Metabolism, Elimination)
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Absorption
Gastrointestinal absorption of an anticancer drug primarily depends on its 
general chemical characteristics, but can also be significantly influenced by 
DDIs. Important factors that may influence drug absorption are: i) changes 
in stomach pH (e.g. due to coadministration of acid suppressive agents) and 
ii) the inhibition of drug transporters (e.g. P-gp) and intestinal enzymes (e.g. 
cytochrome P450 iso-enzyme 3A4; CYP3A4). Acid reducing drugs, like proton 
pump inhibitors (PPIs), increase the intragastric pH. As a result, the solubility 
and thereby the biological availability and systemic exposure of certain 
anticancer drugs is decreased. After dissolution, in the stomach and proximal 
intestine, an anticancer drug has to be transported across de intestinal lumen 
to reach the portal blood circulation. This transport is a complex multifactorial 
process predominantly mediated by passive diffusion, drug transporters (e.g. 
P-glycoprotein) and intestinal metabolic enzymes (CYPs). Either inhibition 
or induction of these drug transporters and intestinal metabolic enzymes may 
substantially influence bioavailability and systemic exposure of an orally 
taken anticancer drug. DDIs concerning absorption do have little effect on 
the pharmacokinetic parameters of intravenously given anti-cancer therapy. 
However, these DDIs are of significant importance with orally administered 
anticancer drugs such as tyrosine kinase inhibitors (eg. DDIs between PPIs 
and TKIs).
Distribution
After absorption, distribution of the drug to the target, is largely measured 
by blood flow and binding affinity to plasma protein (e.g. albumin). If two or 
more highly plasma protein bound drugs are used concomitantly, one drug can 
displace the other from its protein binding site, thereby increasing the fraction of 
unbound and pharmacologically active drug. Although many anticancer drugs 
are highly plasma protein bound (≥99%), there is little evidence to support a 
clinically relevant DDI on the basis of protein completion and displacement 
(eg. DDIs between TKIs and vitamin K antagonists).4
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Metabolism
The phase I oxidative cytochrome P450 pathway (CYPs) in the liver is 
the primary route of drug enzymatic metabolism in humans. Alterations in 
metabolism, through CYP inhibition or induction, has emerged as an important 
factor in the occurrence of DDIs in cancer therapy as most anticancer drugs 
are entirely or partly metabolized by CYPs. CYP induction is the process by 
which concomitant use of certain drugs (e.g. rifampicin5) results in accelerated 
CYP enzyme metabolism. Accelerated anticancer drug metabolism may result 
in a clinically relevant decrease in exposure and drug efficacy. Through CYP 
inhibition (e.g. ketoconazole5) CYP enzyme metabolism of anticancer agents 
is decreased, which may result in elevated serum levels and toxicity. On the 
other hand, for anticancer drugs whose pharmacological activity requires CYP 
metabolism, CYP inhibition can lead to decreased efficacy (e.g. combined 
tamoxifen and paroxetine treatment6).
Elimination
DDIs concerning elimination generally occur due to renal impairment during 
the concomitant use of nephrotoxic comedication. Although some anticancer 
drugs are highly dependent on renal elimination (platina compounds and 
methotrexate), most anticancer drugs are eliminated through liver metabolism 
and subsequent excretion into the feces. Because anticancer drugs are 
predominately excreted through hepatic metabolism, DDIs concerning 
elimination seem to be of minor significance.
Pharmacodynamic DDIs
Pharmacodynamic DDIs are characterized by an additive, synergistic or 
antagonistic effect during concomitant use of two or more drugs which may 
result in either toxic or antitumor effect. As anticancer drugs are usually given 
in combination regiment pharmacodynamic DDIs are used, intentionally, 
to reduce resistance, reduce toxicity and improve antitumor activity of the 
anticancer drug in an additive or even synergistic manner. Nevertheless, 
pharmacodynamic DDIs can also have negative effects during cancer therapy. 
Many anticancer drugs prolong the QTc interval (e.g. anthracyclines) which 
substantially increases the risk for Torsades the Pointes (TdP).7 Concomitant 
use of comedication that prolong the QTc interval in an additive or synergistic 
way may further increase the risk of TdP and sudden heart death during 
anticancer therapy. Although rare, these QTc DDIs can be severe and are highly 
significant in daily practice.
13
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DRUG-DRUG INTERACTIONS IN CANCER PATIENTS; 
EPIDEMIOLOGY AND MANAGEMENT
Since anticancer drugs are usually potent and toxic agents with a narrow 
therapeutic window (figure 3) DDIs are of major concern in oncology.2, 3 
They seem to be responsible for 20-30% of all adverse events and may be 
the cause of death in 4% of all cancer patients, where others may be deprived 
from optimal anticancer therapy through reduced pharmacologic effects.3,8 
In addition, as cancer patients often take many comedication beside their 
anticancer therapy they are particularly at risk for DDIs. However, only 
limited data are available on the prevalence of DDIs in patients being treated 
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Figure 3: Therapeutic window of drugs
The Therapeutic window  of a certain drug is a range in blood concentration which can 
treat disease effectively without having toxic effects (e.g. side effects). Below a mini-
mum concentration the drug is inactive, while above a certain concentration toxicity 
appears. The most effective drug concentration (and dose) should be within the thera-
peutic window.
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with anticancer drugs. In a study in ambulatory cancer patients, 27% of cancer 
patients were exposed to DDIs involving anticancer drugs.9 To our knowledge, 
there is no study available that has included over-the-counter (OTC)-drugs.
When DDIs in cancer patients are not properly managed in clinical practice the 
patients may be deprived from optimal therapy through overdosing or under 
treatment. Remarkably, most cancer patients are not routinely checked for DDIs 
during anticancer treatment. Cancer patients are often treated multidisciplinary 
and a profound overview of all  prescribed drugs, including herbal and OTC-
drugs, is not always available. Furthermore, documenting all drugs, including 
OTC-drugs in one national electronic patient record is not common practice in 
most countries.
NEW CHALLENGES
Historically, conventional cytotoxic drugs were predominantly administered 
intravenously on a non-continuous bases (e.g. once every 3 weeks). However, 
in the past decade there is a shifting paradigm towards specific targeted 
therapies that are predominately administered orally and that are continued 
over much longer periods of time (years). Especially, tyrosine kinase inhibitors 
(TKIs) have rapidly become an established factor in daily oncology practice. At 
present, there are 25 TKIs approved by the US Food and Drug Administration 
(FDA) and European Medicines Agency (EMA).10, 11 The oral route of 
administration for these targeted agents is flexible, convenient and improves 
the quality of life during cancer therapy.12 Despite this advantage, there are new 
challenges that arise in the use of these novel targeted anticancer agents. TKIs 
are generally characterized by a poor and variable bioavailability, resulting in 
significant between-patients variability in plasma levels and exposure. This 
variability is the result of an interplay of factors, including tissue permeability, 
membrane transport and enzymatic metabolism.13 Furthermore, since TKIs 
are used chronically and are metabolized predominantly by CYP enzymes, 
patients on TKIs are at considerable risk for DDIs. Due to the oral 
administration route of TKIs, new DDIs concerning gastrointestinal absorption 
become apparent.14 As nowadays this new class of drugs is extensively used, 
and considering its narrow therapeutic window, there is an increasing chance 
of serious drug interactions.
15
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AIMS AND OUTLINE THESIS
The work described in this thesis aim to create awareness for DDIs in cancer 
therapy by describing the incidence, clinical relevance and giving specific 
recommendations to guide medical oncologists and pharmacists through the 
process of managing DDIs in cancer therapy in daily clinical practice.
In chapter 2, this thesis provides an overview of DDIs in TKI therapy as these 
group of targeted anticancer drugs is highly prone to DDIs (see figure 1). The 
focus of this review will be on the most important DDIs during TKI therapy: 
i)TKIs and acid reducing agents, ii) CYP-inhibitors/inducers and iii) QTc 
interactions. Furthermore, a profound pharmacological background is given, 
several other important issues concerning DDIs in TKI therapy are addressed 
and clear recommendations for the management in clinical practice are given.
In chapter 3 and chapter 4, data are presented regarding the prevalence of 
DDIs in either intravenous and oral anticancer therapy, respectively. The 
purpose of these two studies is to generate data on the prevalence of DDIs 
and to create clinical awareness for potentially harmful drug combinations 
during prescribing anticancer drugs concomitant with other comedication. Due 
to the retrospective design, there remains an unmet need to assess the clinical 
relevance of DDIs in cancer therapy.
Therefore, as a sequel to chapter 3 and chapter 4 and since studies on the 
clinical relevance of DDIs have not yet been performed, in chapter 5 a 
prospective study was designed to identify DDIs leading to actual clinical 
interventions during cancer therapy. The results of this study lead to a closer 
collaboration of clinicians to identify and manage these DDIs before the start 
and during anticancer treatment.
In the prospective study addressed in chapter 5, DDIs between TKIs and acid 
reducing agents (e.g. PPIs) were frequently seen. Although PPIs are extensively 
used during anti-cancer treatment, there is still no clear recommendations on 
how to manage DDIs between TKIs and PPIs. 
16
As intragastric pH and subsequent pH dependent solubility is the “Achilles Heel” 
in TKI absorption, a practical way to by-pass the DDI between TKIs and PPIs 
could potentially be to temporarily lower the stomach pH by taking the TKI with 
an acidic beverage.14 In chapter 6 we therefore evaluated the impact of cola on 
the exposure of erlotinib (during or without PPI use) in patients with lung cancer.
On the other hand, when all pharmacological characteristics of either TKIs and 
PPIs are considered, practical advices based on pharmacological principles 
can be given to manage this drug combination. In chapter 7, we considered 
the pharmacology of either TKIs and PPIs to develop practical guidelines to 
manage this drug interaction in clinical practice. 
A Schematic outline of this thesis is presented in figure 4.
17
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Drug-Drug Interactions
in TKI therapy
( )Review, Chapter 2
Retrospective studies
Prevalence of DDIs in cancer therapy:
- Intravenous anticancer therapy                     ( )Chapter 3
- Oral anticancer therapy                                 ( )Chapter 4
Prospective study
Clinical relevance of DDIs in cancer therapy ( )Chapter 5
Practical solutions
Practical solution for the management of DDIs between
TKIs and PPIs:
- Impact of cola on the exposure of erlotinib   ( )Chapter 6
- Management on pharmacological principles ( )Chapter 7
Figure 4: Schematic outline of this thesis
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Drug-drug interactions with tyrosine-kinase inhibitors
ABSTRACT
In the past decade, many tyrosine-kinase inhibitors have been introduced in 
oncology and haemato-oncology. Because this new class of drugs is extensively 
used, serious drug–drug interactions are an increasing risk. In this Review, we 
give a comprehensive overview of known or suspected drug–drug interactions 
between tyrosine-kinase inhibitors and other drugs. We discuss all haemato-
oncological and oncological tyrosine-kinase inhibitors that had been approved 
by Aug 1, 2013, by the US Food and Drug Administration or the European 
Medicines Agency. Various clinically relevant drug interactions with tyrosine-
kinase inhibitors have been identified. Most interactions concern altered 
bioavailability due to altered stomach pH, metabolism by cytochrome P450 
isoenzymes, and prolongation of the QTc interval. To guarantee the safe use 
of tyrosine-kinase inhibitors, a drugs review for each patient is needed. This 
Review provides specific recommendations to guide haemato-oncologists, 
oncologists, and clinical pharmacists, through the process of managing drug–
drug interactions during treatment with tyrosine-kinase inhibitors in daily 
clinical practice.
24
INTRODUCTION
To improve effectiveness and reduce adverse events of cancer treatment, 
specific targets have been identified in oncology in the past decade. One of the 
most promising groups in targeted therapy are the tyrosine-kinase inhibitors.1 
Tyrosine kinases are key components of signal transduction pathways in the 
cell that relay information about conditions in the extracellular domain or the 
cytoplasm to pass on to the nucleus. As a result, tyrosine-kinase inhibitors 
affect gene transcription and DNA synthesis. Many tumour cells show abnormal 
activity of specific tyrosine kinases and are therefore an appealing target in 
oncology.1
All tyrosine-kinase inhibitors are given orally, which makes administration 
flexible and convenient, and improves quality of life. Another advantage of 
oral administration is that the tyrosine-kinase inhibitors are often taken on a 
continuous daily basis (compared with intermittent use of most chemotherapy), 
which usually improves the exposure time of the tumour to the active drug.
Although tyrosine-kinase inhibitors have some advantages compared with 
traditional chemotherapy, new challenges have arisen in the use of these 
novel targeted drugs. First, tyrosine-kinase inhibitors have specific toxicity 
profiles that differ from those of cytotoxic drugs.2 Toxic effects can be severe 
(eg, cardiovascular side-effects) and some tyrosine-kinase inhibitors can even 
cause secondary tumours (eg, vemurafenib). Because the tyrosine-kinase 
inhibitors are used chronically and are metabolised by cytochrome P450 (CYP) 
isozymes, patients given these drugs are at substantial risk of having drug–drug 
interactions. Furthermore, because of the oral administration route of tyrosine-
kinase inhibitors, new drug–drug interactions concerning gastrointestinal 
absorption have become apparent (eg, cotreatment with proton pump and 
tyrosine-kinase inhibitors).
Drug–drug interactions might be associated with serious or even fatal adverse 
events, or can lead to reduced therapeutic effects of either drug. Interactions 
can be classified into those that are pharmacokinetic and those that are 
pharmacodynamic.3 Pharmacokinetic interactions arise when absorption, 
distribution, metabolism, or elimination of the involved drugs are altered, leading 
to changes in the amount and duration of drug availability at receptor sites. 
The most common pharmacokinetic drug–drug interactions concern absorption 
(incomplete drug absorption is a risk of drug interaction) and metabolisation by 
the cytochrome P450 isozymes. Pharmacodynamic interactions usually refer to 
25
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an interaction in which active compounds change each other’s pharmacological 
effect. The effect can be synergistic, additive, or antagonistic.
In this Review we give an overview of existing data of known or suspected 
drug–drug interactions between tyrosine-kinase inhibitors approved by the 
US Food and Drug Administration or the European Medicines Agency and 
conventional prescribed drugs, over-the-counter drugs, and herbal medicines. 
Furthermore, we provide specific recommendations to guide oncologists, 
haemato-oncologists, and clinical pharmacists through the process of managing 
drug–drug interactions during treatment with tyrosine-kinase inhibitors in daily 
clinical practice.
SEARCH STRATEGY AND SELECTION CRITERIA
We screened the existing scientific literature about known or suspected drug–
drug interactions between US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA)-approved tyrosine-kinase inhibitors and 
conventional prescribed drugs, over-the-counter drugs, and herbal medicines. 
We identified references through searches of PubMed and Embase with 
the search terms [Drug interaction] OR [Drug combination] AND [Drug 
name]. We identified additional information was in the summary of product 
characteristics of the tyrosine-kinase inhibitors, that were FDA or EMA 
approved until Aug 1, 2013.4,5 We reviewed only papers published in English. 
The final reference list was generated on the basis of originality and relevance 
to the broad scope of this Review.
PHARMACOKINETIC DRUG INTERACTIONS: 
ABSORPTION
Gastrointestinal absorption of a drug depends on its inherent characteristics 
(eg, solubility), but can also be affected by drug–drug interactions. At the 
absorption level, these interactions mainly take place with tyrosine-kinase 
inhibitors that have incomplete absorption (eg, bioavailability <50%, first pass 
effect, or dependence on influx or efflux transporters). Important factors that 
can affect absorption of tyrosine-kinase inhibitors are a change in stomach pH 
due to coadministration of an H2 antagonist, proton-pump inhibitor, or antacid, 
and the inhibition of P-glycoprotein and intestinal CYP3A4 in enterocytes.
26
Effect on TKI exposure Refs.
TKI Acid suppressive compound Cmax AUC Alternatives/recommendations
Axitinib Rabeprazol 20mg q.d. 42%↓ 15%↓ H2As, PPIs and antacids can be 
used concomitantly with axitinib.
4, 5
Crizotinib - - - The solubility of crizotinib is pH 
dependent. Solubility sharply 
decreases from over the pH range 
1•6–8•2 No drug interaction study 
has been conducted yet but effects 
can be expected. Acid suppressive 
agents should not be used 
concomitantly.
4, 5
Dasatinib Famotidine 40mg, 10 hours before 
dasatinib
Famotidine 40mg, 2 hours after 
dasatinib
Maalox 30ml, 2 hours before dasatinib
Maalox 30ml, concomitantly with 
dasatinib
Omeprazole 40mg q.d. concomitantly 
with dasatinib
63%↓
-
26%↓
58%↓
42%↓
61%↓
-
-
54%↓
43%↓
H2As: can be used 2 hours after 
dasatinib.
Antacids: can be used 2 hours 
before and after Dasatinib.
PPIs: PPIs should not be used 
concomitantly with dasatinib.
4,5,7
Erlotinib Omeprazole 40mg q.d. concomitantly 
with erlotinib.
Ranitidine 300mg q.d. concomitantly 
with erlotinib
Ranitidine 150mg b.i.d. concomitantly 
with erlotinib (erlotinib, 2 hours 
before and 10 hours after ranitidine
61%↓
54%↓
17%↓
46%↓
33%↓
15%↓
H2As: can be used 2 hours after 
erlotinib. Ranitidine should be 
given in a 150mg b.i.d. regiment.
Antacids: can be used 4 hours prior 
or 2 hours after erlotinib. 
PPIs: should not be used 
concomitantly with erlotinib.
4, 5
Gefitinib Two oral doses of 450 mg ranitidine 
(13 hours and 1 hour before gefitinib)
followed by sodium bicarbonate 
was applied if a pH of ≥ 5 was not 
achieved.
71%↓ 47%↓ H2As: should not be used 
concomitantly with gefitinib.
Antacids: can be used 2 hours 
before  or after gefitinib. 
PPIs: should not be used 
concomitantly with gefitinib.
4, 5
Imatinib Omeprazole 40mg q.d., concomitantly 
with imatinib 
Maalox 20ml, 15 minutes before 
imatinib
-
-
-
-
H2As, PPIs and antacids can be 
used concomitantly with imatinib.
8, 9
Lapatinib Esomeprazole 40mg q.d., 12 hours 
prior to lapatinib
- 27%↓ H2As: should not be used 
concomitantly with lapatinib.
Antacids: can be used 2 hours 
before or after lapatinib. 
PPIs: should not be used 
concomitantly with lapatinib.
4, 5
Table 1: Effects of acid-suppressive compounds on the bioavailability of tyrosine-
kinase inhibitors
27
2
Drug-drug interactions with tyrosine-kinase inhibitors
Effect on TKI exposure Refs.
TKI Acid suppressive compound Cmax AUC Alternatives/recommendations
Nilotinib Esomeprazole 40mg q.d. 
concomitantly with nilotinib
Famotidine 20mg b.i.d. 
concomitantly with nilotinib  
(given 2 hours after nilotinib)
Single oral dose of nilotinib and 
Maalox 20ml, where antacid was 
given 2 h before and after nilotinib
27%↓
-
-
34%↓
-
-
H2As:  can be used 10 hours before 
or 2 hours after nilotinib.
Antacids: can be used 2 hours prior 
or after nilotinib.
PPIs: nilotinib may be used 
concomitantly with PPIs.
10-12
Pazopanib Esomeprazole (evening) 
concomitantly with pazopanib  
(in the morning)
42%↓ 40%↓ H2As: pazopanib should be taken 
at least 2 hours before or 10 hours 
after a dose of an H2A. 
Antacids: can be used 4 hours 
before or 2 hours after pazopanib.
PPIs: take the dose of pazopanib 
in the evening concomitantly with 
the PPI.
4, 5
Regorafenib - - - No study data available yet. 4,5
Ruxolitinib - - - H2As, PPIs and antacids can 
be used concomitantly with 
Ruxolitinib.
4, 5
Sorafenib Esomeprazole concomitantly with 
sorafenib.
- - H2As, PPIs and antacids can be 
used concomitantly with imatinib.
4, 5
Sunitinib - - - Due to the high solubility, no effect 
on sunitinib would be expected 
during H2A, antacid or PPI use. 
Therefore, they may be used 
concomitantly.
4, 5
Vandetanib - - - H2A, antacids, PPIs may be 
concomitantly used with 
Vandetanib. Vandetanib 
demonstrates pH-dependent 
solubility but this is not clinically 
significant.
4, 5
Vemurafenib - - - H2A, antacids, PPIs may be 
concomitantly used with 
Vemurafenib. Vemurafenib 
demonstrates pH-dependent 
solubility but this is not clinically 
significant.
4, 5
Table 1: Continued
H2As=H2-antagonists, PPI=proton pump inhibitors, Refs = references
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Alteration of stomach pH
Besides pH independent, chemical solubility properties, the most important 
factor that affects solubility and the resulting exposure to tyrosine-kinase 
inhibitors is stomach pH.
Because of their weakly basic properties, tyrosine-kinase inhibitors can be 
present in either the ionised or non-ionised form, depending on the pH in 
the stomach and the pKa of the drug (ie, the pH at which the tyrosine-kinase 
inhibitor reaches equilibrium between the ionised and non-ionised form). 
Ionised forms normally dissolve more easily than do non-ionised forms. When 
a tyrosine-kinase inhibitor is coadministered with an acid suppressive drug 
(eg, a proton-pump inhibitor), the pH in the stomach will increase from 1 to 
about 4. Subsequently, the equilibrium of ionised or non-ionised drug will shift 
to the less soluble non-ionised form, and as a result, the bioavailability of the 
tyrosine-kinase inhibitor will decrease.4 If the pKa of a tyrosine-kinase inhibitor 
(eg, dasatinib) is near the pH range 1–4 the shift towards the non-ionised (less 
soluble) form, will be greater than that with an inhibitor with a higher pKa 
(eg, sunitinib). As such, for tyrosine-kinase inhibitors with a pKa of less than 
4–5, co-administration of acid suppressive drugs (eg, antacids, proton-pump 
inhibitors, H2-antagonists) will further reduce solubility and, subsequently, 
bioavailability and exposure to the tyrosine-kinase inhibitor.
In clinical practice, drug–drug interactions between acid suppressive drugs and 
tyrosine-kinase inhibitors can be clinically relevant. The oral absorption of 
crizotinib, dasatinib, erlotinib, gefitinib, lapatinib, and pazopanib is substantially 
altered by concomitant use of acid suppressive treatment. If possible, the 
combination of these tyrosine-kinase inhibitors and an H2-antagonist, proton-
pump inhibitor, or antacid should be avoided. Table 1 provides detailed 
recommendations for the clinical management of these drug–drug interactions.
Inhibition/induction of intestinal enzymes and drug 
transporters
A tyrosine-kinase inhibitor needs to be transported across the gut wall to reach 
the portal blood circulation. This transmembrane transport of the drug is a 
complex multifactorial process mediated by passive diffusion, organic anion and 
cation transporting peptides, multidrug resistance-associated proteins (eg, ATP-
binding cassette [ABC] transporter G2), efflux transporters (eg, P-glycoprotein 
or multidrug resistance protein 1 [ABCB1]) and intestinal metabolic enzymes 
(eg, CYP3A4).
29
2
Drug-drug interactions with tyrosine-kinase inhibitors
After passive diffusion or active transport through the gut lumen (or apical 
membrane), the tyrosine-kinase inhibitor enters the enterocyte where some 
tyrosine-kinase inhibitors undergo cytochrome p450 (CYP)-mediated 
metabolism. Subsequently, the drug or its (active) metabolite will undergo 
either active countertransport (or efflux) back into the gut lumen, or uptake into 
the portal vein by passive diffusion, or active transport through the basolateral 
membrane (figure 1).
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Figure 1: Major sites of pharmacokinetic drug-drug interactions in TKI therapy
1
With increasing stomach pH the bioavailability of TKIs will decrease
2
The relationship between CYPs and drug-transporters in TKI absorption/metabolism is shown
3
Protein-bound molecules are not available to exert pharmacologic effects
TKI= Tyrosine Kinase Inhibitor, P-gp= P-glycoprotein, MRPs= Multidrug Resistance Protein drug transporters, CYPs= Cytochrome P450 enzymes
Enterohepatic recycling
INFLUXINFLUX
EFFLUXMRPsEFFLUX P-gp
CYP3A4 CYPs
Figure 1: Major sites of pharmacokinetic drug–drug interactions in treatment 
with TKIs
TKI=tyrosine-kinase inhibitor. MRPs=multidrug resistance protein drug transporters, P-gp=P-gly-
coprotein. CYPs=cytochrome P450 enzymes. *With increasing stomach pH the bioavailability 
of TKIs decreases. †Protein-bound molecules are not available to exert pharmacological effects. 
‡Shows the association between CYPs and drug transporters in TKI absorption or metabolism.
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P-glycoprotein
The role of P-glycoprotein in the absorption of tyrosine-kinase inhibitors has been 
widely studied. Some tyrosine-kinase inhibitors (eg, crizotinib) are a substrate for 
P-glycoprotein, and consequently, inhibition or induction of this efflux transporter 
by coadministration of another drug might lead to a clinically relevant drug–drug 
interaction (table 2). Other tyrosine-kinase inhibitors (eg, pazopanib, lapatinib, 
and gefitinib) directly inhibit the activity of P-glycoprotein and can increase 
bioavailability of concomitantly used P-glycoprotein substrates. For instance, the 
area under the curve of digoxin is increased by 80% with P-glycoprotein inhibition 
by lapatinib.5, 6 Another example is the rise in SN-38 exposure (the active metabolite 
of irinotecan), which has been attributed to inhibition of P-glycoprotein by lapatinib 
and gefitinib.13, 14 The increased exposure to paclitaxel (roughly 26%) when used in 
combination with pazopanib can also be attributed to inhibition of P-glycoprotein 
by pazopanib.5, 6 Furthermore, the pazopanib area under the curve was increased 
by 59% with P-glycoprotein-related inhibition of lapatinib. However, at reduced 
doses of both drugs, no changes were noted in bioavailability.5, 6
Intestinal CYP3A4
The intestinal metabolic enzyme CYP3A4 exerts its action in close proximity of 
P-glycoprotein in the enterocytes of the gut lumen (figure 1).15 Simultaneous use of 
tyrosine-kinase inhibitors that are substrates for intestinal CYP3A4 together with 
CYP3A4 inhibitors and inducers can change the exposure and toxicity of tyrosine-
kinase inhibitors. An example of a substance that inhibits intestinal CYP3A4 is 
grapefruit, which increases the area under the curve of sunitinib by 11%, or that of 
nilotinib by 29%.16, 17 By contrast, grapefruit juice did not seem to affect the area 
under the curve of imatinib.18 A possible explanation is that grapefruit juice not 
only enhances absorption of CYP3A4 substrates at the enterocyte level, but also 
decreases absorption of organic anion transporting peptides substrates.
Other drug-transporters
Besides P-glycoprotein, several tyrosine-kinase inhibitors (eg, imatinib) have been 
identified as substrates of other drug transporters (eg, organic anion transporting 
peptides, organic cation transporter, breast cancer resistance protein).5, 6 Some 
drugs might inhibit organic anion transporting peptides (eg, ciclosporin) or breast 
cancer resistance protein (eg, lapatinib), but involvement of other mechanisms, 
such as CYP3A4, cannot be ruled out in these drug–drug interactions.19 Evidence 
for drug–drug interactions with tyrosine-kinase inhibitors through inhibition or 
induction of transporters is not yet available.
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TKI Target Absolute
bioavailability
Protein 
binding
CYPs
major
CYPs
Minor and 
other
Inhibits Inducer P-glycoprotein
Axitinib VEGFR 1,2,3 58% >99% CYP3A4 CYP1A2, 
CYP2C19, UGT
CYP1A2, CYP2C8 - -
Crizotinib HGFR; ALK 43% 91% CYP3A4 CYP2D6, 
CYP2C19
CYP3A4 CYP2B6, 
CYP2C8, 
CYP2C9, 
UGT
Substrate,
Inhibitor
Dasatinib PDGFRβ; c-KIT; 
SRC; BCR-ABL; 
EPH
Unknown 96% CYP3A4 CYP2C8, FMO 
and UGT
CYP3A4 - -
Erlotinib HER1-(EGFR) 60% 95% CYP3A4 CYP1A2, CYP2C8, 
CYP1A1, CYP2D6
CYP3A4, CYP2C8, 
CYP1A1
- Substrate
Gefitinib HER1-(EGFR) 60% 90% CYP3A4, 
CYP2D6
CYP1A1 CYP2D6, 
CYP2C19
- -
Imatinib PDGFRβ; c-KIT; 
FLT-3; BCR-ABL
98% 95% CYP3A4 CYP2D6, CYP2C9 CYP3A4, CYP2D6, 
CYP2C9
- -
Lapatinib HER1(EGFR); 
HER2, AKT
Unknown >99% CYP3A4 CYP2C8, 
CYP2C19, 
CYP2C9, CYP1A2, 
CYP2D6
CYP3A4, CYP2C8 - Substrate,
Inhibitor
Nilotinib PDGFRβ; c-KIT; 
BCR-ABL
31% 98% CYP3A4 CYP2C8, CYP2C9, 
CYP1A1, CYP1A2, 
CYP2D6
CYP3A4 CYP2B6, 
CYP2C8, 
CYP2C9
-
Pazopanib VEGFR 1,2,3; 
PDGFRβ; c-KIT
14-39% 99% CYP3A4 CYP1A2, CYP2C8 CYP2D6, CYP1A2, 
CYP3A4, CYP2B6, 
CYP2C8, CYP2C9, 
CYP2C19, CYP2E1
- Inhibitor
Regorafenib VEGFR; PDGFRβ; 
KIT; BRAF
69-83% >99% CYP3A4 UGT CYP2C9; CYP2B6; 
CYP3A4; CYP2C8
- Substrate
Inhibitor
Ruxolitinib JAK 1,2 Unknown 97% CYP3A4, 
CYP2C9
- CYP3A4 - -
Sorafenib VEGFR 2,3; 
PDGFRβ; c-KIT; 
FLT3; BRAF; CRAF
Unknown 99% CYP3A4 - CYP2B6, 
CYP2C8, CYP2C9, 
CYP2C19, 
CYP2D6, CYP3A4
- -
Sunitinib VEGFR 1,2,3; 
PDGFRβ; c-KIT; 
FLT3; SRC
Unknown 90-95% CYP3A4 CYP1A2 - - Inhibitor
Vandetanib VEGFR 2; 
HER1(EGFR); SRC
Unknown 90-94% CYP3A4 FMO-1,3 CYP2D6 CYP3A4, 
CYP2C9, 
CYP1A2
-
Vemurafenib BRAF Unknown >99% CYP3A4* - CYP1A2, CYP2D6 CYP3A4, 
CYP2B6
Substrate,
Inhibitor
Table 2: Pharmacological parameters of tyrosine-kinase inhibitors
This table is constructed from regulatory documents.4,5
*Only minor contribution of CYP3A4 (about 5%).
*Only minor contribution of CYP3A4 (±5%)
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Other factors affecting absorption of tyrosine-kinase inhibitors
Another factor that might affect absorption of tyrosine-kinase inhibitors is the 
formation of an insoluble complex. For instance, bile salt-sequestering drugs 
such as cholestyramine can interfere with regorafenib absorption by formation 
of insoluble complexes. The clinical significance of these drug–drug interactions 
is unknown.5, 6
PHARMACOKINETIC DRUG INTERACTIONS, 
DISTRIBUTION
Distribution is largely measured by blood flow and the binding affinity for the 
plasma proteins albumin and α1-acid glycoprotein. If two drugs that are both 
highly bound to plasma proteins (>90%) are combined, one drug can displace 
the other from its protein binding site, therefore increasing the concentration of 
unbound drug (figure 1).
Although axitinib, lapatinib, and vemurafenib are all highly bound to plasma 
proteins (≥99%), and should theoretically be most susceptible for drug–
drug interactions, little evidence is available to support a clinically relevant 
interaction on the basis of displacement of protein binding sites.5, 6 Imatinib used 
concomitantly with clindamycin leads to altered imatinib exposure because of 
displacement of protein-bound imatinib. As a result, the increased free plasma 
concentration of imatinib leads to a rapid redistribution of the unbound drug into 
the extravascular volume. The clinical relevance of this interaction is unknown.20
All tyrosine-kinase inhibitors are fairly highly bound to plasma proteins (90% 
to >99%; table 2), which, in theory, makes these inhibitors prone to interactions 
with other highly bound drugs, such as warfarin and phenytoin.5, 6, 21, 22 However, 
the evidence for drug–drug interactions concerning protein displacement is 
poor and, in reality, these interactions are more likely to be the consequence of 
other (metabolic) mechanisms.23
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Effect on TKI 
exposure
TKI Inducing 
compound
(CYP3A4)
Inhibitory 
compound
(CYP3A4)
Cmax AUC Alternatives and recommendations Refs.
Axitinib Rifampicin 71%↓ 79%↓ Increase Axitinib dose gradually and 
monitor toxicity in order to obtain 
optimal efficacy.
4, 5, 24
Ketoconazole 50%↑ 106% ↑ Lower axitinib dose to 2 mg b.i.d. 4, 5, 25
Crizotinib Rifampicin 69%↓ 82%↓ Increase crizotinib dose gradually and 
monitor toxicity in order to obtain 
optimal efficacy.
4, 5
Ketoconazole 44%↑ 216%↑ Avoid combination, if necessary extreme 
caution must be taken, dose should be 
lowered and toxicity must be monitored.
4, 5
Dasatinib Rifampicin 81%↓ 82%↓ Initially increase the dose 3-fold and 
then increase stepwise with 20mg based 
on patients tolerability and response.
4
Ketoconazole 384% ↑ 256% ↑ Lower the dasatinib dose to 20-40mg 
q.d.
4, 5, 26
Erlotinib Rifampicin 29%↓ 67-69%↓ Increase the dose to 300mg q.d., if well 
tolerated the dose can be increased after 
2 weeks to 450mg q.d. under monitoring 
of side-effects.
4, 5
Ketoconazole 102% ↑ 86%↑ If combination is indicated and erlotinib 
toxicity is observed, the erlotinib dose 
should be lowered with 50mg steps.
4, 5, 27
Gefitinib Rifampicin 65%↓ 83%↓ Increase gefitinib dose to 500mg q.d. 4, 5, 28
Itraconazole 51% ↑ 78%↑ Avoid combination, if indicated gefitinib 
toxicity must be monitored, no clinical 
data available on the starting dose. 
4, 5, 28
Imatinib Rifampicin 54%↓ 74%↓ Increase imatinib dose by at least 50%. 4, 5, 29
Ketoconazole 26% ↑ 40% ↑ No intervention is needed, but regular 
monitoring for toxicity is recommended.
4, 5, 30
Lapatinib Carbamazepine 59%↓ 72%↓ Gradually increase the lapatinib dose 
to 4500mg q.d. and monitor for liver 
toxicity.
4, 5, 31
Ketoconazole 114%↑ 257%↑ Lower the lapatinib dose to 500mg q.d. 4, 5, 31
Nilotinib Rifampicin 64%↓ 80%↓ Increase the dose gradually depending 
on patients toxicity and efficacy.
32
Ketoconazole 84%↑ 201%↑ Lower nilotinib dose to 400mg q.d. 32
Pazopanib Phenytoin or 
Carbamazepine
50%↓ 30%↓ Gradually increase the pazopanib dose 
with 200mg steps depending on patients 
tolerability
4,5
Ketoconazole 45%↑ 66%↑ Lower the dose by approximately 50% 
or 400mg q.d.
4,5
Table 3: Effects of CYP3A4 induction/inhibition on the exposure of TKIs
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Effect on TKI 
exposure
TKI Inducing 
compound
(CYP3A4)
Inhibitory 
compound
(CYP3A4)
Cmax AUC Alternatives and recommendations Refs.
Regorafenib Rifampicin 50%↓ 20%↓ Avoid the combination with strong 
CYP3A4 inducers, if indicated gradually 
increase the regorafenib dose and 
monitor toxicity in order to obtain 
optimal efficacy.
4,5
Ketoconazole 33 ↑ 40 ↑ Avoid the combination with strong 
CYP3A4 inhibitors, if indicated 
regorafenib toxicity must be monitored.
4,5
Ruxolitinib Rifampicin 52%↓ 71%↓ Increase the dose gradually depending 
on patients toxicity and efficacy.
4, 5, 33
Ketoconazole 33% ↑ 91%↑ Lower the ruxolitinib dose by 50% 
and hematological toxicity must be 
monitored extensively (2 times a week).
4, 5, 33
Sorafenib Rifampicin - 37%↓ Combination can be used safely. 4, 5
Ketoconazole - - Combination can be used safely. 4, 5, 34
Sunitinib Rifampicin 23%↓ 46%↓ Gradually increase the sunitinib dose 
with 12,5mg steps, with a maximum of 
87,5mg q.d. (GIST)
35
Ketoconazole 49%↑ 51%↑ Lower the sunitinib dose maximally to 
25mg q.d.
35
Vandetanib Rifampicin - 40%↓ Co-administration of rifampicin 
results in a moderate increase in 
AUC of vandetanib. By contrast, the 
exposure to the mean active metabolite 
N-desmethylvandetanib was profoundly 
increased (AUC 266% ). CYP3A4 inducers 
therefore need to be avoided during 
vandetanib therapy.
36
Itraconazole - 9% ↑ Combination can be used safely. 36
Vemurafenib - - No data on concomitant use of CYP3A4 
inhibitors/inducers. Caution must 
be taken when co-administration of 
vemurafenib and CYP3A4 inhibitors or 
inducers is indicated.
4, 5
Table 3: Continued
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PHARMACOKINETIC DRUG INTERACTIONS, 
METABOLISM
Phase 1, mostly oxidative, metabolism by cytochrome P450 enzymes (CYPs) is 
the most important route of drug metabolism of drugs in vivo. Although some 
drugs are also metabolised by enterocyte CYP3A4 enzymes, the main site of 
metabolism in the human body is the liver (figure 1).
CYP enzymes can be inhibited in two ways: (1) competitive binding of two 
substrates at the same CYP-enzyme binding site and (2) uncompetitive inhibition 
of CYP enzymes by an inhibitor coadministered with a substrate for the same 
CYP enzymes, leading to an increase in the serum area under the curve of the 
CYP substrate. The net effect on the area under the curve of the CYP substrate 
is dependent on the inhibitory and inducing potency of the coadministered drug. 
Increased or decreased exposure by alteration of CYP activity might cause 
clinically relevant toxic effects or ineffectiveness of treatment with tyrosine-
kinase inhibitors. Table 2 provides an overview of CYPs involved in metabolism 
of tyrosine-kinase inhibitors.
Because drug–drug interactions concerning strong CYP3A4-inhibition or 
induction play a crucial part in treatment with tyrosine-kinase inhibitors, they are 
usually well described in the regulatory assessment report of the manufacturer 
or in primary literature (table 3).
Other metabolic drug–drug interactions
Axitinib
The effects of strong CYP3A4 inhibition and induction on axitinib exposure 
have been thoroughly investigated. However, the effect on Cmax and the area 
under the curve of moderate CYP3A4 inhibitors (eg, fluconazole) needs to 
be assessed in future studies. CYP1A2 and CYP2C19 have a minor role in 
axitinib elimination and so the risk of a clinical relevant drug–drug interaction 
via inhibition or induction of these enzymes is negligible. Furthermore, the 
effect of drug-transporter inhibitors (eg, ciclosporin) on the exposure of axitinib 
has not yet been investigated but deserves attention, because transporters of 
organic anion transporting peptide and breast cancer resistance protein might 
affect axitinib exposure.
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Crizotinib 
Crizotinib is a strong CYP3A4 inhibitor; it increases the area under the curve of 
midazolam by 270%.5, 6 The combination of crizotinib and CYP3A4 substrates 
with a narrow therapeutic window (eg, ciclosporin or simvastatin) should 
therefore be avoided or closely monitored for toxic effects. For combined 
treatment with ciclosporin, therapeutic drug monitoring is recommended.5, 6 The 
product label also warns about co-administration of crizotinib with CYP2B6, 
CYP2C8, CYP2C9, UGT1A1, P-glycoprotein substrates, and drug transporter 
inhibitors, but the clinical significance of these combinations is unknown.5, 6
Dasatinib 
Strong inhibitors of CYP3A4 have a profound effect on dasatinib exposure.5, 6 
The effect of moderate CYP3A4 inhibitors on dasatinib exposure might also be 
clinically relevant, but such data are not available.5, 6 The product label warns 
about the combination of dasatinib and simvastatin. Through (time-dependent) 
inhibition of CYP3A4 by dasatinib, simvastatin Cmax is increased by 37%, and 
the area under the curve is increased by 20%.5, 6 However, because dasatinib 
is a time-dependent inhibitor of CYP3A4 and the dose was not at steady state, 
the above findings could underestimate the CYP3A4 inhibition and the effect 
on simvastatin. The combination of dasatinib and CYP3A4 substrates with 
a narrow therapeutic window should therefore be avoided (eg, change from 
simvastatin to pravastatin), or approached with caution.5, 6
Erlotinib 
Profound reduction in erlotinib exposure has been reported for the potent CYP3A4 
inducer rifampicin,5, 6 and reduced exposure of erlotinib might also take place 
with other strong inducers and moderate inducers (eg, enzalutamide, phenytoin, 
carbamazepine, barbiturates, or St John’s wort).5, 6 The exposure to erlotinib is 
increased with concomitant use of the CYP1A2 inhibitor ciprofloxacin (increased 
Cmax and area under the curve of 17% and 39%, respectively). In the case of 
combined ciprofloxacin and erlotinib treatment, recommendations state that the 
erlotinib dose should only be lowered (using 50 mg steps) if specific toxic effects 
are observed.5, 6 Because of competition for CYPs (3A4 and 1A2), erlotinib might 
increase the international normalised ratio in patients given warfarin,22 increase 
simvastatin exposure (rhabdomyolisis),37 and augment phenytoin toxicity,21 but 
evidence to support these changes is poor. Nevertheless, caution and awareness 
of these potential interactions is needed when coadministering these drugs. 
Carboplatin exposure was increased when concomitantly used with erlotinib, 
whereas no effect was noted with paclitaxel exposure.38
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Gefitinib
Concomitant gefitinib with phenytoin (a moderate-to-strong CYP3A4 inducer) 
results in a 26% decrease in Cmax, and a 47% decrease in the area under the 
curve.39 A potential drug–drug interaction has been reported between herbal 
CYP3A4/5 inducers (eg, ginseng) and gefitinib. After discontinuation of the 
herbal medicines, a patient turned from being a non-responder to a (partial) 
responder.40 In theory, this interaction could also be expected with St John’s 
wort (CYP3A4 inducer). If coadministration of gefitinib and a moderate-
to-strong CYP3A4 inducer cannot be avoided, the gefitinib dose should be 
increased from 250 mg to 500 mg, both once daily. Through weak inhibition 
of CYP2D6, gefitinib can increase the Cmax and the area under the curve of 
metoprolol by 10% and 35%, respectively, although increased metoprolol 
exposure does not seem to be clinically relevant.28 Because of competition for 
CYP3A4, gefitinib might increase the international normalised ratio in warfarin 
treatment.41 CYP3A4-inducing anti-epileptics significantly lowered gefitinib 
exposure.42 Finally, sorafenib decreases the exposure to gefitinib (decrease in 
Cmax and area under the curve of gefitinib by 38% and 26%, respectively) by an 
unknown mechanism, leaving sorafenib unaffected.43
Imatinib
Drug–drug interactions described with phenytoin, St John’s wort, and enzyme-
inducing anti-epileptic drugs show a consistent decrease in imatinib exposure.44, 
45, 46 If co-administration of imatinib and a strong CYP3A4 inducer is needed, the 
imatinib dose should be increased by at least 50%. Concomitant use of single-
dose ketoconazole results in an non-significant increase in imatinib single-dose 
exposure.30 Furthermore, because of CYP3A4 auto-inhibition by imatinib at 
steady state, coadministration of ritonavir did not have an effect on imatinib 
exposure.47 By contrast, severe toxic effects have been noted when imatinib was 
concomitantly used with the strong CYP3A4 inhibitor voriconazole.48 Taking 
the safety profile into account, coadministration of imatinib and strong CYP3A4 
inhibitors should be possible without dose adjustments. However, caution is 
needed, and regular monitoring for toxic effects is recommended.49 Ciclosporin 
and imatinib can also mutually affect each other’s exposure, but changes are 
small and regarded as clinically irrelevant.50 Liver toxicity was noted during 
concomitant use of ginseng (a CYP3A4 inhibitor) and imatinib, but this outcome 
could also be caused by ginseng itself.51 Because of strong inhibition of CYP3A4 
by imatinib, simvastatin exposure was markedly increased.52 If the combination 
is needed, simvastatin should be switched to another weakly CYP3A metabolised 
statin, such as rosuvastatin.53 CYP3A4 inhibition by imatinib might lead to high 
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nifedipine exposure, and thus form gallbladder stones; however, evidence is not 
convincing.54 Through weak inhibition of CYP2D6, imatinib can increase the 
Cmax and area under the curve of metoprolol by 8% and 23% respectively, but 
this finding has no clinical implications.55 Because of possible competition for 
CYPs, imatinib might increase the international normalised ratio in warfarin 
treatment, but again, evidence is weak.56
Lapatinib
If coadministration of lapatinib and a strong CYP3A4 inducer is needed, the once 
daily lapatinib dose should be gradually increased stepwise from 1250–1500 
mg (normal dose) to 4500 mg. Furthermore, if the lapatinib dose is increased 
to 4500 mg once daily, clinicians should be aware of the possible hepatotoxic 
effects of lapatinib metabolites with concomitant use of dexamethasone (a 
moderate CYP3A4 inducer).57 CYP3A4 inducing anti-epileptics significantly 
lower lapatinib exposure.58 When coadministered with irinotecan, the Cmax 
of the active metabolite SN-38 was increased by 32% and the area under the 
curve was increased by 41%.13 By contrast, no differences were noted in the 
exposure of lapatinib.13 The reported effect is suspected to be multifactorial 
with contributions of, among others, inhibition of CYP3A4 by lapatinib.13 
When lapatinib was given in combination with paclitaxel, the exposure of both 
drugs was increased by 21% and 23%, respectively, possibly by inhibition of 
CYP2C8.59 Because lapatinib is an inhibitor of CYP3A4 and CYP2C8, the 
product label recommends that the combination of lapatinib and CYP3A4 and 
CYP2C8 (eg, repaglinide) substrates with a small therapeutic window should 
therefore be avoided or approached with caution.5, 6
Nilotinib
By weak inhibition of CYP3A4, nilotinib can increase the Cmax of midazolam by 
20% and the area under the curve by 30%.5, 6 Nilotinib did not have a significant 
effect on warfarin or imatinib exposure, and so can be used concomitantly.60
Pazopanib
By weak inhibition of CYP3A4 and CYP2D6, pazopanib might increase the 
exposure of midazolam and dextromethorphan.61 In the same study, pazopanib 
did not have a significant effect on warfarin (CYP2C9 specific), omeprazole 
(CYP2C19 specific), and caffeine (CYP1A2 specific).61 Coadministration 
of pazopanib eye drops with orally taken ketoconazole roughly doubled the 
pazopanib area under the curve.5, 6 Pazopanib increased the area under the curve 
and Cmax of paclitaxel (a substrate for CYP2C8, CYP3A4, and P-glycoprotein) 
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by 26% and 31%, respectively, without changing tolerability.5, 6 In combination 
with lapatinib 1500 mg (moderate, competitive CYP3A4, P-glycoprotein, and 
breast cancer resistance protein inhibitor), the pazopanib (800 mg) area under 
the curve and Cmax were increased by 59% and 51%, respectively. However, 
at a lower pazopanib (400 mg) and lapatinib dose (1000 mg), no statistically 
significant effect was seen for the area under the curve or Cmax.
5, 6
Regorafenib
When given concomitantly with ketoconazole, the area under the curve of 
regorafenib was increased by 33% and the Cmax by 40%. Furthermore, a decrease 
of more than 90% was noted in the area under the curve and Cmax of the (active) 
regorafenib metabolite. According to the package label, concomitant use of 
strong inhibitors of CYP3A4 activity should be avoided because their effect 
on the steady state exposure of regorafenib and its active metabolites has not 
been studied.5, 6 Co-administration with the strong CYP3A4 inducer rifampicin 
resulted in a reduction in the area under the curve and Cmax of regorafenib of 
50% and 20%, respectively. Furthermore, an increase of three to four times was 
noted in exposure of regorafenib’s active metabolites. Because the net effect 
of the combination of strong CYP3A4 inducer and regorafenib is unknown, 
these combinations should preferably be avoided.5, 6 The inhibition of UGT1A1 
by regorafenib resulted in an increase of 44% in area under the curve of SN-
38 (active metabolite of irinotecan). An increase in area under the curve of 
irinotecan of roughly 28% was also noted. This finding shows that regorafenib 
can increase systemic exposure to UGT-substrates, such as irinotecan.62 A study 
was done to evaluate the effect of regorafenib on probe substrates of CYP2C8 
(rosiglitazone), CYP2C9 (s-warfarin), CYP2C19 (omeprazole), and CYP3A4 
(midazolam). No effects were reported.5, 6
Ruxolitinib
Compared with strong CYP3A4 inhibitors, concomitant use of the moderate 
CYP3A4 inhibitor erythromycin results in a less profound increase in Cmax of 
8% and area under the curve of 27%. If coadministration with strong CYP3A4 
inhibitors and inhibitors of both CYP3A4 and CYP2C9 (eg, fluconazole) is 
necessary, ruxolitinib dose should be reduced by 50% and haematological 
toxicity should be monitored extensively (eg, twice a week).5, 6, 33 Concomitant 
use of the potent CYP3A4 inducer rifampicin decreased the area under the 
curve of ruxolitinib by 71%. However, only a 10% decrease in the overall 
pharmacodynamic activity was noted. This finding might be explained by the 
increased exposure to the active metabolites of ruxolitinib.33
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Sorafenib
CYP3A4 inducers have an effect on sorafenib exposure.5, 6 By contrast, strong 
CYP3A4 inhibitors did not seem to have any effect on the Cmax and area under the 
curve of sorafenib. However, this study was not done at steady state of sorafenib 
and inter-individual variation was high, with an increase in the area under the curve 
noted for some participants, and a decrease noted for others after co-administration 
of sorafenib with ketoconazole.34 Substrates of CYP2C19 (omeprazole), CYP2D6 
(dextromethorphan), and CYP3A4 (midazolam) were co-administered with 
sorafenib, with only minor, clinically insignificant, effects.63 However, sorafenib 
reduced gefitinib exposure (Cmax was reduced by 26% and area under the curve by 
38%), but gefitinib had no effect on sorafenib exposure.43 Sorafenib exposure was 
significantly decreased in the presence of CYP3A4-inducing anti-epileptic drugs.64 
The international normalised ratio should be monitored during concomitant use 
of warfarin and sorafenib.65 When sorafenib was continuously coadministered 
with paclitaxel or carboplatin, increases in the area under the curves of paclitaxel, 
6-OH paclitaxel, and sorafenib were reported,5, 6 although the pharmacokinetics 
of carboplatin were unaffected.5, 6 Coadministration of paclitaxel and carboplatin 
with sorafenib, with a 3 day break in sorafenib dosing (2 days before and on the 
day of paclitaxel and carboplatin administration), had no significant effect on the 
pharmacokinetics of paclitaxel.5, 6 Thus, a drug–drug interaction might be bypassed 
by the introduction of a 3 day break from sorafenib. When co-administered with 
sorafenib, the area under the curve of doxorubicin was increased by 21%.5, 6 
Furthermore, coadministration of capecitabine and sorafenib had no significant 
effect on sorafenib exposure, but increased the area under the curve exposure of 
capecitabine by 15–50%, and increased fluorouracil exposure by 0–52%.5, 6 The 
clinical significance of these findings is unknown, but changes in exposure of 
up to 50% could have an effect on clinical outcome. After co-administration of 
irinotecan with sorafenib (400 mg), the area under the curve of SN-38, roughly 
doubled.5, 6 Concomitant administration of low doses of sorafenib (100 mg or 200 
mg twice daily) did not result in significant changes in SN-38.5, 6 In a small study 
in six patients, irinotecan had no significant effect on sorafenib exposure when 
sorafenib was given in low doses (100–200 mg twice daily), but when sorafenib 
was given at 400 mg twice daily together with 125 mg/m2 irinotecan, sorafenib 
exposure increased by 68%.5, 6 Coadministration of sorafenib and dacarbazine 
led to decreased exposure of dacarbazine (the area under the curve reduced by 
23%), but the clinical relevance of this drug–drug interaction remains unknown.66 
Neomycin decreased the area under the curve of sorafenib by 54%, probably 
because of eradication of gastrointestinal bacterial glucorinidase activity, resulting 
in a decrease in the enterohepatic recycling of sorafenib.5, 6
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Sunitinib 
Coadministration of sunitinib and ifosfamide (CYP3A4 inducer) led to a 
significant decrease in sunitinib exposure.67
Vandetanib 
Co-administration of rifampicin results in a moderate decrease of 40% in 
the area under the curve. By contrast, the exposure to the most important 
active metabolite N-desmethylvandetanib was profoundly increased during 
coadministration of rifampicin (increases of 266% in area under the curve 
and 414% in Cmax).
36 Because of the net effects of the decrease of vandetanib, 
and the major increase of its active metabolite are unknown, CYP3A4 
inducers should be avoided during vandetanib treatment.36 By contrast with 
the CYP3A4 inducer rifampicin, the CYP3A4 inhibitor itraconazole had 
no effect on vandetanib exposure. This finding implies that the effect of 
rifampicin on vandetanib exposure might be mediated by metabolic pathways 
other than CYP3A4, such as P-glycoprotein. The product label warns about the 
drug–drug interaction with warfarin, but no clinical evidence is available to 
support this.5, 6
Vemurafenib 
No clinical data are available about the effect on vemurafenib exposure when 
concomitantly used with strong CYP3A4 inhibitors or inducers, and so caution 
should be taken when giving vemurafenib with either.5,6 Vemurafenib had 
moderate, clinically insignificant, effects on exposure of dextromethorphan 
(CYP2D6), midazolam (CYP3A4), or caffeine (CYP1A2), and no effects on 
omeprazole (CYP2C19) or warfarin (CYP2C9).5,6
Summary
In summary, all tyrosine-kinase inhibitors are metabolised by CYP enzymes, 
which make them prone to metabolic drug–drug interactions.5, 6 Regulatory 
assessment reports mainly investigate interactions with the most potent CYP 
inducers and inhibitors. Additional clinical studies should be done to fully 
assess the effect of moderate and strong CYP inducers and inhibitors at steady 
state, next to the present extrapolation of kinetic data from single-dose studies. 
On the basis of these results, adequate guidelines can be developed for dose 
adjustments of tyrosine-kinase inhibitors to counter drug–drug interactions.
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P-glycoprotein
Some tyrosine-kinase inhibitors are substrates or inhibitors of P-glycoprotein. 
In theory, the exposure of some tyrosine-kinase inhibitors (eg, erlotinib) could 
increase during coadministration of P-glycoprotein inhibitors (eg, verapamil or 
ciclosporin). Furthermore, because of P-glycoprotein inhibition by sunitinib, 
colchicines-related toxic effects were noted.68 Clinical data are scarce and more 
research is needed to fully understand the role of P-glycoprotein in exposure to 
tyrosine-kinase inhibitors.
PHARMACOKINETIC DRUG INTERACTIONS, 
ELIMINATION
Drug–drug interactions related to elimination generally occur due to renal 
impairment, either caused by the parent drug or during concomitant use of other 
nephrotoxic comedication. Most tyrosine-kinase inhibitors are eliminated by liver 
metabolism and subsequently excreted in faeces as metabolites or unchanged, 
with minor contributions of renal clearance. Because tyrosine-kinase inhibitors 
are largely eliminated by hepatic metabolism, drug–drug interactions that take 
place through changes in renal elimination seem to be of minor importance. 
However, drug transporters (eg, P-glycoprotein, organic anion transporting 
peptides, organic cation transporter, and breast cancer resistance protein), that 
are also found in the kidneys, are important for the elimination of tyrosine-
kinase inhibitors.69 Because of the possible inhibition of the organic cation 
transporter by erlotinib, cellular accumulation of cisplatin in renal tubular cells 
might be restricted and, as a result, specific cisplatin-based nephrotoxic effects 
might be prevented.70 Furthermore, the drug–drug interaction between imatinib 
and methotrexate might affect methotrexate transport and elimination.71 More 
research is needed to fully assess the positive effect of changes in expression of 
renal drug transporters on the pharmacokinetics of tyrosine-kinase inhibitors.
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PHARMACODYNAMIC INTERACTIONS
Pharmacodynamic drug–drug interactions can happen when the pharmacological 
effect of one drug is changed by another through action on mechanisms associated 
with the same physiological process or effect. Although pharmacodynamic 
interactions can be used intentionally (eg, methotrexate and folic acid), they 
can also be harmful (eg, cisplatin and lisdiuretics).
Some case reports describe pharmacodynamic interactions between tyrosine-
kinase inhibitors and other drugs. For instance, imatinib can increase 
methotrexate toxicity by causing fluid retention, and sunitinib and imatinib can 
antagonise levothyroxine treatment by interference with thyroid hormones at 
the pituitary level.72, 73 Furthermore, concomitant use of antibiotics that affect 
the flora of the gastrointestinal tract might interfere with the enterohepatic 
circulation of regorafenib and might decrease regorafenib absorption.5, 6 Other, 
mainly additive, pharmacodynamic drug–drug interactions have been described 
between tyrosine-kinase inhibitors and other anticancer drugs, but this event is 
beyond the scope of this Review.
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Prolongation of the QTc interval
Many classic anticancer drugs can prolong the QTc interval (eg, anthracyclines). 
This prolongation is also frequently reported with use of tyrosine-kinase 
inhibitors,5, 6 which is probably caused by interaction with hERG K+ channels. 
This interaction results in a change in electrical flow and delayed pulse 
conduction, and therefore, QTc prolongation (figure 2).
74 
The potential of a tyrosine-kinase inhibitor to prolong the QTc interval is 
usually related to its chemical structure and plasma concentration. Such QTc 
prolongation might be further increased by CYP3A4 inhibition by another drug, 
or by the simultaneous use of another drug that can prolong the QTc interval 
(eg, sotalol) alongside a tyrosine-kinase inhibitor.74 Table 4 lists the QTc 
interval prolonging properties of tyrosine-kinase inhibitors. The Arizona CERT 
Index lists tyrosine-kinase inhibitors (eg, vandetanib, nilotinib, lapatinib, and 
sunitinib), and other drugs that might affect the QTc interval.
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Although rare, prolongation of the QTc interval and subsequent development 
of Torsades de pointes is a severe, life-threatening side-effect of treatment 
with tyrosine-kinase inhibitors. Medical oncologists should be better informed 
about the risk of coadministration of drugs that prolong the QTc interval in 
patients given tyrosine-kinase inhibitors. Pharmacists should routinely check 
for concomitant use of such prolonging drugs and CYP3A4 inhibitors. Special 
attention should given to QTc interval-prolonging 5HT3 antagonists, antibiotics, 
antifungals, and over-the-counter drugs (eg, domperidone), because these drugs 
are frequently used by patients with cancer concomitantly with tyrosine-kinase 
inhibitors. Unless absolutely necessary, coadministration QTc-prolonging 
tyrosine-kinase inhibitors and drugs that prolong the QTc interval and CYP3A4 
inhibitors should be avoided. If needed, an ECG should be obtained 24–48h 
before, and 1 week after, the start of the concomitant treatment.
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QTc-interval prolongation Events*
TKI Yes No Yes No 
Axitinib · ·
Crizotinib · ·
Dasatinib · ·
Erlotinib · ·
Gefitinib · ·
Imatinib · ·
Lapatinib · ·
Nilotinib · ·
Pazopanib · ·
Regorafenib · ·
Ruxolitinib · ·
Sorafenib · ·
Sunitinib · ·
Vandetanib · ·
Vemurafenib · ·
This table is constituted from regulatory documents.4,5 
*Torsades de pointes or sudden (heart) death.
Table 4: QTc-interval prolonging properties of tyrosine-kinase inhibitors
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RECOMMENDATIONS FOR CLINICAL PRACTICE
In the past few years, tyrosine-kinase inhibitors have rapidly become an 
established part of oncology practice, but have also presented new challenges, 
such as the increased risk of drug–drug interactions.
Apart from sorafenib and vandetanib, tyrosine-kinase inhibitors’ exposures are 
greatly affected by CYP3A4 inhibitors and inducers, and clinical intervention is 
often needed (table 3). Furthermore, acid-reducing drugs, such as proton-pump 
inhibitors, can profoundly affect the bioavailability of most tyrosine-kinase 
inhibitors and need clinical attention (table 1).
Drug–drug interactions that lead to prolongation of the QTc interval are rare, but 
can have fatal consequences and should be accounted for (table 4). Table 5 lists 
the main points about drug–drug interactions.
P-glycoprotein substrates with a narrow therapeutic window (eg, digoxin, 
ciclosporin, and tacrolimus) should be extensively monitored (eg, by therapeutic 
drug monitoring) during the use of tyrosine-kinase inhibitors that inhibit 
P-glycoprotein (table 2). The combination of grapefruit juice and sunitinib 
or nilotinib should be avoided.16, 17 Other product labels discourage intake of 
grapefruit juice only on theoretical assumptions (eg, pazopanib and lapatinib).5, 6 
To improve the safe use of tyrosine-kinase inhibitors in clinical oncology, a 
profound assessment of co-prescribed drugs, herbal supplements, lifestyle food 
and drinks (eg, grapefruit juice), cardiac risk factors, and physical examination 
is needed. To undertake this assessment, oncologists and haemato-oncologists 
should collaborate closely with clinical pharmacists, family doctors, and other 
medical specialists (eg, cardiologists). Additionally, more clinical research 
is needed (with for instance the new anti-androgen enzalutamide; a strong 
CYP3A4 inducer) about drug–drug interactions in treatment with tyrosine-
kinase inhibitors to provide a profound basis for drug reviews and to fully 
understand the interaction potential of these inhibitors. In case of a suspected 
interaction, and if pharmacokinetic data are not available, physicians and 
pharmacists should balance the available evidence, if possible, extrapolate 
available pharmacokinetic data for an individual patient, and monitor closely 
for toxic effects and response.
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TKIs prone to significantly interact with: Assessment of clinical relevance:
Acid suppressive agents (PPIs, H2As and antacids)
crizotinib, dasatinib, erlotinib, gefitinib, lapatinib and pazopanib
Concomitant use of acid suppressive agents can significantly 
affect the drug absorption of these TKIs. If possible, the 
combination must be avoided or the time of drug intake must 
be split by at least several hours
Strong CYP3A4 inhibitors* and strong CYP3A4 inducers**
axitinib, crizotinib, dasatinib, erlotinib, gefitinib, imatinib, 
lapatinib, nilotinib, pazopanib, regorafenib, ruxolitinib, 
sunitinib, vemurafenib
Concomitant use of strong CYP3A4 inhibitors/inducers can 
significantly influence the exposure to these TKIs. Dose 
adjustments are highly recommended
Other QTc-interval prolonging drugs 
crizotinib, gefitinib, lapatinib, nilotinib, pazopanib, sorafenib, 
sunitinib, vandetanib, vemurafenib
Concomitant use of other QTc-interval prolonging drugs along 
with these TKIs can significantly prolong the QTc-interval. 
If indicated, it is strongly recommended that an ECG is 
obtained 24-48 hours before and one week after initiating the 
concomitant therapy
Table 5: Highlights of the most significant DDIs in TKI therapy
This table only shows the highlights and is constituted from table 1,3 and 4. For more detailed 
information, see table 1,3 and 4.
H2As=H2-antagonists, PPI=proton pump inhibitors
*ketoconazole, itraconazole and voriconazole
** rifampicin and enzalutamide
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ABSTRACT
Introduction
In cancer patients, drug interactions may intensify adverse events or reduce 
antitumour effects. We assessed the prevalence of potential drug interactions 
(PDIs) among ambulatory cancer patients on i.v. treatment using an advanced 
screening method. 
Methods
Data on drugs used for comorbidities, anticancer agents, over-the-counter (OTC) 
drugs, and comorbidities were collected by means of a structured interview 
among the patients and review of medical charts. PDIs were identified using 
electronic (Drug Interaction Facts software, version 4.0) and manual screening 
methods (peer-reviewed reports). 
Results
In this study, 278 patients were enrolled. We identified 348 PDIs. Of all 
patients, 161 (58%) had at least one PDI. Of all PDIs, 34% was classified 
as major and 60% as moderate. Coumarins, quinolones, antiepileptics, and 
hydrochlorothiazide were frequently part of a PDI. Interactions that potentially 
cause QT interval prolongation, gastrointestinal toxicity, and central nervous 
system depression were also common. In multivariate analysis, an increasing 
number of drugs [odds ratio (OR) = 1.4, confidence interval (CI) 1.23–1.52; P < 
0.001] and the use of an OTC drug (OR = 0.56, CI 0.32–0.97; P = 0.045) were 
risk factors. 
Conclusions
PDIs are common in patients treated for an (haemato-) oncological disease. 
Screening for potential interactions should take place routinely before 
administering chemotherapy.
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INTRODUCTION
The pharmacological treatment of patients with cancer is associated with 
multiple side-effects.1 Although the cause of side-effects usually lies in the 
toxicity of the drugs themselves, drug interactions can reinforce or intensify 
adverse events and even seem to be the cause of death in 4% of cancer patients.2 
Cancer patients are particularly susceptible for drug interactions as they often 
use several drugs as part of the cancer treatment on top of the medication 
prescribed to manage comorbidities.3
Potential drug interactions (PDIs) in nature are subdivided into pharmacokinetic 
and pharmacodynamic interactions.4 Pharmacokinetic interactions alter the 
absorption, distribution, metabolism, or excretion of a drug. The majority 
of pharmacokinetic interactions are the result of inhibiting or inducing 
the cytochrome P450 liver enzymes.3 Since many anticancer agents are 
metabolised via this mechanism, PDIs involving cytochrome P450 may occur.5 
A pharmacodynamic interaction is characterised by an additive, synergistic, or 
antagonistic effect, thereby influencing the response of a drug.4
The occurrence of PDIs in general clinical practice and their determinants has 
extensively been studied.2, 6–9 However, only limited data are available on the 
occurrence of PDIs in patients being treated with anticancer agents and, to our 
knowledge, there is no study available that has included over-the-counter (OTC) 
medication. In a Canadian study in ambulatory cancer patients, it has been 
shown that 27% of cancer patients were exposed to PDIs involving anticancer 
agents.3 Certain types of cancers (mainly brain tumours) and comorbidities 
appeared to be risk factors. In hospitalised cancer patients, the use of eight or 
more drugs and a hospital stay of >6 days were identified as risk factors for 
PDIs.10 OTC medication is popular in cancer patients, either to prevent or treat 
symptoms of disease or to promote health and well-being.11 
59
3
Potential drug interactions in cancer therapy
Due to the lack of information about the drugs in use to treat comorbidities, 
prescribing oncologists may not always be aware of PDIs in their patients. 
In addition, since the community pharmacy is usually not informed by 
the oncologist on the treatment with anticancer agents, general practitioners 
may not be aware of PDIs when prescribing drugs for a new complaint. 
OTC medication is not always identified. Although computer-based 
medication prescription systems are in use in hospitals as well as in 
community pharmacies, they are not linked. Electronic identification of 
PDIs between drugs to treat comorbidities and anticancer agents is not yet 
available. 
The aim of the present study was to gain more insight into the prevalence of 
PDIs among ambulatory cancer patients on i.v. treatment of an (haemato-) 
oncological disease using a novel more extensive screening method. The 
prevalence of PDIs with OTC drugs was also analysed. Possible risk factors 
for the occurrence of these potential drug-related problems were investigated 
as well.
METHODS
Study design
A two-centre cross-sectional study of the epidemiology of PDIs was carried 
out during a 5-month period in 2009 among all ambulatory cancer patients 
treated i.v. with anticancer agents at the (haemato-) oncology outpatient day 
care department of the VU University Medical Center and the Zaans Medical 
Center. The VU University Medical Center is a large tertiary referral hospital, 
while the Zaans Medical Center is a small community hospital situated in the 
Amsterdam area. The study was registered under number NTR2238.
Patients
All patients with a solid tumour or a haematological malignancy on i.v. treatment 
with anticancer agents were asked to participate in the study. Exclusion criteria 
were as follows: unable to fill out questionnaires, the use of clinical trial 
medication, a lack of command of the Dutch language, and age <18 years. All 
participating patients were asked to sign an informed consent. The study was 
approved by the medical ethics review board of both institutes.
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Procedures
Patients were asked questions by means of a structured interview (RWFVL). 
Questions concerned comorbidities and the use of OTC drugs. To determine 
the type of comedication, an overview of drugs prescribed over the previous 6 
months was obtained from the community pharmacy. The actual use, both on a 
continuous base and an incidental use, was discussed with the patient. Data on 
the type of anticancer agents, diagnosis, aim of treatment (palliative/adjuvant), 
treatment start date, and comedication in use for administration of anticancer 
agents were collected by means of a medical chart review and, if necessary, 
by means of an interview of the prescribing doctor. Data on renal function 
(creatinine) and liver function tests [aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and γ-glutamyltransferase (γ-GT)] were obtained from 
the laboratory database of the hospital. We defined a laboratory abnormality 
as an increase of 50% or higher above the upper limit of normal as measured 
within the 4 weeks preceding the interview (upper normal limits: AST ≤35 U/l, 
ALT ≤40 U/l, γ-GT ≤44 U/l, creatinine ≤99 μmol/l). 
Drugs were subdivided into four groups: ‘anticancer agents, supportive care 
drugs, drugs to treat comorbidity, and OTC drugs. We defined ‘anticancer 
agents’ as medication to treat solid tumours or haematological malignancies, 
‘supportive care agents’ as medication to treat cancer- and/or therapy-related 
symptoms, ‘drugs to treat co-morbidity’ as a noncancer clinical condition that 
required pharmacological treatment, and ‘OTC drugs’ as (alternative) drugs and 
Classification Description
Level severity
1 Major: life-threatening or permanent damage
2 Moderate: deterioration of patient’s status, treatment is required
3 Minor: bothersome or little effect
Level documentation
1 Established: proven to occur in well-controlled studies
2 Probable: very likely, but not proven clinically
3 Suspected: may occur; some good data, but needs more study
4 Possible: could occur, but data are very limited
5 Unlikely: doubtful; no good evidence of a clinical effect
Table 1: Classification of potential drug interactions
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food supplements used by the patients on their own initiative without prior 
consultation of a doctor. For each patient, we counted the number of drugs by 
group. If a drug contained two or more pharmacologically active ingredients, 
each drug was counted individually in the analysis (e.g. sulfamethoxazole 
combined with trimethoprim). The drug was counted only once when a patient 
was taking the same medication in more than one formulation (e.g. long- and 
short-acting morphine). 
Drugs were screened for PDIs by the Drug Interaction Facts software (Facts 
and Comparisons, version 4.0)12, which has been shown to have an accuracy 
of >95% in detecting interactions.13 The Drug Interaction Facts software for 
PDIs classifies interactions by the level of severity and the level of scientific 
evidence (Table 1). The potential severity of a PDI was classified as major if the 
effects are potentially life threatening or capable of causing permanent damage; 
moderate, when the effects may cause a deterioration in a patient’s clinical 
status or if an additional treatment, hospitalisation, or an extended hospital 
stay may be necessary; or minor, if the effects are usually mild and should not 
significantly affect the therapeutic outcome. The level of scientific evidence of 
a PDI was classified on a five-point documentation scale. Level 1 means that 
a PDI was supported by well-controlled human studies and level 5 means that 
the documentation of a PDI is of poor quality or only theoretical. Of note, PDIs 
that might result in reduced anticancer activity were not scored as severe if the 
interaction would lead to lower toxicity, such as the combination of irinotecan 
and St John’s wort.14
Drugs were also screened by a clinical pharmacologist for combinations of 
drugs with potential QT interval prolongation and/or torsades de pointes-
inducing properties using the Arizona Center for Education and Research 
on Therapeutics system and peer-reviewed reports on scientific evidence for 
potential QT interaction. Because of the potentially severe consequences, we 
classified all drug combinations with risk for QT interval prolongation as 
major.15 Drugs associated with an increased risk of falling [central nervous 
system (CNS) depressant agents] were identified manually using handbooks 
and peer-reviewed reports on scientific evidence. A combination of two CNS 
depressant agents was counted as one interaction, defined as a CNS interaction 
in the analysis. All CNS interactions were classified as moderate. Drugs were 
also screened for the combination between nonsteroidal anti-inflammatory drugs 
(NSAIDs) and corticosteroids, anticoagulants, aspirin, or selective serotonin 
reuptake inhibitors (SSRIs) defined as gastrointestinal (GI) interaction using 
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the Drug Interaction Facts software and peer-reviewed reports on scientific 
evidence. These combinations are known to increase the risk for GI bleeding. 
Because of the potentially severe consequences, all GI interactions were 
classified as major.
To identify PDIs involving OTC drugs, pharmacology handbooks and peer-
reviewed reports were screened manually. Theoretical interactions were not 
included in the analysis. Because of lack of clinical significance, interactions of 
minor severity were also excluded. The medication screened for PDIs were the 
drugs in the four groups mentioned above: anticancer agents, supportive care 
drugs, drugs to treat comorbidity, and OTC drugs. A PDI was only counted in 
the analysis when an anticancer agent or a supportive care drug was involved.
Statistical analysis
Descriptive statistics (mean ± standard deviation or median) were applied to 
characterise the whole study sample with regard to demographics, cancer type, 
treatment objective, type of anticancer agents, comorbidities, number of drugs 
per patient, laboratory abnormalities, and interaction characteristics (severity, 
level of scientific evidence, onset, and mechanism). 
Univariate and multivariate logistic regression analyses were carried out 
to identify the potential risk factors for the occurrence of PDIs. The number 
of potential interactions per patient was the dependent variable. Covariables 
were age, number of drugs, study centre (Zaans Medical Center and VU 
University Medical Center), treatment intent, treatment type, presence of 
comorbidities, cancer type, tumour type (haemato-oncology/oncology), 
laboratory abnormalities, and the use of an OTC drug. Gender was not included 
as a covariable due to the fact that certain cancer types only occur in men 
or women. For binary or nominal variables, the largest group was taken as 
the reference. Variables with univariate P values <0.05 were included in the 
multivariate analysis. In the multivariate analysis, a P value of <0.05 was 
considered statistically significant. The data were adjusted for confounders and 
effect modifiers.
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N %
Study population 278 100
Age in years* 61 (19-82) -
Sex
     Female 124 45
     Male 154 55
Hospital
     VU University Medical Center 158 56.8
     Zaans Medical Center 120 43.2
Cancer type
     Oncology 223 80.2
     Haemato-oncology 55 19.8
Cancer type oncology
     Gastrointestinal 75 27.0
     Breast 66 23.7
     Lung 23 8.3
     Genitourinary 21 7.6
     Gynaecological 21 7.6
     Other 17 6.0
Cancer type haemato-oncology
     Malignant lymphoma 26 9.3
     Plasma cell dyscrasia 12 4.3
     Leukaemia 11 4.0
     Myelodysplastic syndrome 5 1.8
     Immunocytoma 1 0.4
Treatment intent
     Curative/Adjuvant 131 47.1
     Palliative 147 52.9
Cancer treatment
     Chemotherapy 195 70.1
     Monoclonal antibodies 36 12.9
     Hormone therapy 1 0.36
     Combinations 46 16.5
No. of drugs used per patient* 9 (2-22) -
No. of drugs used per patient per group*
     Anti-cancer agents 2 (1-5) -
     Supportive care drugs 2 (0-6) -
     Drugs for co-morbidities 3 (0-14) -
     OTC drugs 1 (0-7) -
No. of co-morbidities per patient* 1 (0-6) -
Total laboratory abnormalities** 98 40.0
Laboratory values*
      Creatinine 72 (39-354) -
      Aspartate aminotransferase 27 (11-204) -
      Alanine aminotransferase 26 (5-266) -
      Gamma-glutamyltransferase 40 (2-1205) -
*Median (range)
**Because of missing data, denominator is 245
OTC=over the counter
Table 2: Baseline characteristics
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RESULTS
Patient characteristics
Between August and December 2009, a total of 278 patients were asked to 
participate in the study; there were no refusals. Table 2 lists the baseline 
characteristics of the patients. The mean age of the patients was 61 years (range 
19–82 years) and 45% were female. The patients used nine (range 2–22) drugs 
per patient and 82% of the patients used at least one OTC drug. Fifty-eight 
percent of the patients had at least one comorbidity.
Drug interactions
For 278 patients, 348 PDIs were identified (Table 3). In 161 patients (58%) [95% 
confidence interval (CI) 52% to 64%], at least one PDI was found. In 34% of all 
cases, the interaction was classified as major and in 60% as moderate. In 40% 
and 60%, an anticancer agent and a supportive care drug, respectively, were 
involved. In 11% of all 348 interactions, an OTC drug was part of the PDI. Sixty-
four percent of all PDIs concerned a pharmacodynamic interaction; thirty-three 
percent of the PDIs concerned a CNS interaction. For 83% of the major and 
moderate PDIs, the level of scientific evidence was 2 (probable) or 3 (suspected).
The PDIs for combinations including an anticancer agent or a supportive care 
drug are shown in Tables 4 and 5, respectively. Almost 20% of all PDIs could be 
attributed to a drug combination with coumarins, quinolones, antiepileptics, or 
hydrochlorothiazide. The other 80% of the PDIs showed a wide variety of drug 
classes. PDIs that may result in QT interval prolongation, GI toxicity, and CNS 
depression (falling) accounted for, respectively, 16%, 11%, and 33% of all PDIs.
Potential risk factors
In the univariate analysis, the number of drugs, the presence of comorbidities, 
and the use of OTC drugs were associated with a higher number of PDIs 
(Table 6). Age was not associated with a higher number of PDIs (P = 0.223). 
When patients were divided into two groups comprising younger and older 
than 61 years, age was also without effect. Although this subgroup was small, 
the use of mAbs as monotherapy showed a lower risk. After adjustment for 
confounders, the effect of the number of drugs and the use of an OTC drug 
remained significant (P < 0.001 and P = 0.045, respectively).
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PDIs N %
Total 348 100
Potential drug interaction per patient* 1 (0-7) -
Drug interactions by group
       Anti-cancer agent  involved 138 39.7
       Supportive care drug involved 210 60.3
Level of severity
       Major 118 33.9
       Moderate 210 60.3
       Minor 20 5.7
Level of scientific evidence
       1 0 0
       2 242 69.9
       3 46 13.2
       4 47 13.5
       5 11 3.7
Drug interaction mechanism
       Pharmacodynamic 224 64.4
                QT-interval prolongation 56 16.1
                GI-interaction 39 11.2
                CNS-interaction 116 33.3
                Other PD-interactions 13 3.7
       Pharmacokinetic 92 26.4
       Unknown 32 9.2
Table 3: Prevalence, classification and mechanism of potential drug interactions 
(PDIs) among cancer patients
*median (range)
GI=gastro-intestinal, CNS=central nervous system, PD=pharmacodynamic
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Potential drug interactions between anti-cancer agents and supportive care drugs
N Description Severity Scientific 
evidence
Ondansetron + Doxorubicin/Epirubicin/
                         Tamoxifen [15,24]
37 Drug combinations can prolong QT-interval Major 2
Potential drug interactions between anti-cancer agents and drugs to treat co-morbidities
Coumarine + Capecitabine/Etoposide/
                      Carboplatin/Gemcitabine 
                      [25,26,27]
11 Chemotherapy-induced protein displacement and 
inhibition of coumarines metabolism with higher 
risk of bleeding
Major 2
Doxorubicin + Sotalol/Amiodarone/
                         Clarithromycin/Levofloxacin
                         [15,24]
6 Drug combinations can prolong QT-interval Major 2
Bleomycin + (PEG)Filgrastim [28] 4 Possible pulmonary toxicity Major 3
Methotrexate + Prednisolone [29] 1 Prednisolone may decrease the total clearance of 
methotrexate.
Major 4
Methotrexate + Aspirin [30] 1 Aspirin may increase plasma concentrations of 
methotrexate with an increased risk of bone marrow 
and hepatic toxicity
Major 3
Quinolones + Carboplatin/Etoposide/
                       Mitoxantrone/Vincristine/
                       Cisplatin/Cyclophosphamide/ 
                       Doxorubicin [31]
13 Absorption of quinolones may be decreased due to 
damaged gastrointestinal mucosa 
Moderate 5
Coumarine + Cyclophosphamide/Fluorouracil/
                      Paclitaxel [32,33,34]
10 Chemotherapy-induced protein displacement and 
inhibition of coumarines metabolism with higher 
risk of bleeding
Moderate 2
Hydrochlorothiazide + Cyclophosphamide/
                                      Fluorouracil [35]
7 Myelosuppression may be increased by thiazides Moderate 4
CNS-interactions* 7 Combinations of CNS-depressant drugs may increase 
the risk of falling
Moderate 2/3
Phenytoin + Cyclophosphamide/Etoposide/
                     Vincristine/Doxorubicin 
                     [36,37]
5 Plasma concentrations and therapeutic effect of 
phenytoin or cytotstatic agent may be altered
Moderate 3/4
Valproic acid + Cisplatin/Doxorubicin/
                          Bleomycin [38]
4 Lower AUC valproic acid possibly due to disturbed 
gastrointestinal absorption or increased metabolism
Moderate 4
Cyclophosphamide + Allopurinol [39] 2 Toxicity (bone marrow depression) may be increased Moderate 4
Other§ 7 - Moderate 3/4
Potential drug interactions between anti-cancer agents and OTC drugs
Methotrexate + Ibuprofen [30] 2 Toxicity of methotrexate may be increased by 
ibuprofen
Major 3
Folic acid + Capecitabine/Fluorouracil [40] 18 Toxic effects of capecitabine may be increased by 
folic acid
Moderate 4
Irinotecan + St.John’s Wort [14] 2 Plasma concentrations and pharmacological effects 
of irinotecan may be decreased
Moderate 3
*  Azacitadine+Levocetirizine, Codeine+Procarbazine, Thalidomide+Levocetirizine/Tramadol/
Oxycodon/Morphine and Oxazepam+Procarbazine.
§  Flurouacil+Metronidazole, Claritromycine+Vinorelbine, Claritromycine+Irinotecan, 
Cyclophosphamide+Digoxin, Doxorubicine+Digoxin, Docetaxel+Metronidazole and 
Metronidazole+Paclitaxel.
Table 4: Potential drug interactions involving anticancer agents
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* Clemastine+Metoclopramide and Lorazepam+Metoclopramide
§  Clemastine+Temazepam/Oxazepam/Morphine/Codeine/Diazepam/Fentanyl/Levocetirizine/Lo-
razepam/Pregabaline/Cetirizine/Levetiracetam/Loperamide/Mirtazapine/Olanzapine/Oxycodon/
Paroxetine/Sertraline/Tramadol Metoclopramide+Fentanyl/Oxazepam/Temazepam/Levocetirizine/
Oxycodon/Amitriptyline/Diazepam/Midazolam/Mirtazapine/Zolpidem/Zopiclon/Pregabaline/Valproic 
acid Lorazepam+Temazepam/Morphine/Hydrochlorothiazide/Nitroglycerine/Oxycodon/Zopiclon 
Dexamethasone + Oxazepam
± Cyclosporine+Metoclopramide, Clarithromycin+Dexamethasone and Dexamethasone+Phenytoin
OTC=Over-The-Counte
Table 5: Potential drug interactions involving supportive care drugs
Potential drug interactions between multiple supportive care drugs
N Description Severity Scientific 
evidence
CNS-interactions* 23 Combinations of CNS-depressant drugs may 
increase the risk of falling
Moderate 2/3
Potential drug interactions between supportive care drugs and drugs to treat co-morbidities
Dexamethasone + Diclofenac/Naproxen/  
                              Rofecoxib/Indomethacin/  
                              Prednisolone [41]
25 Combinations of corticosteroids and NSAIDs may 
cause gastrointestinal toxicity
Major 2
Ondansetron + Levofloxacine/Sotalol/  
                         Amiodaron/Clarithromycin/ 
                         Flecainide [15]
14 Drugs combinations can prolong QT interval Major 2
Aprepitant + Ethinylestradiol [42] 1 Plasma concentrations and pharmacological 
effects of ethinylestradiol may be decreased
Major 3
Aprepitant + Fentanyl [43] 1 Aprepitant may increase plasma concentrations 
of fentanyl
Major 3
Fluvoxamine + Metoclopramide [44] 1 Serotonin syndrome with extrapyramidal 
movements may occur
Major 3
CNS-interactions§ 85 Combinations of CNS-depressant drugs may 
increase the risk of falling
Moderate 2/3
Coumarine + Dexamethasone/Aprepitant 
[45,46]
12 The anticoagulation effect of coumarines may be 
in/decreased
Moderate 3
Quinolones + Dexamethasone [47] 7 The risk of ciprofloxacin induced tendon rupture 
may be increased
Moderate 3
Dexamethasone + Ethinylestradiol [48] 5 Pharmacological effects of dexamethasone may 
be increased
Moderate 3
Other± 3 - Moderate 3/4
Potential drug interactions between supportive care drugs and OTC drugs
Dexamethasone + Ibuprofen/Naproxen 
[41]
14 Combinations of corticosteroids and NSAIDs may 
cause gastrointestinal toxicity
Major 2
Ginkgo biloba + Metoclopramide 1 Combinations of CNS-depressant drugs may 
increase the risk of falling
Moderate 3
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Variable Unadjusted OR 
(95% CI)
Unadjusted 
P value
Adjusted OR 
(95% CI)
Adjusted 
P value
Age 0.99 (0.97-1.01) 0.223
No. of drugs 1.41 (1.27-1.56) <0.001 1.36 (1.23-1.52) <0.001
Hospital
VU University Medical Center 1.0 (reference)
Zaans Medical Center 0.78 (0.50-1.29) 0.357
Treatment intent
Curative/adjuvant 1.06 (0.66-1.71) 0.805
Palliative 1.0 (reference)
Cancer type 0.327
Gastrointestinal 1.0 (reference)
Breast 1.92 (0.97-3.79) 0.060
Lung 1.93 (0.73-5.08) 0.186
Genitourinary 1.37 (0.52-3.63) 0.528
Gynecological 0.93 (0.35-2.46) 0.890
Other oncology 2.47 (0.79-7.69) 0.120
Haemato-oncology 1.07 (0.53-2.14) 0.859
Tumour type
Oncology 1.0 (reference)
Haemato-oncology 0.92 (0.50-1.67) 0.774
Treatment type 0.021 0.280
Chemotherapy 1.0 (reference) 1.0 (referent)
Mabs 0.37 (0.17-0.78) 0.010 0.51 (0.21-1.22) 0.130
Combinations 1.13 (0.64-1.97) 0.681 1.06 (0.56-2.00) 0.851
Presence of co-morbidities
Yes 1.0 (reference) 1.0 (referent)
No 0.50 (0.31-0.81) 0.005 0.83 (0.48-1.46) 0.833
Laboratory abnormality
Yes 1.0 (reference)
No 1.11 (0.66-1.87) 0.705
Treatment duration (months) 1.00 (0.99-1.01) 0.511
Use of ³1 OTC drugs
Yes 1.0 (reference)
No 0.42 (0.26-0.71) 0.001 0.56 (0.32-0.97) 0.045
OR= odds ratio, CI= confidence interval. Mabs=Monoclonal antibodies, OTC=Over-The-Counter
Table 6: Univariate and multivariate analyses of risk factors for the occurrence of 
potential drug interactions
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DISCUSSION
This study showed that the occurrence of PDIs in ambulatory cancer patients 
was high, with more than half of the patient group presenting with at least one 
PDI. This situation is even more alarming because one-third of the patients had 
a major PDI that may result in serious clinical consequences. The majority of 
the major and moderate PDIs were supported by scientific evidence of level 2 
or 3 (probable or suspected). We also found that 80% of the patients used OTC 
drugs, which resulted in 10% of cases with a PDI. This is particularly alarming 
because the use of OTC drugs is generally not registered either in the patient’s 
medical chart or at the community pharmacy. 
Another important finding in this study was the high prevalence of PDIs that 
may result in serious adverse events, including QT interval prolongation, GI 
toxicity, and CNS depression (falling). This has not previously been described 
in literature and is of particular concern because of the high risk of harm to the 
patients’ quality of life and increase of health care costs. 
Numerous drugs representing a wide range of pharmacological classes have 
been associated with QT interval prolongation. The possibly serious and even 
fatal consequences of drug combinations that may cause prolongation of the 
QT interval have resulted in the recommendation to avoid the prescription of 
many drug combinations.15 Due to the extensive use of QT interval prolongation 
drugs, such as quinolones, doxorubicin, and ondansetron by cancer patients, QT 
interactions may form a significant problem in (haemato-) oncology. 
Falling in elderly patients is a major public health concern. Prescribed CNS 
depressant medication is an important contributor to the risk of falling in elderly 
people and the use of multiple CNS depressant agents may even increase this 
risk.41, 42 Several commonly used drugs (e.g. psychotropic and cardiovascular 
drugs) are identified as a risk factor for falls.43-45 These CNS interactions 
may be specifically harmful in cancer patients due to the high prevalence of 
osteoporosis and thereby the risk for hip fractures.46 
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NSAIDs are frequently prescribed for pain related to cancer. However, their use 
should be restricted because of potential GI toxicity. Additional pharmacological 
risk factors for the development of NSAID-related ulcers include concomitant 
use of corticosteroids, anticoagulants, aspirin, and SSRIs.47, 48 Due to the 
extensive use of corticosteroids and anticoagulants, these PDIs are of particular 
concern in (haemato-) oncology. 
The number of drugs and the use of one or more OTC drugs were associated with 
an increased risk for the occurrence of PDIs. It is to be expected that the number 
of drugs is a determinant, simply because the number of drug combinations is 
increased. This finding is in agreement with other studies.3 The association of 
OTC drugs with the increased number of PDIs shows that these drugs are often 
involved in PDIs.
The strength of this study is the high response since all patients were willing 
to participate. In addition, the study was carried out in two hospitals. These 
factors increase the representativeness of the data. We also used an advanced 
screening method for the detection of PDIs, which led to more valuable data 
on the occurrence of PDIs. The inclusion of OTC drugs in the analysis resulted 
in findings that are unique on their own. The cross-sectional design forms 
another strength of the study. The patients were interviewed on the basis of 
their medication overview obtained from the community pharmacy and their 
medical chart, which increased the validity of the data on drugs taken. However, 
a prospective study would provide the opportunity to investigate the clinical 
consequences of PDIs. PDIs not involving an anticancer agent or a supportive 
drug were excluded in this study but may also be a subject for future analysis.
 
In conclusion, the present study shows a high prevalence of PDIs in ambulatory 
cancer patients. It is not known to what extent medical doctors were aware of 
these PDIs and whether they had made attempts to avoid a particular combination 
of drugs or took measures to prevent complications of PDIs. Buajordet et al. have 
suggested that drug interactions are responsible for the death of 4% of hospitalised 
cancer patients.2 Therefore, oncologists might largely be unaware of interactions of 
anticancer agents or supportive care drugs with medication to treat comorbidities 
or the use of OTC drugs or they may underestimate the risk of a PDI. Professional 
insight into the clinical consequences of PDIs in cancer patients is not well 
known and should be further explored. Physicians and clinical pharmacists must 
collaborate to develop a routine computer-based screening method to identify PDIs 
upon drug prescription, which includes the awareness of the use of OTC drugs.
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ABSTRACT
Introduction
Potential drug–drug interactions (PDDIs) in patients with cancer are common, 
but have not previously been quantified for oral anticancer treatment. We 
assessed the prevalence and seriousness of potential PDDIs among ambulatory 
cancer patients on oral anticancer treatment.
Methods
A search was conducted in a computer-based medication prescription system for 
dispensing oral anticancer drugs to outpatients in three Dutch centres. Potential 
drug–drug interactions were identified using electronic (Drug Interaction Fact 
software) and manual screening methods (peer-reviewed reports).
Results
In the 898 patients included in the study, 1359 PDDIs were identified in 426 
patients (46%, 95% confidence interval (CI)=42–50%). In 143 patients (16%), a 
major PDDI was identified. The drug classes most frequently involved in a major 
PDDI were coumarins and opioids. The majority of cases concerned central 
nervous system interactions, PDDIs that can cause gastrointestinal toxicity and 
prolongation of QT intervals. In multivariate analysis, concomitant use of more 
drugs (odds ratio (OR)=1.66, 95% CI=1.54–1.78, P<0.001) and genito-urinary 
cancer (OR=0.25, 95% CI=0.12–0.52, P<0.001) were risk factors.
Conclusions
Potential drug–drug interactions are very common among cancer patients on 
oral cancer therapy. Physicians and pharmacists should be more aware of these 
potential interactions.
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INTRODUCTION
Drug–drug interactions in patients with cancer are common, and most drug–
drug interactions can cause considerable adverse drug reactions (ADRs)1. In the 
general population, it has been reported that 20–30% of all ADRs are caused by 
drug–drug interactions.1 Drug–drug interactions are estimated to be the cause 
of death in ∼4% of cancer patients.2 Patients treated systemically for cancer are 
particularly at risk for drug–drug interactions. Typically, patients with cancer 
receive a high number of drugs concomitantly, including cytotoxic agents, 
hormonal agents, targeted agents, and supportive care agents among medication 
prescribed to treat comorbidities. An additional problem is that the mean age of 
cancer patients is increasing. Older patients generally have more comorbidities 
for which they also receive drug treatment.3 The risk for drug–drug interactions 
in elderly cancer patients is further increased because of altered age- and 
comorbidity-related physiologic changes (e.g., altered drug absorption due to 
mucositis or altered excretion due to renal and hepatic impairment).4
Here, a potential drug–drug interaction (PDDI) was defined as the occurrence 
of a potentially harmful combination of prescribed drugs in a given patient, 
rather than the occurrence of an actual adverse event for a patient.
In clinical practice, PDDIs can be distinguished as pharmaceutical, 
pharmacokinetic, and pharmacodynamic interactions4. Pharmaceutical PDDIs 
occur for instance when two chemically or physically incompatible compounds 
are combined (e.g., cisplatin and mesna)5. Pharmacokinetic interactions refer to 
an influence on the absorption, distribution, metabolism, or elimination of the 
drug itself or a combination of drugs. A common pharmacokinetic interaction 
concerns drugs metabolised by the cytochrome P450 (CYP) enzymes. By 
inhibition or induction of CYP iso-enzymes, blood and tumour concentrations, 
antitumoural effects, and toxicities of specific anticancer therapies may be 
altered. Other pharmacokinetic interactions may result from, that is, inhibition 
of the ABCB1 efflux-transporter (or P-glycoprotein); by altering the activity 
of ABCB1, the bioavailability of anticancer drugs may be influenced. 
Pharmacodynamic drug interactions usually occur when two or more drugs 
have a similar mechanism of action. The effect can be synergistic, additive, 
or antagonistic. Pharmacodynamic drug interactions can be beneficial (e.g., 
enhanced pharmacologic effects with fluorouracil and leucovorin), but may 
also be potentially harmful (e.g., ototoxicity with furosemide and cisplatin)6.
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In general medicine, the prevalence of PDDIs and their determinants has been 
evaluated in several studies.7-9 By contrast, data on the prevalence of PDDIs 
with anticancer drugs are scarce. Two studies, conducted in ambulatory 
cancer patients, found that 27–58% of all patients had at least one PDDI.10, 11 
Determinants for PDDIs were an increasing number of drugs, the use of OTC 
drugs, type of medication (drugs to treat comorbid conditions only), and the 
presence of brain tumours. However, these studies included only outpatients 
receiving intravenous anticancer treatment at a day-treatment facility.10, 11 
A retrospective database study, involving cancer patients on oral anticancer 
therapy, found that 5% of all patients had at least one potentially interacting 
drug combination.12
In the last decade, the availability and use of oral anticancer agents has increased 
dramatically. In comparison with parenteral treatment, the administration of oral 
agents is usually believed to be more convenient for the patient.13 However, due 
to chronic use and the fact that most anticancer drugs are metabolised by CYPs, 
patients on oral anticancer agents are at considerable risk for PDDIs.4 Moreover, 
a relative lack of collaboration between medical oncologists, pharmacists, and 
general practitioners, and the fact that computer-based medication prescription 
systems in hospitals and community pharmacies are usually not connected leads 
to PDDIs frequently going unnoticed.13
At present, epidemiological data regarding harmful PDDIs during oral 
anticancer therapy are scarce in the literature. Therefore, the aim of this study 
was to investigate the prevalence of PDDIs among ambulatory cancer patients 
on oral anticancer treatment, with the primary intent to create awareness among 
oncologists and pharmacists regarding the risk of potentially harmful drug–drug 
interactions. The secondary objective was to obtain more insight into possible 
determinants for the occurrence of these PDDIs.
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METHODS
Study design and patients
A multicentre cross-sectional study of the prevalence of PDDIs was conducted 
in ambulatory cancer patients treated with oral anticancer drugs in three Dutch 
centres: the Maastricht University Medical Center (Maastricht), St. Radboud 
University Medical Centre (Nijmegen), and Deventer Teaching Hospital 
(Deventer). All ambulatory patients with the diagnosis of a solid tumour or a 
haematological malignancy, who were receiving one of more oral anticancer 
therapies (with or without additional intravenous anticancer drugs), were 
included in the study. Exclusion criteria were (i) the use of (oral) experimental 
trial agents, (ii) age <18 years, and (iii) the use of oral anticancer drugs for non-
malignant diseases. This study was registered under number ISRCTN01739090, 
and was approved by the medical ethics boards of all three participating institutes.
Procedures
A retrospective search was conducted in the computer-based medication prescription 
system of the hospital pharmacy in these three centres for the dispensing of oral 
anticancer drugs to outpatients over a period of 12 months (between 1 October 
2010 and 1 October 2011). Medications were classified into three groups; 
‘anticancer drugs’, ‘supportive care drugs’, and ‘drugs to treat additional diseases/
comorbidities’. Anticancer drugs were defined as oncolytic drugs (Anatomical 
Therapeutic Chemical code (ATC-code) L01) and antihormonal agents (ATC-code 
L02). In addition, data on supportive care and co-medication were collected using 
the same computer-based medication prescription system of the hospital pharmacy. 
Supportive care drugs included antiemetic and analgesic drugs. Drugs for chronic 
and incidental use (e.g., dexamethasone during chemotherapy) were included in 
this study as long as they were used concurrently as was defined by Tobi et al.14 
Information concerning type of cancer and comorbidities was collected by medical 
chart review. In this study, comorbidities were defined as all other diseases an 
individual patient might have, other than the primary disease of interest (cancer).
Renal function [creatinine] and liver function parameters (aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), and γ-glutamyl-transferase (γ-GT)) were 
extracted from the laboratory database of the hospital while an individual patient 
was receiving an oral anticancer agent. Laboratory abnormalities were defined 
as an increase of >50% above the upper limit of normal (upper normal limits 
in all three medical centres: ASAT⩽35 U/L, ALAT⩽40 U/L, γ-GT⩽44 U/L, 
creatinine⩽99 μmol/L).
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Potential drug–drug interactions between drugs and over-the-counter (OTC) 
medication were not studied. When a drug formulation contained two or more 
pharmacologically active ingredients each drug was counted individually in the 
analysis (e.g., tramadol/acetaminophen). However, when a patient was taking 
the same medication in more than one formulation (e.g., long- and short-acting 
morphine) the drug was counted only once.
In this study, we have identified drug–drug combinations, within the same 
patient, for drugs that are known for having interacting effects, rather than the 
occurrence of an actual adverse event in an individual patient. Potential drug–
drug interactions were identified by using the Drug Interaction Facts software 
(Facts and Comparisons, version 4.0, 2006)15, which is a commonly used and 
reputable source. It has been shown to have an accuracy of over 95% in detecting 
interactions.16 Drug Interaction Facts software classifies interactions by the 
level of severity and the level of scientific evidence. A detailed classification of 
level of severity and scientific evidence is shown in Figure 1.
Figure 1: Classification of potential drug–drug interactions (Drug Interaction Facts15).
a Potential drug-drug interaction
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The medication regimen of each patient was also screened for:
   1    Drug combinations with potential QT-interval prolongation and/or torsades 
de pointes inducing properties using the Arizona CERT system list 1 (risk of 
torsades) and list 2 (possible risk of torsades).17 Because of the potentially 
severe consequences, all drug combinations with risk for QT prolongation 
were classified as major (QT interaction). The QT-interval prolonging 
potential of drugs is generally well documented and QT interactions were 
classified as ‘probable’ as was defined in Figure 1.
   2    Drugs associated with an increased risk of falling (central nervous system 
(CNS)-depressant agents). First, the medication regimen of each patient 
was manually screened for CNS-depressant agents by using handbooks 
and peer-reviewed reports on scientific evidence.18-23 A combination of 
two CNS-depressant agents was counted as one interaction and defined 
as CNS interaction in the analysis. All CNS interactions were classified 
as moderate. The CNS-depressant potential of drugs is described in the 
literature, and CNS interactions were classified as ‘probable’ as was 
defined in Figure 1.
   3    Drug combinations between non-steroidal anti-inflammatory drugs 
(NSAIDs) and corticosteroids, anticoagulants, aspirin, bisphosphonates, or 
selective serotonin reuptake inhibitors (SSRIs). These combinations were 
defined as a gastrointestinal (GI) interaction and were identified by using 
the Drug Interaction Facts software and peer-reviewed reports on scientific 
evidence.15, 24-26 The GI interactions may increase the risk of GI bleeding. 
Due to the potentially severe consequences all GI interactions were 
classified as major. The GI interactions are generally well documented, 
and were classified as ‘probable’ as was defined in Figure 1.
A PDDI was only counted in the analysis when an ‘anticancer agent’ or a 
‘supportive care drug’ was involved; thus, PDDIs resulting from the treatment of 
comorbidities were disregarded. Interactions of minor severity, being clinically 
not relevant, were not included in the analysis.
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Statistical analysis
To compute patient demographics, cancer type, comorbidities, number of drugs 
used per patient, laboratory abnormalities, and drug interaction characteristics 
(severity, scientific evidence, and mechanism), descriptive statistics were used. 
Subsequently, univariate and multivariate binary logistic regression analyses 
were performed to identify the potential risk factors for the occurrence of 
PDDIs. The occurrence of at least one DDI per patient was called the dependent 
variable. Predictor variables tested included age, number of drugs, presence of 
comorbidities (yes/no), cancer type, treatment type, solid tumour or haemato-
oncology disease and laboratory abnormalities. Gender was not included as a 
predictor variable as certain cancer types only occur in men or women. The 
largest group per predictor variable was taken as the reference (Ref.) for binary 
or nominal variables. In the multivariate analysis predictor, variables with 
univariate P-values <0.1 were included. Predictor variables in the multivariate 
analysis with a P-value of <0.05 were considered statistically significant. 
The data were adjusted for confounders and effect modifiers. Data were 
collected and analysed in SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS
Patient
A total of 898 patients were included in this study, with a median age of 61 years 
(range 18–95 years), of which 58% were female. The median number of drugs 
used per person was five (range 1–24 drugs). Demographic characteristics are 
listed in Table 1. In 898 patients, a total of 31 different oral anticancer drugs 
were identified as stated in Table 2.
Drug interactions
In total, 1359 PDDIs were identified in 426 patients (46%, 95% CI=42–50% 
Figure 2). In 143 patients (16%) at least one major PDDI was identified. Of all 
PDDIs, 15% and 83% were classified as major and moderate PDDIs, respectively. 
In 14% of all PDDIs, anticancer drugs were involved. A pharmacodynamic PDDI 
was found in 86% of all cases. The majority of cases concerned CNS interactions 
(n=848), GI interactions (n=97), and QT interaction (n=45). Most PDDIs (86%) 
were supported by level 2 (probable) or level 3 (suspected) scientific evidence. 
A stratification of the identified PDDIs by ‘level of severity’, ‘level of scientific 
evidence’, and ‘mechanism of drug interaction’ is listed in Figure 2.
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n %
Study population 898 100
Age in yearsa 61 (18-95) -
Sex
     Female 518 57.7
     Male 380 42.3
Hospital
     Radboud University Medical Center 463 51.6
     University Hospital Maastricht 362 40.3
     Deventer Hospital 73 8.1
Cancer type
     Solid Malignancy 766 85.3
     Haemato-oncology 132 14.7
Cancer type solid malignancy
     Breast 273 30.4
     Gastro-intestinal (GI) 257 28.6
     Genito-urinary (GU) 102 11.4
     Neurological 79 8.8
     Lung 28 3.1
     Gynaecologic 13 1.4
     Other 15 1.6
Cancer type haemato-oncology
     Leukaemia 40 4.5
     Myeloproliferative disease 36 4.0
     Malignant lymphoma 32 3.5
     Plasma cell dyscrasia 15 1.7
     Myelodysplastic syndrome 8 0.9
     Immunocytoma 1 0.1
No. of drugs used per patienta 5 (1-24) -
No. of drugs used per patient per groupa
     Oral anti-cancer agents 1 (1-3) -
     Supportive care drugsb 1 (0-9) -
     Other 2 (0-17) -
No. of co-morbidities per patienta,c 1 (0-8) -
Laboratory valuesa
      Creatinine 72 (26-568) -
      Aspartate aminotransferase 27 (4-1188) -
      Alanine aminotransferase 23 (5-845) -
      Gamma-glutamyltransferase 39 (8-1712) -
Total laboratory abnormalitiesd 110 12.2
a Median (range)
b Antiemetics and pain medication
c As we retrospectively retrieved co-morbidity data from the oncology patient  
  files the real number of co-morbidities could have been higher
d  Because of missing data, the denominator is n=690. Liver failure (94), kidney failure (14), 
combination (2)
Table 1: Demographic characteristics
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Drug class (ATC-code) Drugs (n)
Oncolytics (L01)
Alkylating agents Temozolomide (75), Chlorambucil (34), Cyclophosphamide (26), Lomustine (9), Melphalan 
(9), Procarbazine (9), Busulfan (1)
Antimetabolites Capecitabine (258), Hydroxyurea (41), Fludarabine (9), Mercaptopurine (8), Thioguanine 
(3), Uracil-Tegafur (2), Methotrexate (1)
Protein kinase inhibitors Imatinib (30), Sunitinib (27), Erlotinib (10), Dasatinib (9), Nilotinib (8), Sorafenib (4), 
Everolimus (4), Thalidomide (1)
Topoisomerase inhibitors Etoposide(19), Topotecan (1)
Other oncolytics Tretinoin (3)
Antihormonal agents (L02)
Anti-oestrogens Tamoxifen (171)
Enzyminhibitors Anastrozole (75), Letrozole (29), Exemestane (5)
Anti-androgens Bicalutamide (76), Flutamide(3)
Abbreviations: ATC code=Anatomical Therapeutic Chemical code.
Table 2: Oral anticancer drugs identified
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Table 3: Major drug-drug interactions found in the database search
Potential drug-drug interactions involving anti-cancer agents 
n Description Severity Scientific 
evidence
Tamoxifen + Ondansetron/ Granisetron/ Sotalol/ 
Erythromycin/ Levofloxacin/ Methadone/ 
Risperidone/ Azithromycina 17
28 Drug combinations can prolong QT-interval. Major 2
Coumarines + Capecitabine/Tamoxifen/ 
Etoposide27, 28
17 Hypoprothrombinemic effects of coumarines 
may be increased, bleeding may occur.
Major 2
Methotrexate + Sulfamethoxazole/ 
Trimethoprim/ Acetylsalicylic acid29, 30
12 Increased pharmacologic effects of 
methotrexate with an increased risk of bone 
marrow and hepatic toxicity.
Major 2
(Es)omeprazole + Dasatinib/Nilotinib31 4 Proton Pump Inhibitors may decrease the 
plasma concentration of Tyrosine Kinase 
Receptor Inhibitors
Major 3
Methotrexate + Prednisolone32 2 Prednisolone may decrease the total 
clearance of methotrexate.
Major 2
Methotrexate + Amoxicillin/Clavunate33 1 Penicillins may decrease the total clearance 
of methotrexate.
Major 4
Perphenazine + Tamoxifen34 1 Pharmacologic effects of tamoxifen may be 
decreased by Perphenazine Coadministration 
may increase the risk of breast cancer 
recurrence.
Major 4
Potential drug-drug interactions involving supportive care drugs 
NSAIDsb + Corticosteroidsc/ SSRIsd/  
Dipyridamole/ Clopidogel/ Alendronate24, 25
98 Increased risk of GI bleeding. Major 2
SSRI’s + Metoclopramide/ Tramadol35, 36                                         16 Serotonin syndrome is a potential risk with 
this combination.
Major 4
Fentanyl + Fluconazole/ Aprepitant/ 
Ketoconazole/ Diltiazem/Itraconazole37, 38
12 Increased pharmacologic effects and plasma 
concentrations of fentanyl
Major 2
Haloperidol + Granisetron/Metoclopramide
Ofloxacin + Methadone17
5 Drug combinations can prolong QT-interval. Major 2
Fluconazole + Methadone39 1 Increased plasma concentration and 
pharmacologic effects of methadone.
Major 4
Abbreviations: GI=gastrointestinal; NSAIDs=non-steroidal anti-inflammatory drugs;  
PDDI=potential drug–drug interaction; SSRIs=selective serotonin reuptake inhibitors.
a  References in this table are only mentioned to clarify for the identification of a PDDI.  
For a comprehensive overview of all references, go to Facts&Comparisons15
b NSAIDs: Acetylsalicylic acid, Diclofenac, Ibuprofen, Meloxicam, and Naproxen
c Corticosteroids: Budesonide, Dexamethasone, and Prednisolone
d SSRIs: (Es)citalopram, Fluoxetine, Paroxetine, and Venlafaxine
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Potential drug–drug interactions involving anticancer drugs and supportive 
care agents are listed in Table 3. As the variety of drug classes is diverse, only 
PDDIs with potentially major consequences are reported. The drug classes 
most commonly involved in major PDDIs were coumarins and opioids. The QT 
interactions and GI interactions were also observed frequently.
Figure 2: Prevalence, classification, and mechanism of potential drug interactions. 
aPotential drug-drug interactions.
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Risk factors
All patients were included in the binary logistic regression analysis. In the 
univariate analysis, the number of drugs, treatment type, cancer type, and the 
presence of comorbidities were associated with higher risk for PDDIs. No 
statistically significant association was found for age (P=0.124), tumour type 
(solid/non-solid malignancy; P=0.327), or laboratory abnormalities (P=0.295). 
Results of the univariate and multivariate binary logistic regression analyses 
are listed in Table 4. After adjustment for confounders, the number of drugs 
(odds ratio (OR) 1.66 (1.54–1.78); P<0.0001) and cancer type (genito-urinary 
cancer, OR 0.25 (0.12–0.52); P<0.0001) remained statistically significant.
Table 4: Univariate and multivariate binary logistic regression analysis
Variable Unadjusted OR 
(95% CI)
Unadjusted 
P value
Adjusted OR 
(95% CI)
Adjusted 
P value
Age 1.01 (1.00-1.02) 0.124 - -
No. of drugs 1.65 (1.54-1.76) < 0.0001 1.66 (1.54-1.78) < 0.0001a
Treatment type
Oncolytics 1.0 (Ref.) - 1.0 (Ref.) -
Antihormonal agents 0.39 (0.29-0.52) < 0.0001 0.61 (0.29-1.29) 0.196
Others 2.12 (0.79-5.66) 0.134 1.27 (0.32-5.05) 0.735
Cancer type
Breast 1.0 (Ref.) 1.0 (Ref.)
Gastrointestinal 2.35 (1.66-3.34) < 0.0001 0.65 (0.29-1.44) 0.290
Haemato-oncology 1.69 (1.10-2.58) < 0.016 0.45 (0.19-1.06) 0.067
Genito-urinary 0.53 (0.31-0.91) 0.021 0.25 (0.12-0.52) < 0.0001a
Neuro-oncological 1.32 (0.79-2.20) 0.293 0.59 (0.24-1.49) 0.264
Other oncology 2.99 (1.66-5.41) < 0.0001 1.10 (0.45-2.68) 0.832
Tumour type
Oncology 1.0 (Ref.) - - -
Haemato-oncology 1.20 (0.83-1.75) 0.327 - -
Presence of co-morbidities
No 1.0 (Ref.) - 1.0 (Ref.) -
Yes 2.06 (1.58-2.70) < 0.0001 1.02 (0.70-1.48) 0.923
Laboratory abnormality
No 1.0 (Ref.) - - -
Yes 1.24 (0.83-1.87) 0.295 - -
Abbreviations: CI=confidence interval; OR=odds ratio; Ref.=Referent
a Statistically significant
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DISCUSSION
To our knowledge, this is the first study to investigate the prevalence of PDDIs 
among cancer patients that are on oral anticancer treatment. In this analysis, we 
detected a high prevalence of PDDIs with 46% of all patients being exposed 
to at least one PDDI. More importantly, these PDDIs were not just theoretical 
in nature, 16% of all patients had at least one major PDDI that may have had 
harmful side effects and which usually would have needed intervention or 
intensive monitoring.
Most PDDIs (86%) were supported by level 2 or level 3 scientific evidence. In 
the majority of PDDIs, a supportive care agent was involved (86%). Potential 
drug–drug interactions with coumarins, whose anticoagulant effects may be 
altered, and fentanyl, through which plasma concentrations and toxicity of 
fentanyl may be increased, were most frequently registered. This also counted 
for drug combinations that may have led to QT-interval prolongation, or to GI 
toxicities. The highest prevalence concerned CNS interactions that accounted 
for up to 73% of all PDDIs.
The drug–drug combinations of coumarins with certain oral anticancer agents 
(e.g., capecitabine) may result in altered anticoagulant effects and haemorrhage 
due to the increased hypoprothrombinemic effects of coumarins.27, 28, 40 In case 
of a PDDI, anticoagulant effects should be closely monitored and the dose of 
coumarins must be adjusted accordingly. Combinations of strong CYP3A4 iso-
enzyme inhibitors/inducers and anticancer drugs can be potentially harmful.41, 
42 In this study, the combination of fentanyl and strong CYP3A4 iso-enzyme 
inhibitors (e.g., itraconazole) was frequently found. This CYP3A4 inhibitor may 
decrease the metabolic elimination of this opioid, resulting in increased plasma 
concentrations and pharmacologic effect of fentanyl. Closely monitoring for 
signs of excessive narcotic effects of fentanyl is indicated and dosage reduction 
may be required.37, 38
Drug combinations that could lead to QT-interval prolongation, or to GI 
toxicity, can have serious or even fatal consequences, like torsade de pointes 
and NSAIDs induced ulcers, respectively.17, 24, 25 Due to the extensive use of QT-
prolonging drugs (e.g., ondansetron) and drugs that can cause GI toxicity (e.g., 
NSAIDs) in (haemato)-oncology these PDDIs may cause significant health 
risks. Concerning QT interactions, there is very little information to guide 
clinicians about the risks of concomitantly using QT-prolonging drugs, and how 
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these PDDIs should be managed. Moreover, the evidence for risk of Torsades 
de point is often imperfect. Nevertheless, QT interactions are presumed to have 
the potential for life-threatening consequences. Drug–drug combinations that 
could lead to QT-interval prolongation or to GI toxicity should, if possible, be 
avoided.
The high prevalence of CNS interactions is of particular concern, since injuries 
resulting from balance disorders may have a major impact on public health. 
The authors acknowledge that a large number of cancer patients need CNS 
depressant medication (e.g., opioids, antidepressants, and benzodiazepines). 
However, due to the increased risk of osteoporosis and the extensive use of 
CNS-depressant drugs, cancer patients are particularly at risk for fractures.22 
Prescribed CNS-depressant drugs can result in an up to 47% increased risk of 
falls.43 Prescription of combinations of CNS-depressant drugs may even further 
increase this risk.21 Although combinations of CNS-depressant drugs are often 
used for therapeutic reasons, oncologists and other health-care professionals 
should minimise the number of CNS depressant drugs prescribed, or at least 
carefully assess combinations of CNS-depressant drugs and monitor for signs 
of balance disorders.
In this study, the number of drugs used concomitantly has been identified as a 
risk factor for the occurrence of PDDIs. Genito-urinary cancer showed a lower 
risk. It is not surprising that an increasing number of drugs used is associated 
with an increased risk of PDDIs and is in agreement with other studies.10, 11 
Patients with genito-urinary cancers were less likely to be exposed to PDDIs. A 
plausible explanation for this lower risk could be the relatively mild interaction 
profile of bicalutamide, which was predominately used for the oral treatment 
of prostate cancer in our studied population. However, many medical centres 
still use flutamide and nilutamide for the treatment of prostate cancer, which 
do have interacting potentials. This questions the generalisability of prostate 
cancer as a risk factor.
A great strength of this study was that the medication data in the computer-
based medication prescription system were based on ‘actual concurrent use’.14 
If an oral anticancer drug was dispensed in the hospital pharmacy, then the 
actual use of other drugs (e.g., supportive care drugs’ and ‘drugs to treat 
additional diseases/comorbidities’), both on a continuous base and an incidental 
use, was always discussed with the patient and registered in the computer-
based medication prescription system. Other strengths of our study included 
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the large multicentre sample size, cross-sectional design, use of a large variety 
of oral anticancer agents, objective identification of PDDIs based on highly 
sensitive screening software (Facts and Comparisons, version 4.0, 2006; and 
the additional screening for QT, GI, and CNS interactions).16 These factors 
increase the validity and representativeness of this study.
A major limitation of this study is that it does not investigate the clinical impact 
of the PDDIs. Although Buajordet et al estimated that PDDIs are responsible 
for the death of 4% of hospitalised cancer patients, insights into the clinical 
consequences of PDDIs in cancer patients remains largely unknown and should 
be further explored in prospective studies.2 Also, the true relevance of some 
drug–drug interactions identified by Drugs Interaction Facts software or the 
additional manual search may sometimes be questioned (e.g., NSAIDs and 
bisphosphonates or NSAIDs and SSRIs). Furthermore, it is not known to what 
extent precautions (e.g., dosage adjustments) were taken by the health-care 
professionals to prevent potentially harmful PDDIs. Since these precautions 
are not being accounted for in this study, this may lead to an over-detection of 
PDDIs by electronic PDDI databases, as was concluded by Chan et al.44 Another 
limitation of this study was that we did not study PDDIs between prescription 
drugs and OTC medication. In our previous study, OTC drugs were involved 
in 11% of all PDDIs.11 Although drug combinations with OTC drugs were not 
investigated in this study (due to the retrospective search in the computer-based 
medication prescription system), PDDIs with OTC drugs are relevant and can 
be potentially harmful.42, 45
Our findings were largely in accordance with other studies.10, 11 Conversely, a 
comparable retrospective database study, conducted in Eastern cancer patients 
using oral anticancer therapy, found that only 5% of all patients had at least one 
PDDI.12 A possible explanation for the higher prevalence of PDDIs in our study 
may be the additional search for QT, GI and CNS interactions. Nevertheless, the 
existence of potentially harmful PDDIs should not be neglected and needs the 
explicit attention of pharmacists and medical doctors.
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CONCLUSIONS
Over the past years there has been a sharp shift and focus towards oral 
anticancer drugs. The present study shows that besides their possible benefits, 
cancer patients on oral anticancer therapy are at considerable risk for PDDIs. 
It remains unknown to what extent pharmacies and medical doctors were 
actually aware of these PDDIs and whether they took adequate measures to 
prevent potentially harmful drug–drug combination. Therefore, the impact of 
the identified PDDIs on clinical outcomes remains partly unknown and should 
be further investigated in detail in future prospective studies. In the Erasmus 
University Medical Centre, a prospective clinical trial such as this to explore 
important remaining questions recently closed for patient accrual. For instance, 
the effects of duration of anticancer drug treatment and the dose of the drugs 
that may interact will be studied in detail.
This is particularly relevant as with the increasing numbers of new oral anticancer 
agents that become available, the risk for PDDIs will consequently increase. 
Despite this fact, in current daily practice medication review is not always 
common practice. We realise that many combinations of interacting drugs are 
unavoidable and may be administered together if appropriate precautions are 
taken (e.g., monitoring and dosage adjustment). However, this requires a solid 
medication review of all drugs used at every patient visit by an oncologist or 
pharmacist. Therefore, in an ideal situation, all drugs prescribed by oncologists, 
general practitioners, and other health-care professionals should be documented 
electronically, including patient’s medical status, in computer-based patient 
records to identify and prevent potentially harmful PDDIs.
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ABSTRACT
 
Introduction
Drug–drug interactions (DDIs) are of major concern in oncology, since cancer 
patients typically take many concomitant medications. Retrospective studies 
have been conducted to determine the prevalence of DDIs. However, prospective 
studies on DDIs needing interventions in cancer patients have not yet been carried 
out. Therefore, a prospective study was designed to identify DDIs leading to 
interventions among ambulatory cancer patients receiving anticancer treatment. 
Methods
Patients starting with a new treatment regimen with i.v. or oral anticancer 
medication were asked to participate. The patients’ medication was checked 
for DDIs by using drug interaction software. An expert team of clinical 
pharmacologists evaluated the relevance of these identified DDIs. If a 
DDI was qualified as potentially clinically relevant, an intervention was 
proposed to the treating (hemato)oncologist. Several variables were studied 
as determinants for performing an intervention. Descriptive statistics 
and uni- and multivariate logistic regression analyses were carried out. 
Results
In this study, 302 patients were included. A total of 603 DDIs were identified by the 
drug interaction software and judged by the expert team. Of all 603 DDIs, 120 DDIs 
were considered potentially clinically relevant. These 120 DDIs, present in a total 
of 81 patients, resulted in a clinical intervention already executed by the (hemato)
oncologist in 39 patients (13%), while an additional intervention was proposed 
by a clinical pharmacologist in 42 patients (14%). The number of comorbidities 
and the number of ‘over-the-counter’ drugs were identified as determinants. 
Conclusions
Clinical interventions on DDIs are frequently required among patients starting 
with anticancer therapy. Structured screening for these potentially clinically 
relevant DDIs, by (hemato)oncologists in close collaborations with clinical 
pharmacologists, should take place before the start and during anticancer treatment.
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INTRODUCTION
Drug–drug interactions (DDIs), defined as the occurrence of a harmful 
combination of prescribed drugs in a given patient, are preventable medication 
errors associated with serious or even fatal adverse events.1 In vivo DDIs 
can be classified into two groups: pharmacokinetic and pharmacodynamic 
DDIs.2 In pharmacokinetic DDIs, the pharmacokinetic properties (absorption, 
distribution, metabolism or excretion) of a certain drug are altered by another 
drug. In pharmacodynamic DDIs, an additive, synergistic or antagonistic effect 
occurs when two drug are used concomitantly (e.g. fluorouracil and leucovorin).
DDIs are of major concern in oncology, since patients typically use many drugs 
beside their anticancer therapy.3, 4 In addition, most anticancer drugs are potent 
and toxic drugs with a narrow therapeutic index.5 Remarkably, in most countries, 
cancer patients are not routinely checked for DDIs. Despite these concerns, 
only three retrospective studies have been conducted on the prevalence of 
DDIs involving anticancer drugs.3, 4, 6 Two of these studies were conducted in 
ambulatory cancer patients receiving i.v. anticancer treatment and, in these 
studies, it was concluded that 27%–58% of all patients had at least one DDI.4, 6 
Comparable results were found in a multicenter study on ambulatory cancer 
patients treated with oral anticancer medication.3 Several studies also identified 
determinants for DDIs in anticancer therapy: the number of co-medications, 
the use of over-the-counter (OTC) drugs, the type of (anticancer) medication 
and the presence of certain tumors were associated with the occurrence of 
DDIs.3, 4, 6 However, due to the retrospective setting of these studies, it is 
unknown whether these DDIs were true medication errors, or if these DDIs 
represented drug–drug combinations selected intentionally by the (hemato)
oncologist (and handled e.g. by intensive monitoring). Therefore, a prospective 
study was designed to identify DDIs leading to clinical interventions among 
ambulatory cancer patients starting a new oral and/or i.v. anticancer regimen. 
The secondary objective of this study was to obtain more information on 
potential determinants for DDIs leading to interventions.
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METHODS
Study design and patients
A prospective intervention study was designed for patients treated with anticancer 
drugs at the Erasmus MC Cancer Institute (Rotterdam, The Netherlands). All 
patients treated in the outpatient department with oral or i.v. anticancer drugs, 
starting a new regimen between April 2013 and February 2014, were asked to 
participate. Exclusion criteria were: age <18 years, language barrier and the use 
of anticancer drugs for nonmalignant disease. This study was approved by the 
medical ethics committee of the Erasmus Medical Center.
Procedures
Patients were asked to participate in this study before the start of a new treatment 
regimen of anticancer therapy. Data on demographic characteristics, use of co-
medication, OTC drugs, relevant consumption of food (supplements), such as 
grapefruit juice, and comorbidities were collected in a structured interview with 
the patient. To help identify the actual use of the co-medication, a 6-month 
overview of prescribed medication was collected from the community pharmacy. 
Data on the use of anticancer drugs, supportive care drugs, diagnosis and 
treatment intent (palliative/curative) were collected by medical chart review. 
Patients were also asked if the medical oncologist had already conducted a 
medication-related intervention on the day of the last outpatient visit.
The types of medication were subdivided into four categories: ‘anticancer 
drugs’, ‘supportive care drugs’, ‘drugs to treat comorbidities’ and ‘OTC drugs 
[including food (supplements)]. Anticancer drugs were defined as all cytostatic, 
antihormonal and targeted drugs to treat malignancies, while supportive care 
drugs were defined as all drugs supporting the anticancer treatment (e.g. 
antiemetics). Drugs to treat comorbidities were defined as all agents used for 
noncancer disease. OTC drugs included all (herbal) drugs, food (supplements) 
and vitamins that were used without prescription at the time of the interview. 
Drugs were counted as pharmacologically active components. If one formulation 
contained multiple pharmacologically active ingredients, these ingredients were 
each counted individually in the analysis. When a drug was taken in different 
dosages or administration routes, it was counted as one drug. 
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Following the interview, the patient’s medication was checked for DDIs by 
use of the Micromedex drug–drug interaction software program.7 To maximize 
accuracy, an additional medication review was conducted by using a second 
drug–drug interaction software program ‘www.drugs.com’.8 
DDIs were classified by mechanism in three major groups: pharmacokinetic 
DDIs, pharmacodynamic DDIs and DDIs with unknown mechanisms. 
Pharmacodynamic DDIs were subdivided into: (i) central nervous system (CNS) 
interactions, defined as combinations of drugs associated with drowsiness an 
increased risk of falling, (ii) QTc interactions, defined as drug combinations 
with potential QTc interval prolongation and/or Torsades de pointes inducing 
properties, (iii) Gastrointestinal (GI) interactions, defined as drug combinations 
that may increase the risk of GI-bleeding and (iv) Other pharmacodynamic 
DDIs. 
DDIs found in either one or both databases were counted once in the analysis. 
A DDI was only included in the analysis when either an ‘anticancer drug’ or 
a ‘supportive care drug’, as defined above, was involved. An overview of the 
patient’s demographic characteristics, comorbidities and identified DDIs, was 
sent to an expert team consisting of three certified clinical pharmacologists. 
The expert team members first assessed the DDI lists for the need to intervene 
in a certain DDI based on the used medication and the individual characteristics 
of the patient. If the individual advices of the expert team were inconsistent, 
consensus had to be reached. If a DDI was identified as needing an intervention, 
an advice on how to manage this DDI was sent to the (hemato)oncologist in 
charge of the patient. In close collaboration with the expert team, the (hemato)
oncologist responsible for the patient, decided whether to carry out the proposed 
intervention. If an intervention was carried out, the DDI was considered to be 
potentially clinically relevant (Figure 1).
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Figure 1: Study flowchart
*Committee: expert team consisting of three clinical pharmacologists
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Statistical analysis
Descriptive statistics were used to analyze the patients’ demographics, cancer type, 
comorbidities, number of drugs and DDI characteristics. Univariate and multivariate 
binary logistic regression analyses were used to identify potential determinants for 
DDIs leading to interventions. The dependent variable was ‘the occurrence of at least 
one intervention per patient by the expert team’ and predictor variables included age, 
number of drugs, number of OTC drugs, tumor type, treatment intent, type of therapy 
and number of comorbidities. Predictor variables with univariate P values <0.05 
were stepwise included in the multivariate analysis. When the predictor variable 
changes the β coefficient with >10%, it was included in the multivariate model.
The primary end point in this exploratory study was the percentage of clinical 
intervention due to DDIs. It was estimated that DDIs would led to an intervention 
in 8% of all ambulatory cancer patients. With a sample size of 300 patients and an 
estimated intervention percentage of 8%, the 95% confidence interval for assessment 
of this percentage would be 5%–12%.
RESULTS
Patient characteristics
A total of 368 patients were asked to participate, of which 302 patients (82%) were 
included in this study (Figure 1). The mean age was 61 years (range 22–84 years) 
and half of all patients were male (Table 1). In total, 87% of the patients were 
diagnosed with a solid malignancy of which gastrointestinal, breast and genito-
urinary malignancies were most frequently seen. The median number of drugs 
used per patient was 10 (range 1–25) and 81% of all patients used at least one OTC 
drug. The median number of comorbidities per patient was 1 (range 0–7) and 57% 
of all patients suffered from at least one comorbidity.
Drug-drug interactions
In total, 603 DDIs were identified and assessed for the need for interventions (Table 
2). Of all DDIs, 120 DDIs with a wide variety of pharmacological classes, were 
considered potentially clinically relevant. These 120 DDIs, present in a total of 
81 patients, resulted in a clinical intervention already executed by the (hemato)
oncologist in 39 patients (13%, see Figure 1), while an additional intervention 
was proposed by a clinical pharmacologist in 42 patients (14%). The (hemato)
oncologist executed all interventions (100%) that were proposed by the expert 
team. On the other hand, all interventions already executed by the (hemato)
oncologist where retrospectively judged as potentially clinically relevant by the 
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n %
Study population 302 100
Age (years)a 61 (22-84) -
Sex
     Male 152 50.3
     Female 150 49.7
No. of comorbidities per patientb 1 (0-7) -
Cancer type
     Solid malignancy 264 87.4
     Haemato-oncology 38 12.6
Cancer type solid malignancy
     Gastrointestinal (GI) 121 40.1
     Breast 58 19.2
     Genito-urinary (GU) 29 9.6
     Gynaecologic 17 5.6
     Neurological 14 4.6
     Other 25 8.3
Cancer type haemato-oncology
     Malignant lymphoma 21 7.0
     Plasma cell dyscrasia 11 3.6
     Leukaemia 4 1.3
     Myelodysplastic syndrome 2 0.7
Treatment intent
     Palliative 151 50.0
     Curative 151 50.0
Cancer treatment
     Chemotherapy 153 50.7
     TKIs/mTORi 21 7.0
     mABs 13 4.3
     Anti-hormonal therapy 2 0.7
     Combinationc 113 37.3
No. of drugs used per patientb 10 (1-25) -
No. of drugs used per patient per groupb
     Anti-cancer agents 2 (1-6) -
     Supportive care drugs 3 (0-7) -
     Drugs for comorbidities 4 (0-15) -
     OTC and herbal drugsd 1 (0-9) -
a Mean (range). 
b Median (range). 
c Combination anticancer drugs and/or radiotherapy. 
OTC drugs= over-the-counter drugs.
Table 1: Baseline characteristics of patients included in the study
110
expert team. Coumarins, corticosteroids and NSAIDs were frequently involved in 
the interventions. Also OTC drugs, herbal substances and food supplements (e.g. 
grapefruit juice) were extensively used and frequently involved in a DDI leading to 
an intervention. Interestingly, none of the identified CNS interactions (n = 187) was 
considered to require an intervention by the expert team nor by the treating (hemato)
oncologist. In one case, a DDI (mercaptopurine and allopurinol) was identified by 
the drug interaction software program and scored as potentially clinically relevant 
by the expert team. Due to unfortunate logistic problems, the hemato-oncologist 
was informed only after 7 days. Despite an intervention, the patient developed bone 
marrow suppression, which recovered without sequela. An overview of all DDIs 
with an intervention conducted is given in Table 3 and Table 4, respectively.
DDIs n %
Total no. 603 100
Drug interaction mechanism
     Pharmacodynamic 407 67.5
          CNS-interaction 187 31.0
          QT-interaction 110 18.2
          GI-interaction 81 13.5
          Other pharmacodynamics interaction 29 4.8
     Pharmacokinetic 126 20.9
     Unknown 70 11.6
DDIs with an intervention n %
Total no. 120 19.9a
Drug interaction mechanism 
     Pharmacodynamic 52 8.6
          QT interval prolongation 10 1.7
          GI interaction 26 4.3
          Other pharmacodynamics interaction 16 2.6
     Pharmacokinetic 34 5.6
     Unknown 34 5.6
Number of patients ≥1 intervention n %
Carried out by the medical oncologist:
     Based on recommendation of clinical pharmacologists 42 13.9b
     On own initiative of medical Oncologist 39 12.9b
a Denominator is 603 DDIs b Denominator is 302 patients
Table 2: Identified drug–drug interactions (DDIs) and drug–drug interactions with 
an Intervention
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n Description Intervention
Drug interactions involving anticancer agents 
    Chemotherapeutics + 
    Herbal substancesa
14 The influence of herbal substances on 
chemotherapeutics is unknown, but may 
be harmful
Stop herbal substances on 
theoretical basis 
    Chemotherapeutics + 
    Immunosuppressanta 
4 Concomitant use of Immunosupressants 
and chemotherapeutics may have 
an undesired additional effect on 
immunosuppressive load
Stop immunosuppressant 
on theoretical basis
    Coumarinsa +  Imatinib/ Everolimus/  
    Paclitaxel/ Irinotecan 9
4 Chemotherapy-induced protein 
displacement and inhibition of coumarins 
metabolism with higher risk of bleeding
Intensify INR monitoring 
    Pazopanib + Antacid 10 1 Exposure to pazopanib may be decreased Stop antacid
    Chemotherapeutics + 
    Valproic acid 
1 Valproic acid may cause future drug-drug 
interactions in cancer patients
Replace valproic acid
Drug interactions involving supportive care drugs
    Corticosteroidsb + NSAIDsc 11 18 Combination may result in increased risk 
of GI ulcerations or bleeding
Add PPI and/or stop NSAID
    Acenocoumarol + Dexamethasone/  
    Ranitidine 9,12
4 Combination may result in increased 
risk of bleeding or diminished effect of 
coumarins
Additional INR monitoring
Table 3: Interventions on drug-drug interactions performed by the medical 
oncologist on own initiative
Abbreviations: INR=international normalized ratio; ECG=electrocardiogram; GI=gastro-intestinal; 
PPI=proton pump inhibitor; TDM=therapeutic drug monitoring; NSAID: non-steroidal anti-inflam-
matory drug.
a DDIs on theoretical bases, no reference available
b Corticosteroids: dexamethasone and prednisolone
c NSAIDs: Acetylsalicylic acid, ibuprofen, naproxen and diclofenac
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n Description Intervention
Drug interactions involving anticancer agents 
    Grapefruit + Cyclophosphamide/ 
    Vinblastine/ Doxorubicin/ Vincristine/ 
    Docetaxel 9
13 Grapefruit may increase the 
plasma concentrations of these 
chemotherapeutics by CYP3A4 inhibition
Stop grapefruit
    Coumarinsa + Carboplatin/
    Doxorubicin/ Bortezomib 9
7 Chemotherapy-induced protein 
displacement and inhibition of coumarin 
metabolism with higher risk of bleeding
Intensify INR monitoring 
    Capecitabine + Herbal substancesb,c 5 The influence of herbal substances on 
capecitabine is unknown, but may be 
harmful.
Stop herbal substances on 
theoretical basis 
    Doxorubicin + Sotalol/ Granisetron/ 
    Ondansetron;  Sunitinib + Sotalol 14
4 Additive QT-prolongation may occur ECG monitoring
    Corticosteroidsd + Tiaprofenic acid/ 
    Ibuprofen/ Acetylsalicylic acid 11
3 Combination may result in increased risk 
of GI ulcerations or bleeding
Add PPI
    Pazopanib + Antacid 10 2 Exposure to pazopanib may be decreased Stop antacid
    Carbamazepine + Paclitaxel 15 1 CYP3A4 inducing properties of 
carbamazepine may lead to a decreased 
exposure to paclitaxel
TDM of carbamazepine
    Diltiazem + Paclitaxel 15 1 CYP3A4 inhibition of diltiazem may lead 
to an increased plasma concentration of 
paclitaxel
Inform oncologist about this 
interaction
    Imatinib + Simvastatin 16 1 Imatinib may increase the plasma 
concentrations of simvastatin by 
inhibiting CYP3A4
Replace simvastatin by pravastatin
    Allopurinol + Mercaptopurine 17 1 Toxicity (bone marrow suppression) may 
be increased
Replace allopurinol
    Vincristine + Fluconazole 18 1 Exposure to vincristine may be increased Replace fluconazole
    Irinotecan + Magnesium citrate 19 1 Irinotecan causes diarrhea in the majority 
of treated patients. Using a laxative 
might therefore be unfavorable
Stop magnesium citrate
    Methotrexate + Naproxen 20 1 May result in increased plasma 
concentrations of methotrexate and 
increased methotrexate toxicity
Stop naproxen
Table 4: Drug-drug interactions leading to interventions based on recommendation 
by clinical pharmacologists
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Table 4: Continued
n Description Intervention
Drug interactions involving supportive care drugs
    Corticosteroidsc + NSAIDse  11 5 Combination may result in increased risk 
of GI ulcerations or bleeding
Add PPI
    Dexamethasone + Grapefruit 21 9 Induction of CYP3A4 may lead to changes 
in dexamethasone plasma concentrations
Stop grapefruit on theoretical basis 
    Dexamethasone + Blood glucose 
    lowering agentsf  22
6 The hyperglycemic effects of 
dexamethasone may interfere with blood 
glucose control
Recommend close clinical 
monitoring of glycemic control.
    Anti-emeticsg +Flecainide/ Sotalol/
    Quetiapine 14
6 Additive QT-prolongation may occur ECG monitoring
    Acenocoumarol + Corticosteroidsd/  
    Ranitidine 9
5 Combination may result in increased 
risk of bleeding or diminished effect of 
coumarins
Additional INR monitoring
    Dexamethasone + Echinacea 24 1 Effectiveness of dexamethasone may be 
decreased
Stop Echinacea
INR=international normalized ratio; ECG=electrocardiogram; GI=gastro-intestinal; PPI=proton pump 
inhibitor; TDM=therapeutic drug monitoring; NSAID: non-steriodal anti-inflammatory drug.
a Coumarins: fenprocoumon and acenocoumarol; b Herbal substances: Camu camu, Bitter melon, 
Curcuma, Graviola, Catsclaw; c DDIs on theoretical bases, no reference available; d Corticosteroids: 
dexamethasone and prednisolone;e NSAIDs: Acetylsalicylic acid, ibuprofen and naproxen; f Blood 
glucose lowering agents: insulin, metformin and glimepiride; g Anti-emetics: granisetron, ondansetron
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Potential risk factors
Binary logistic regression was used to assess potential determinants for 
performing an intervention. An overview is given in Table 5. In the univariate 
binary logistic regression analysis, number of comorbidities, number of drugs, 
number of OTC drugs and tumor type were associated with an increased risk for 
DDIs leading to an intervention. No association was found for age, treatment 
intent and treatment type. In the multivariate binary logistic regression analysis, 
number of comorbidities [odds ratio (OR) 1.40 (95% confidence interval (CI) 
1.00–1.96)] and number of OTC drugs [OR 1.41 (95% CI 1.13–1.78)] remained 
statistically significant.
Determinant Unadjusted OR
(95% CI)
Unadjusted 
P value
Adjusted OR 
(95% CI)
Adjusted
P value
Age 0.99 (0.96-1.02) 0.371
No. of comorbidities 1.47 (1.12-1.93) 0.006 1.40 (1.00-1.96)∑ 0.048*
No. of drugs 1.14 (1.06-1.24) 0.001 1.03 (0.93-1.14)π 0.590
No. of OTC drugs 1.42 (1.16-1.74) 0.001 1.41 (1.13-1.78)¥ 0.003*
Tumour type
     Oncology 1.00 (reference)
     Haemato-oncology 2.59 (1.15-5.83) 0.022 2.50 (0.99-6.34)α 0.053
Treatment intent
     Palliative 1.00 (reference)
     Curative 1.40 (0.72-2.70) 0.320
Treatment type
     Chemotherapy 1.0 (reference)
     TKIs/mTORi 1.05 (0.28-3.87) 0.944
     Combination 1.19 (0.60-2.36) 0.616
Table 5: Univariate and multivariate logistic analysis of determinants for performing 
an intervention
*statistically significant
∑ Adjusted for No. of drugs, No. of OTC drugs and Tumour Type
π Adjusted for No. of comorbidities, No. of OTC drugs and Tumour Type
¥ Adjusted for No. of comorbidities and Tumour Type
α Adjusted for No. of comorbidities and No. of OTC drugs
No.= number
OTC drugs= over-the-counter drugs
TKIs= tyrosine kinase inhibitors
mTORi= mammalian Target Of Rapamycin inhibitors
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DISCUSSION
To our knowledge, this is one of the first studies that prospectively investigated 
the need for interventions due to DDIs in oncology. In total, 120 DDIs were 
considered to be potentially clinically relevant. More importantly, next to the 
intervention already carried out by the (hemato)oncologists themselves, this 
resulted in additional interventions proposed by the clinical pharmacologist in 
42 patients (14%).
The prevalence of DDIs is largely in accordance with similar studies.3, 4, 6 A 
possible explanation for the relatively high median number of drugs used by 
the patients in our study might be the inclusion of herbal and other OTC drugs 
and the inclusion of both oral and i.v. anticancer drugs. A prospective study 
that looked into DDIs affecting anticancer agents concluded that the frequency 
of pharmacokinetic DDIs that were associated with a published clinical effect 
was low. However, they solely screened for pharmacokinetic DDIs and the 
study methods and population was highly different from the current study (e.g. 
different drug interaction software used, no tyrosine kinase inhibitors included 
and different tumor types) which may explain the relative low percentage of 
relevant DDIs in that study.9 
Coumarins and GI interactions (especially the combination of corticosteroids with 
NSAIDs), where frequently involved in an intervention, as were combinations 
of drugs that are known to cause QTc interval prolongation. Coumarins, which 
are routinely used for the treatment of thrombosis, are highly prone for DDIs 
with anticancer drugs. In case of a DDI between coumarins and anticancer 
drugs, the anticoagulant effect may be altered and a clinical intervention (by 
intensified monitoring of the anticoagulant effect and possible dose adjustment) 
is recommended. Also, NSAIDs and corticosteroids are extensively used in 
(hemato)oncology. When used concomitantly, gastrointestinal ulcerations or 
bleedings may occur and, based on patient characteristics and risk factors, 
an intervention (e.g. adding a proton pump inhibitor) is often required.10 
Combinations of QTc interval prolonging drugs are also frequently seen in 
(hemato)oncology practice. The risk of QTc interval prolongation increases 
by the concomitant use of more QTc interval prolonging drugs and by CYP 
inhibition due to another drug. Especially antiemetics (e.g. domperidone and 
5HT3-antagonists) and certain anticancer drugs (tamoxifen, tyrosine kinase 
inhibitors and anthracyclines) have the capacity to prolong the QTc interval.
11 
Although rare, these drug combinations can lead to QTc interval prolongation 
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and Torsades de pointes; and may therefore have severe consequences. ECG 
monitoring is recommended 24–48h before, and 1 week after, the start of the 
concomitant use of QTc interval prolonging drugs.
2
In accordance with previous studies, the prevalence of drug combinations, 
with the ability to increase the risk of falling (CNS interactions), was high in 
this study.3, 4 Since co-administration of multiple central nervous depressant 
drugs is frequently seen and cancer patients already have an increased risk 
of fractures due to osteoporosis, one might expect that some of these CNS 
interactions were identified as potentially clinically relevant. Nevertheless, 
none of these CNS interactions were identified as such by the expert group. A 
possible explanation might be that in most cancer patients, in a certain stage of 
their disease, the benefits of central nervous depressant drugs, (e.g. morphine or 
benzodiazepines) in order to treat therapy- and disease-related side-effects, are 
considered to outweigh the increased risk of falling. However, withdrawal from 
central nervous depressant drugs may be an effective method in the prevention 
of falling.12 In the future, the rational use of multiple central nervous depressant 
drugs in (hemato)oncology should be determined.
In order to increase accuracy, two web-based databases were used in this study 
to identify DDIs.7, 8 Although Micromedex has proven to be highly accurate, 
a more sensitive detection of QTc, GI and CNS interactions was seen when 
‘Drugs.com’ software was used concomitantly.13 On the other hand, ‘drugs.
com’ software is random in identifying other DDIs than QTc, GI and CNS 
interactions, which results in the detection of many irrelevant DDIs. Therefore, 
we recommend for future studies to use Micromedex as the basis for detecting 
DDIs, with additional screening for QTc, GI and CNS interactions by the ‘Drugs.
com’ software. Even then, many clinically irrelevant DDIs will be detected, so 
more specific screening tools need to be developed. Clinical rules, combining 
DDIs with patient data (such as renal function) may be helpful.14 
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The number of comorbidities and the number of OTC drugs used concomitantly 
with anticancer drugs were identified as potential determinants for performing 
an intervention. This is consistent with other studies and not surprising since 
(hemato)oncologists are often not aware of the use of OTC drugs (such as 
complementary and alternative medicine) and that these drugs are extensively 
used by cancer patients and frequently involved in DDIs.4, 5, 15 Surprisingly, the 
number of concomitantly used drugs was not identified as a determinant. This 
may be caused by the fact that the number of concomitantly used drugs and the 
number of comorbidities are usually highly correlated in multivariate analyses. 
A strength of our study is that, for the first time, DDIs leading to an intervention 
by clinical pharmacologists were prospectively studied in cancer patients. Based 
on the actual concurrent medication used by the patient, a profound assessment 
was made whether to intervene or not. Also, the inclusion of OTC drugs in the 
analysis was important. OTC drugs are frequently used by cancer patients, are 
often involved in DDIs and might lead to harmful side-effects.4, 15 
One of the limitations of this study is the lack of a control group. Due to the 
fact that we did not include a group in whom DDIs were identified but not 
reacted upon, it is not possible to assess whether or not the interventions 
averted any adverse drug events. More research is necessary to fully explore 
the effect of DDIs on adverse drug events and clinical outcome (e.g. to compare 
hospitalization rates). Furthermore, therapeutic drug monitoring (TDM), where 
blood drug concentrations and pharmacokinetic parameters are matched with 
pharmacodynamics (such as toxicity and clinical outcome) is a possible way to 
investigate the true clinical relevance of DDIs in oncology. The implementation 
of TDM in oncology should be further explored.5 
Screening of DDIs by a clinical pharmacologist doubled the number of clinical 
interventions that were already executed by a medical oncologist. Cancer 
patients are often treated multidisciplinary and a sound overview of all (newly) 
prescribed drugs, including OTC drugs, is not always available. Subsequently, 
documenting all drugs, including OTC drugs in one electronic patient record and 
close collaboration between (hemato)oncologists and clinical pharmacologists, 
is necessary to facilitate a profound medication review. 
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In this study, the prevalence of DDIs that need intervention is high. To maximize 
safe and effective concomitant drug use, the Erasmus MC cancer Institute 
is currently implementing medication review, before and during anticancer 
therapy, in clinical oncology practice for all patients. 
In conclusion, the present prospective study shows that, next to the intervention 
already carried out by the (hemato)oncologists, in 14% of patients, interventions 
were carried out based on recommendations of clinical pharmacologists. As the 
complexity of prescription process increases, more specific screening tools for 
the detection of DDIs are necessary, in order to increase the efficiency and 
cost-effectiveness of the medication review by clinical pharmacologists and 
(hemato)oncologists. The results of this study will help physicians and clinical 
pharmacologists to be more aware of DDIs in (hemato)oncology and should 
lead to a closer collaboration to identify and manage these DDIs before the start 
and during anticancer treatment.
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ABSTRACT
Introduction
Erlotinib is dependent on stomach pH for its bioavailability. When erlotinib 
is taken concurrently with a proton pump inhibitor (PPI), stomach pH will 
increase, resulting in a clinically relevant decrease of erlotinib bioavailability. 
In this study, we hypothesized that this drug-drug interaction (DDI) could be 
reversed by taking erlotinib with the acidic beverage cola. Also in patients 
without a PPI, effects of cola on erlotinib bioavailability were studied.
Methods
In this randomized cross-over pharmacokinetic study in non-small cell lung 
cancer (NSCLC) patients, we studied intra-patient differences in absorption 
(AUC0-12h) after a 7 day period of concomitant treatment of erlotinib, with or 
without esomeprazole, for 7 days with either Coca-Cola Classic or water. At the 
7th and 14th day, patients were hospitalized during 1 day for PK sampling.
Results
Twenty-eight evaluable patients were included in the analysis. In the patients 
taking erlotinib and esomeprazole with cola, the mean AUC0-12h increased with 
39% (range -12% up to +136%; P=.004) whereas in patients without a PPI, the 
mean AUC0-12h was only slightly higher (9%; range -10% up to +30%, P=.03) 
after erlotinib intake with cola.
Conclusions
Cola generated a clinically relevant and statistically significant increase in 
the bioavailability of erlotinib during esomeprazole treatment. In patients not 
taking a PPI, the effects of cola were marginal. These findings can be used to 
optimize the management of drug-drug interactions between PPIs and erlotinib.
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INTRODUCTION
Erlotinib is an oral reversible tyrosine kinase inhibitor (TKI) of the epidermal 
growth factor receptor (EGFR) effective in non-small cell lung cancer 
(NSCLC). The advantage of the oral administration route of erlotinib causes a 
highly relevant new problem. The gastrointestinal absorption of erlotinib is a 
complex multifactorial process which is characterized by a poor and variable 
bioavailability, resulting in significant intra- and intersubject variability in 
exposure.1 One of the most important factors that influences erlotinib absorption 
is intragastric pH.2,3 Because of its weakly basic properties, erlotinib can be 
present in either the ionised and non-ionised form, depending on the intragastric 
pH. In case of an elevation in intragastric pH the equilibrium shifts towards 
the less soluble non-ionised erlotinib form and drug absorption will decrease. 
The concomitant use of acid reducing agents such as proton pump inhibitors 
(PPIs) therefore leads to a clinically significant drug-drug interaction (DDI) 
with erlotinib.2-5 In a study with healthy volunteers, the concurrent use of the 
PPI omeprazole significantly reduced the AUC and Cmax of erlotinib with 46% 
and 61% respectively.6 As a result, the product label of erlotinib states that 
PPIs should not be taken concurrently with erlotinib. Recently, the concomitant 
use of erlotinib and acid suppressive agents was shown to be associated with 
decreased erlotinib efficacy in NSCLC patients.5 Since a PPI is often indicated 
during erlotinib therapy, pharmacists and medical oncologists are confronted 
with challenges.2,7
A solution for managing this DDI is not yet available. A practical way to by-pass 
the DDI between erlotinib and PPIs could potentially be to temporarily lower 
the stomach pH by taking erlotinib with an acidic beverage, such as cola. The 
classic form of this beverage has a pH of 2.5, leading to a temporary decrease 
of the stomach pH after intake. Other studies have shown that the absorption 
of weakly basic drugs, such as ketoconazole and itraconazole, was enhanced 
when taken concomitantly with Coca-Cola.8,9 Due to similar physicochemical 
basic properties, we hypothesize that this positive effect could also be the 
case with erlotinib. In this study we therefore evaluated the impact of cola on 
the absorption of erlotinib (with and without esomeprazole) in patients with 
lung cancer.
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METHODS
Study design and procedures
This is an open label, two-way, randomized, cross-over study in patients taking 
erlotinib for NSCLC. This study was performed at the Erasmus MC Cancer 
Institute in Rotterdam, the Netherlands, between March 2014 and June 2015. 
This study was approved by the medical ethics committee of the Erasmus 
Medical Center (MEC14-046) and was registered at www.trialregister.nl under 
number NTR4540.10 A total of 28 patients on steady state erlotinib therapy were 
allocated to one of two study groups of 14 patients (study groups 1 and 2, see 
Figure 1). Study group 1 received erlotinib (Tarceva®; at any dose, day 1-14, at 
10 AM) taken with 250 mL Coca-Cola Classic® or 250 mL water. Study group 2 
received erlotinib (Tarceva®; day 1-14, at any dose, at 10 AM) and esomeprazole 
40 mg (Nexium®; day 5-7 and 12-14, 7 AM) taken with 250 mL Coca-Cola 
Classic® or 250 mL water. After allocation to one of the study groups patients 
were randomized into 2 sequence arms (arm A and B, n=7). Sequence arm A 
first took erlotinib with water (for 7 days) followed by Coca-Cola Classic® 
(for 7 days). Arm B took Coca-Cola Classic® and water in the reversed order. 
On days 7 and 14, patients were admitted for 24-hours into the hospital for PK 
sampling (for study design, see Figure 1). Before signing informed consent, 
the use of interacting co-medication, (over-the-counter) OTC-drugs, herbal/
food supplements were collected in a structured anamnesis with the patient. 
Figure 1: study design
Erlotinib (at any dose); QD
On day 1-28
Study group 1 and 2
Esomeprazole 40mg; QD
On day 19-21 and day 26-28
Study group 2 only!
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Figure 1: study design
PK= pharmacokinetic sampling day
Erlo= erlotinib
*Coca-Cola Classic®
Depending on sequence arms: A→B or B→A
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Medication used by the patient was assessed for drug-drug interactions by using 
the drug-drug interaction software program Micromedex.11 To ensure steady 
state concentrations, patients had to use erlotinib for a minimum of 14 days 
before entering the study. In study group 2, once daily 40 mg esomeprazole 
was given (for at least) 3 days before both PK-sampling days (3 hours before 
erlotinib intake) in order to achieve maximum elevation in intragastric pH.12,13 
Also patients who were using PPIs chronically before entering the study 
were allowed to participate into the study as long as they were willing to use 
esomeprazole 40 mg (Nexium®) for 3 consecutive days before both PK sampling 
days according to the protocol. Patients underwent an overnight fast before both 
PK days. On both PK-days, erlotinib was taken in the hospital. Since this was a 
study population of regular lung cancer patients with an indication for an EGFR 
TKI, erlotinib dose reductions due to toxicity were allowed. Patient compliance 
was assessed using a patient diary.
Eligibility
Eligibility criteria included patient age ≥ 18 years with histological or 
cytological confirmed diagnosis of lung cancer for which treatment with 
erlotinib monotherapy has been indicated, use of erlotinib monotherapy at any 
dose for at least 2 weeks prior to participation in the study, WHO Performance 
Status of 0 or 1 and no concurrent use of (OTC) medication or medication 
known to interact with either erlotinib or esomeprazole. Exclusion criteria 
included pregnant or lactating patients and a clear language barrier.
Pharmacokinetics
Blood samples for the analysis of erlotinib were collected prior to erlotinib 
dosing and 0.5h; 1h; 1.5h; 2h, 2.5h; 3h; 3.5h; 4h; 6h; 8h; 12h and 24h 
(13 samples/ hospitalization for all sequence arms) after erlotinib administration. 
Esomeprazole levels were not measured. At each time-point, blood samples 
were collected in 6 mL lithium heparin blood collection tubes. After collection, 
blood samples were processed to plasma (within 10 minutes by centrifugation 
for 10 minutes at 2,000 g at 4°C). Plasma was transferred into polypropylene 
tubes (1,8 mL Nunc vials), which was subsequently stored at T <-70°C until the 
time of analysis at the Laboratory of Translational Pharmacology (Josephine 
Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands). Pharmacokinetic 
parameters of erlotinib were calculated using weighted non-compartmental 
analyses with WinNonlin 6.3 (Pharsight Corp., Mountain View, CA) and 
included area under the plasma-concentration time curves (AUC0-12h), maximum 
concentration (Cmax) and time to Cmax (Tmax).
129
6
Influence of the acidic beverage cola on the absorption
Statistics
The primary objective was to determine the intra-patient differences in 
absorption (expressed by the AUC0-12h and Cmax) after a 7 day period of 
concomitant treatment of erlotinib (with or without esomeprazole for 3 days) 
with Coca-Cola and 7 days of erlotinib with water, or vice versa. Each patient 
acted as his/her own control. 
In this exploratory study, the primary endpoint was the relative difference (RD) 
between erlotinib AUCcola and erlotinib AUCwater, calculated for each patient 
as: RD = (AUCcola – AUCwater) / AUCwater. Coca-Cola was considered to have 
an impact on the erlotinib AUC when the absolute value of RD was at least 
25% (i.e. less than or equal to -25%, or at least +25%).14 Assuming an intra-
individual standard deviation of the difference between AUCcola and AUCwater of 
30%, 14 evaluable patients per study group (= without or with esomeprazole) 
had to be included to obtain 80% power (2-sided significance level α = 0.05) to 
detect this difference of 25% or more.15
In order to evaluate the impact of Coca-Cola on the AUC, i.e. compare AUC 
with Coca-Cola (AUCcola) and AUC with water (AUCwater), we used the Stata-
command ‘pkcross’, which was designed to analyze cross-over experiments 
[StataCorp. 2013. Stata: Release 13. Statistical Software. College Station, TX: 
StataCorp LP]. This command uses ANOVA models to analyze the data (please 
refer to Stata base reference manual, release 13, pages 1594-1602, for a detailed 
description). In this way possible period effects (first versus second `PK 
sampling period’) and sequence effects (A à B versus B à A) were taken into 
account, assuming that no carryover effect exists. In case of a dose reduction 
(due to toxicity) PK data were normalized to a dose of 150 mg erlotinib. The 
P-value to indicate whether the mean AUC and mean Cmax were significantly 
different after water versus after cola, was the P-value assigned to the treatment 
effect using the `pkcross’ command. This was evaluated separately for patients 
who used esomeprazole, and for those who did not.
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RESULTS
Patient characteristics
A total of 35 patients were enrolled of which 28 were evaluable, 14 in each study 
group. Seven patients were excluded from the study for varying reasons (i.e. the 
use of Diet Coca-Cola® (n=1), the use of generic brand esomeprazole instead 
of Nexium® (n=1), progression of disease prior to both PK sampling periods 
(n=2), impossibility to venipuncture (n=1)) and on patients own initiative 
(i.e. withdrawal of consent (n=2)). Baseline characteristics are shown in table 1. 
The majority of patients were male (61 %) and the median age was 63 years.
 
Characteristics N %
No of patients 28  100
Age (years)    
    Median (range) 63 (39-77)  
Sex    
    Female 11 39
    Male 17 61
Race    
    Caucasian 24 86
    Asian 4 14
BMI (kg/m2)    
    Mean (range) 24,2 (19-31)  
Tobacco use    
    Current (< 1 month) 2 7
    None 26 93
ECOG-performance status    
    0 15 54
    1 13 46
Pre-treatment chemotherapy    
    Yes 8 29
    No 20 71
EGFR mutation
    Yes 14 50
    No 10 36
    Unknown 4 14
Dosage erlotinib    
    50mg 1 4
    100mg 4 14
    150mg 23 82
Table 1: subject characteristics at baseline
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Pharmacokinetics, safety and tolerability
In patients taking erlotinib and esomeprazole (study group 2, Table 2), the mean 
AUC0-12h was 39% higher (range -12% up to +136%; P=.004), while the mean 
Cmax was 42% higher (range -4% up to +199%; P=.019) after cola, compared to 
water intake (Figure 2). In patients taking erlotinib without esomeprazole (study 
group 1, Table 3), the mean AUC0-12h was 9% higher (range -10% up to +30%; 
P=.03), while the mean Cmax was comparable (0%; range -19% up to +18%; 
P= .62) after cola intake (Figure 2). Time to Cmax (Tmax) was not significantly 
altered in study group 1 (18%; range -60% to +194%, P=.75) and study group 2 
(0%; range -20% to +52%, P=.99).
Erlo = erlotinib
Esom= esomeprazole 40 mg q.d
* Median (range)
** In case of a dose reduction (due to toxicity) PK data were normalized to a dose of 150 mg erlotinib
Parameter Erlo+Esom+Water (A) Erlo+Esom+Coca-Cola (B) Difference % (range)
Erlotinib dose* 150 (100-150) 150 (50-150)
Erlotinib
AUC 0-12h (µg×h/ml), geometric 
mean (geometric mean CV%)
9.0 (19.9%) 11.8 (14.9%) 39% (-12% to +136%), 
P=.004
Cmax (µg/ml), geometric mean 
(geometric mean CV%)
1.08 (152%) 1.43 (112%) 42% (-4% to +199%), P=.012
Table 2: summary of pharmacokinetic parameters study group 2
(Erlotinib + Esomeprazole + water vs. Coca-Cola)
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Parameter Erlo + Water (A) Erlo + Coca-Cola (B) Difference % (range)
Erlotinib dose* 150 (50-150) 150 (50-150)
Erlotinib**
AUC 0-12h (µg×h/ml), geometric mean 
(geometric mean CV%)
17.3 (8.5%) 18.6 (7.7%) 9% (-10% to 30%), P=.03
Cmax (µg/ml), geometric mean 
(geometric CV%)
2.10 (68%) 2.09 (64%) 0% (-19% to +18%), P=.62
Table 3: Summary of pharmacokinetic parameters for study group 1
(Erlotinib+water vs. Coca-Cola)
Erlo = erlotinib
* Median (range)
** In case of a dose reduction (due to toxicity) PK data were normalized to a dose of 150 mg erlotinib
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Figure 2: Mean dose corrected concentration vs. time profiles are shown for erlotinib alone administered with water or Coca-Cola Classic
A B(Treatment arm , n=14) and erlotinib + esomeprazole with water or Coca-Cola Classic (Treatment arm , n=14).
Figure 2: pharmacokinetic profile
Mean dose corrected concentration vs. time profiles are shown for erlotinib alone administered 
with water or Coca-Cola Classic® (Treatment group A, n=14) and erlotinib + esomeprazole with 
water or Coca-Cola Classic® (Treatment group B, n=14)
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Adverse events were generally mild and resolved without medical intervention. 
Erlotinib was well tolerated when administered with either cola or water (also 
in patients with known gastro-esophageal reflux disease). One subject in study 
group 1 developed grade 3 skin toxicity and hospital admission was required. 
After standard of care treatment the patient was discharged from hospital 
without sequela but showed progression during erlotinib therapy. In this patient 
the erlotinib was stopped and the patient was excluded from the study. Erlotinib 
treatment related AEs primarily affected the skin (e.g. grade 1 rash) and gastro-
intestinal system (e.g. nausea, diarrhea). For details see table 4. There were no 
known deviations in the patients diaries concerning study adherence.
* All grade 1 according to CTC-AE version 4.03
** Grade 1 or 2 according to CTC-AE version 4.03
¥ One patient with grade 3 skin toxicity according to CTC-AE version 4.03
PPI (n=14) Non-PPI (n=14)
Water Cola Water Cola
Diarrhea* 2 (14%) 2 (14%) 3 (21%) 6 (43%)
Nausea* 1 (7%) 2 (14%) 1 (7%) 1 (7%)
Vomiting* 0 0 1 (7%) 0
Rash** ¥ 9 (64%) 11 (79%) 9 (64%) 11 (79%)
Fatigue** 8 (57%) 8 (57%) 7 (50%) 7 (50%)
Table 4. Treatment related adverse events (AEs) during study period
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DISCUSSION
In this study, we showed that the use of cola significantly increases the mean 
exposure of erlotinib in patients using esomeprazole. This is most probably 
based on an increased solubility and absorption. Furthermore, in patients taking 
cola instead of water, the mean exposure to erlotinib also significantly increased, 
although this effect was clinically irrelevant. The observed pharmacokinetic 
parameters were comparable to previous reports.6 Our study confirms that pH-
dependent solubility plays a key role in erlotinib absorption and that a can 
(250 mL) of cola can enhance erlotinib absorption by temporarily lowering the 
intragastric pH.
Although H2-antagonists (e.g. ranitidine) and antacids can substantially affect 
erlotinib bioavailability, esomeprazole (Nexium®; at regular dose; 40 mg q.d.) 
was used in our study as this is currently the most effective acid reducing agent 
on the market.2,12,13 Furthermore, when using esomeprazole instead of other PPIs 
(e.g. pantoprazole), other factors such as inhibition of relevant drug-transporters 
which may also alter erlotinib pharmacokinetics (e.g. P-glycoprotein) can be 
ruled out.16 To our knowledge, there are no other interactions (e.g. based on 
altered metabolism or clearance) between erlotinib and esomeprazole, besides 
those based on altered intragastric pH, that may alter erlotinib pharmacokinetics.
A three day period before PK days was assumed to maximize the acid reducing 
effects, but also to minimize the period a patient was exposed to the unwanted 
drug-drug interaction between esomeprazole and erlotinib.6,12,13. This assumption 
was supported by the observation that there were no significant differences in 
AUC0-12h and Cmax between patients taking esomeprazole for 3 days and on a 
continuous basis.
In this study, a large inter-patient variability in either AUCs and other 
pharmacokinetic parameters was observed. Several factors could explain this 
variability. Most probably, the absorption from the gut itself varies highly 
between patients. Adherence to the protocol during the study period (for instances 
by drinking of other (volumes of) acidic beverages or not taking erlotinib on an 
empty stomach) is unlikely to be the cause of variability, as the study protocol was 
explained thoroughly and patient diaries were heavily protocolled and checked by 
the investigators. More probable reasons are inter-patient differences in gastric 
emptying and gastrointestinal motility. Possibly, cola may not enhance absorption 
in all patients, as the gastric pH may also physiologically vary, as the effects may 
be lower if the gastric pH is lower in one patient compared to another.1
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A limitation of this study is that we did not measure intragastric pH. As some 
patients might suffer from altered gastric acid secretion (e.g. achlorhydria or 
Zollinger-Ellison syndrome), large interpatient variations in intragastric pH can 
be expected. Because of the weak basic properties and an acid dissociation 
constant (i.e. the pH at which equilibrium is reached between the ionised and 
non-ionised form) near the stomach pH range of 1 to 4 (Erlotinib pKa=5.4), 
intragastric pH shifts lead to a more significant shift towards the non-ionized 
(less soluble) form and subsequent lower bioavailability, compared to TKIs 
with a higher pKa (e.g. sunitinib, afatinib
6). This may partly explain the large 
variation seen in this study in erlotinib absorption. Measuring the intragastric 
pH per patient might give additional insights into the effect of cola intake on 
intragastric pH and subsequent absorption. Another limitation of this study is 
that it was not designed to explore effects of long term cola co-administration 
on the outcome of anti-cancer treatment with erlotinib. Since the study design 
was purely based on pharmacokinetic and chemical parameters (i.e. pH effect 
and subsequent erlotinib solubility and absorption) and the relative short time 
(i.e. 7 days) that patient were taking erlotinib with cola (instead of water), it 
did not allow us to evaluate the impact of cola on erlotinib efficacy. Therefore, 
the clinical impact of cola on erlotinib efficacy should be unraveled in further 
research.
In theory, in patients with elevated intragastric pH and subsequent impaired 
absorption (e.g. achlorhydria and gastrectomy), the use of cola may also 
increase bioavailability of erlotinib or other TKIs with a relatively low pKa. 
Due to the nocturnal duodenogastric reflux peak during sleep, the intragastric 
pH is at night, on average, higher compared to morning stomach pH.13 Many 
patients take a tyrosine kinase inhibitor ante noctem.17 In theory, when a patient 
decides to take erlotinib ante noctem, cola could help increase bioavailability 
by temporarily lowering intragastric pH. The effect of cola on these subgroups 
should be further explored in future studies.
In clinical practice there is often a hard indication for the use of PPIs during 
erlotinib therapy (e.g. patient using corticosteroids and NSAIDs or with 
(recurrent) gastroesophageal reflux disease). On the other hand, physicians 
are faced with product label guidelines that advise to “avoid the combination” 
or to switch to less effective H2A-antagonists or antacids (taken 2 hours after 
erlotinib).6 When erlotinib and a PPI are given concomitantly, the AUC of 
erlotinib steeply decreases.6 This suggests that lower bioavailability due to PPI 
use (up to 46% for erlotinib6) may deprive patients from optimal therapy.5,18 
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Thus, in case the combination between a PPI and erlotinib is inevitable, the pH 
lowering effects of cola may help physicians to optimize erlotinib therapy.
Although ingredients of cola, such as caffeine, may potentially interact with 
erlotinib pharmacokinetics, it is more likely that pH dependent solubility is the 
predominant factor in erlotinib absorption.3,19 Erlotinib is a Biopharmaceutics 
Classification System (BCS)20 class 2 drug, characterized by poor solubility but 
high intestinal permeability, which means that in vivo erlotinib bioavailability is 
predominantly limited by its solubility.3,20 When dissolved, erlotinib is rapidly 
and extensively (>90%) absorbed across the intestinal membrane.3
Although cola can be associated with several disadvantages, such as dental 
corrosion and gastroesophageal irritation, it is (for most people) a palatable 
drink which is readily available worldwide. Furthermore, Coca-Cola Classic 
has the clear advantage of a substantial lower pH (pH~2,5) compared to other 
acidic beverages such as orange juice (pH~4), 7-Up (pH~3,5) and diet (cola) 
products (pH~3 to 4). In theory, drinks with higher pH might not be as effective 
in enhancing erlotinib absorption as Coca-Cola Classic. Additionally, although 
not studied, higher volumes of cola might acidify the stomach even more and 
erlotinib absorption could be further enhanced. However, in our study 250cc 
of cola was well tolerated and higher volumes might be less convenient for the 
patient (especially in the morning).
In conclusion, the use of cola provides a potential and easy to implement way 
to significantly improve erlotinib bioavailability, especially during concomitant 
use of esomeprazole. These findings can be used to optimize the management 
of the existing drug-drug interaction between erlotinib and PPIs. Potentially, 
effects of cola on erlotinib exposure may be extrapolated to other TKIs with a 
pH-dependent solubility (e.g. dasatinib, gefitinib and nilotinib) but this remains 
to be evaluated in further studies. And potentially also other acidic beverages 
(i.e. orange juice and other carbonated drinks) may have similar effects as cola. 
Also, this should be explored in future trials.
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INTRODUCTION
Tyrosine kinase inhibitors (TKIs) have rapidly become an established factor 
in daily oncology practice.1 They have been shown to be effective in a wide 
variety of solid and hematologic malignancies. At present, there are 25 TKIs 
approved by the FDA.2 Many new TKIs are under investigation, and indications 
for existing TKIs are rapidly expanding.2 Use of the oral administration route 
of TKIs offers logistic flexibility and is convenient for the patient.3 Despite 
these advantages, the oral route of administration also causes a highly relevant 
new problem. TKIs are generally characterized by a poor and variable 
bioavailability, resulting in significant between-patient variability in plasma 
levels and exposure. This variability is the result of an interplay of factors, 
including tissue permeability, membrane transport and enzymatic metabolism.4 
Most importantly, acid-inhibitory drugs, like proton pump inhibitors (PPIs), 
increase the intragastric pH, which decreases the solubility and thereby the 
biological availability of most TKIs and was shown to be associated with 
decreased TKI efficacy.5
Although PPIs are extensively used during anti-cancer treatment, there is still 
much controversy on how to manage drug-drug interactions (DDIs) between 
TKIs and PPIs.6, 7 For some TKIs, the effect of a PPI on absorption from the gut 
is thoroughly investigated and specific guidelines for the management of such 
DDIs are provided in the product label.2 For most others, only basic pre-clinical 
pharmacokinetic or in vitro chemical studies (e.g. on pH dependent solubility) 
have been executed and specific guidelines for the management of these DDIs 
are not provided. Since cancer patients on TKI therapy are often ‘poly-pharmacy’ 
patients and may heavily rely on drugs such as vitamin K antagonists, non-
steroid anti-inflammatory drugs (NSAIDs), and corticosteroids, they are at risk 
for gastro-intestinal reflux disease or peptic ulcer disease. Therefore, for many 
cancer patients there is a solid indication for gastro-protection or treatment of 
gastro-intestinal symptoms with PPIs during treatment.8, 9 Indecisive guidelines 
(predominately given in the product label)2 such as ‘screen for toxicity’ or ‘avoid 
combination’ still pose prescribers for a dilemma whether or not to continue the 
combined treatment in individual patients.1
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UNRAVELLING THE DRUG-DRUG INTERACTION 
BETWEEN TKIs AND PPIs
To appreciate the background of the DDIs between TKIs and PPIs, theoretical 
pharmacokinetic and pharmacodynamic principles and known pharmacokinetic 
DDI studies have to be considered.
TKI absorption and intragastric pH
Although the absorption of TKIs may be influenced by many factors, the 
major determinant in TKI absorption is the pH-dependent solubility.1, 10 Crucial 
physiological factors that affect pH dependent solubility and TKI absorption, 
are intragastric pH and the dissociation constant pKa. Since TKIs are weakly 
basic, there is an equilibrium between the ionized and non-ionized form that 
is dependent on intragastric pH and the pKa of the TKI. At normal acidic 
intragastric pH (pH range 1 to 2), the equilibrium shifts to the ionized form. 
Since the ionized form has better solubility, TKI absorption from the gastro-
intestinal tract is optimal at low intragastric pH. However, when the intragastric 
pH is elevated (e.g. due to concurrent PPI use), the balance shifts towards the 
non-ionized form of the drug and solubility and bioavailability may decrease 
significantly. Another important factor determining the absorption rate is the 
pKa as this is the pH at which there is an equilibrium between the ionized and 
non-ionized form. TKIs with a pKa near the pH range of the stomach (pH 1-4; 
e.g. erlotinib, dasatinib) are usually more affected by intragastric pH than TKIs 
with a higher pKa (e.g. imatinib and afatinib) because of a larger shift towards 
the less soluble non-ionized drug form with higher pH.1, 11 Consequently, TKIs 
with a pKa near 4 to 5 typically show an intragastric pH dependent solubility 
and therefore are more prone to clinically relevant drug-drug interactions with 
PPIs.1
PPI pharmacodynamics
Besides TKI bioavailability, the pharmacodynamic profile of PPIs is important 
to consider for management of DDIs between TKIs and PPIs. PPIs are highly 
effective acid inhibitory agents and are registered in a once daily dose for the 
majority of their indications. Although this dosing strategy is usually effective 
in controlling gastro-oesophageal reflux disease, PPIs do not elevate the 
intragastric pH over the full 24-hour range (see figure 1).12-15 There are two 
important explanations for this 24-hour variation in acid suppression: i) the 
delayed onset of the pharmacological effect of PPIs and ii) the duration of 
pharmacological action.15, 16
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For most PPIs, the acid-inhibitory effects (defined by an intragastric pH above 
4)17, 18 will only be reached 3 to 4 hours after intake.15, 16 This delayed onset of 
action is caused predominantly by the use of enteric coated tablets or capsules. 
Since PPIs are easily protonated, they are unstable at low (intragastric) pH and 
therefore a coating is indicated. Polymer coatings are stable at low intragastric 
pH, but break down easily at higher intestinal pH. As a result, the PPI is 
protected against degradation in the stomach and arrives intact in the duodenum 
where absorption takes place. The resulting delay of acid-inhibitory effects after 
administration amounts up to an average of 3-4 hours (figure 1). 
Administration
of TKI and PPI
Figure 1: Schematic 24-hours Intragastric pH curve with enteric coated PPI q.d.
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TKIs that are less affected by
pH-dependent solubility:
Afatinib*, Axitinib, Cabozantinib, Crizotinib,
Imatinib, Nilotinib, Nintedanib*, Pazopanib,
Ponatinib, Ruxolitinib*, Sorafenib, Sunitinib*,
Trametinib*, Vandetanib, Vemurafenib*
TKIs that are affected by
pH-dependent solubility:
Bosutinib, Dabrefenib*, Dasatinib, Erlotinib,
aGefitinib, Ibrutinib*, Lapatinib, Regor fenib*
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Schematic 24-hours intragastric pH curve during PPI use (enteric coated, q.d.) with delayed onset of action (3-4 hours), duration of action (12-14 hours with q.d. use) and the nocturnal duodenogastric reflux peak
(obtained by the supine position during sleep). Figure was derived with permission from Hunfeld et al.
14
* Based on “in vitro” pre-clinical studies only  TKI= Tyrosine Kinase Inhibitor  PPI= Proton Pump Inhibitor  q.d.= once daily; , ,
Figure 1: schematic 24-hours Intragastric pH curve with enteric coated PPI q.d.
Schematic 24-hours intragastric pH curve d ri g PPI use (enteric coated, q.d.) with delayed 
onset of action (3-4 hours), duration of action (12-14 hours with q.d. PPI use) and the nocturnal 
duodenogastric reflux peak (obtained by the supine position during sleep). Figure was derived with 
permission from Hunfeld et al.15
* Based on “In vitro” pre-clinical studies only; TKI=Tyrosine Kinase Inhibitor, PPI=proton pump 
inhibitor, q.d.=once daily
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Although most PPIs are characterized by a short half-life (t½) of approximately 
1 to 2 hours, the pharmacodynamic effects on intragastric pH last much longer, 
because of its irreversible covalent binding to the proton pumps. After 2 to 3 
days of daily use a steady state in acid inhibition is reached.12, 19 Meanwhile, 
new proton pumps are generated in vivo on a continuous basis, and subsequently 
gastric acid will be secreted from these new pumps, compensating the elevated 
pH.15 As a consequence, the intragastric pH will start to decrease again and 
drops to pH values < 4 within 12-14 hours after PPI administration (figure 1).15
On the other hand, during nighttime, physiological duodenogastric reflux occurs 
as a result of the supine position during sleep. As a result, there is an elevation 
in intragastric pH during nighttime which sharply returns to baseline after 
getting out of bed (figure 1).15 Furthermore, a substantial proportion of patients 
above 80 years of age suffer from achlorhydria; a state in which the production 
of hydrochloric acid in the stomach is low or absent and the intragastric pH is 
substantially elevated.20 Both nighttime duodenogastric reflux and achlorhydria 
in older patients may profoundly alter TKI bioavailability. Of note, in serious 
gastro-oesophageal reflux disease, physicians may prescribe a PPI in a twice 
daily dose. In contrast to a once daily dose, more frequent (and often higher) 
dosing of PPIs (e.g. twice daily dose or continuous dosing) leads to a greater 
and more constant elevation of intragastric pH above a pH of 4 over the full 
24-hours range.9
Available drug-drug interaction studies and study design
As mentioned above, the intragastric pH is not elevated over the full 24-hours 
range during PPI therapy. Therefore, outcomes of drug-drug interaction studies 
between a PPI and a TKI are highly dependent on the study design, and 
especially the time of intake for both TKI and PPI. Two types of studies can 
be distinguished: i) the TKI and PPI are administered concomitantly and ii) the 
TKI is administered 2 to 3 hours after the intake of the PPI. There are strengths 
and limitations for both types of study designs. 
When the drugs are taken concomitantly and if the observed effect is low/nihil, 
this may indicate that there is indeed no interaction between the two drugs, but 
it may also well be that a DDI would have been observed if the PPI would have 
been taken at another moment in time2, 21. As mentioned before, when the TKI 
and PPI are administered concomitantly, there is the 3-4 hour window after PPI 
intake in which the TKI absorption will not be significantly affected by the PPI, 
potentially leading to a false perception that no DDI occurs. For some TKIs (e.g. 
axitinib and nilotinib)2, the question remains if an alternative time schedule of 
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PPI to TKI intake would lead to an increase or decrease of the TKI absorption, 
as this is unfortunately studied rarely. Therefore, if no clinically relevant effect 
is seen in studies while these drugs are taken at the same time, the subsequently 
drawn conclusion that “TKI and PPI may be used concomitantly” should –in 
our opinion– be replaced by “TKI and PPI must be used concomitantly”, to 
guarantee a safe use.
When a TKI is administered a few hours after a PPI, the intragastric pH is 
almost certainly elevated. When no pH dependent solubility is expected a study 
setup where the TKI is administered a few hours after the PPI might be the best 
study setup to completely rule out an absorption based DDI as was shown for 
cabozantinib.22
MANAGEMENT OF TKI-PPI DRUG INTERACTIONS
There is often a hard indication for the concomitant use of TKIs and PPIs. In 
clinical practice however, it is often advised to avoid the combination or to switch 
to less effective acid suppressive drugs such as antacids and H2-antagonists (e.g. 
ranitidine).12 As a result, the patient is often deprived from optimal therapy for 
gastro esophageal reflux disease. In addition, H2-antagonists and antacids may 
also compromise the TKI bioavailability leading to an inadequate antitumor 
effect.1, 2
For several TKIs approved by the FDA the effect on bioavailability has only 
been studied in vitro whereas pH dependent solubility and TKI absorption 
in vivo is often multifactorial.4 In this case, only preclinical in vitro data on 
chemical pH dependent solubility may not predict the true in vivo effects on 
bioavailability (e.g. afatinib)2 of a concomitantly used PPIs. If it is stated (e.g. 
in the assessment report of the FDA)2 that there is no significant DDI between a 
certain TKI and PPI this should, in our opinion, be confirmed in an adequately 
designed in vivo pharmacokinetic drug-drug interaction study.
There is a lot of discussion whether TKIs and PPIs are really incompatible. 
For instance, there is the interesting suggestion by Ter Heine et al. that when 
the PPI dose (in this case pantoprazole) is relatively low, erlotinib can be used 
concomitantly. However, this recommendation is based on a study performed in 
a single patient and solid pharmacokinetic data provided in the FDA assessment 
report stated otherwise (mentioning a 46% and 61% decrease in erlotinib AUC 
and Cmax respectively).
2, 23 Although many pharmacokinetic DDI studies have 
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already been conducted and published in either an FDA assessment report or 
scientific literature, a clear advice on the management of the DDI between 
PPIs and TKIs is rarely given. Studies on alternative time schedules of PPI 
to TKI intake to completely rule out a DDI are also scarcely available, and 
drawn conclusions on the management (e.g. can be used concomitantly) may 
not always be 100% solid.
Due to the nocturnal duodenogastric reflux peak, intragastric pH is elevated 
during sleep. On theoretical grounds (and regardless of PPI use) the 
bioavailability of TKIs is not optimal when taken ante noctem and should be 
avoided and product label recommendations to administer the TKI in the evening 
should be avoided (e.g. pazopanib)2. Furthermore patients --especially those of 
80 years and older-- on TKI therapy might suffer from achlorhydria with a 
suboptimal absorption as a result.20 More research is needed to investigate TKI 
bioavailability during nighttime sleep and achlorhydria.
When using pantoprazole instead of other PPIs, TKI pharmacokinetics may be 
altered through inhibition of drug transporters such as P-glycoprotein (P-gp).24 
Since many TKIs are substrates for P-gp (e.g. erlotinib and lapatinib) physicians 
should prescribe pantoprazole with great caution or switch to other PPIs, such 
as omeprazole, during TKI therapy. Moreover, for these TKIs, results obtained 
from drug interaction studies with omeprazole may not be extrapolated directly 
to pantoprazole. More research is needed to explore the clinical significance of 
the DDI between pantoprazole and TKIs.
We recently showed that the intake of erlotinib with an acidic beverage (cola) 
enhanced the bioavailability by almost 40% in patients also taking esomeprazole.25 
Through temporarily lowering the intragastric pH by administering the TKI 
with cola the DDI between TKIs and PPIs can be bypassed (partly). Especially, 
when there is a hard indication for twice daily use of a PPI (and subsequent 
continuous 24-hours intragastric pH elevation), in our opinion, cola may be a 
simple and practical solution to manage the DDI between TKIs and PPIs.
When all pharmacological characteristics and data of either TKIs and PPIs are 
considered, a balanced, practical and safe advice on how to manage this drug 
combination can be given. Since the intragastric pH is not elevated over the 
whole 24-hour range as shown in figure 1, a target period of low intragastric pH 
can be used to safely administer the TKI.
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In conclusion, to properly manage the DDIs between TKIs and PPIs, a twice 
daily PPI dose must first be brought back to a once daily regimen, whereas the 
PPI must be given in an enteric coated formulation. If the TKI is administered 
in the morning, a couple of hours prior to intake of the PPI, the enteric coating 
of the PPI will provide a target period of low intragastric pH during which TKIs 
with a pH dependent solubility can pass through a stomach with sufficiently 
low pH. More research on alternative timing schedules of PPI to TKI intake, 
achlorhydria and nighttime TKI absorption is necessary as this will provide 
further insights into the effects of elevated intragastric pH on TKI bioavailability.
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GENERAL DISCUSSION AND SUMMARY
Although cancer is a significant and leading public health burden among men 
and women worldwide, treatment options are rapidly evolving. Among these, 
the use of anticancer drugs is still the cornerstone in the treatment of most 
forms of cancer. However, the significant progress in the development of novel 
(targeted) anticancer drugs is also associated with many challenges as was 
described in detail chapter 1.
Since most anticancer drugs have narrow therapeutic windows it is important 
to “get the dose right” in order to optimize drug exposure and minimalize 
resistance and toxicity. To accomplish this there is a shifting paradigm towards 
individualized therapy. Along with other factors, the use of comedication 
and the subsequent risk for DDIs is one of the key factors influencing 
systemic drug exposure in cancer patients. DDIs can be divided in two 
groups: “pharmacokinetic” and “pharmacodynamic” drug interaction. When 
pharmacokinetic and/or pharmacodynamic parameters are modified by the 
concomitant use of comedication, systemic exposure and effect of the anticancer 
drug might be affected and may lead to unpredictable effect and toxicity of the 
therapy. This thesis investigated the occurrence and clinical relevance of DDIs 
during anticancer therapy and specific recommendations to guide clinicians 
through the process of managing DDIs in daily clinical practice were given.
Traditionally, the pharmacological focus of conventional anticancer drugs have 
been on targeting DNA processing and cell division. Although these anticancer 
drugs can be very effective, their lack of selectivity usually leads to serious 
toxicity which may limit their use. In order to improve efficacy and diminish 
adverse events of cancer treatment, more specific targets have been identified 
the past decade. One of the most promising groups in ‘targeted therapy’ are the 
TKIs. All TKIs are administered orally which significantly improves patient 
quality of life. Although TKIs have advantages over traditional chemotherapy, 
there are new challenges that arise. The oral route of administration, the fact 
the TKIs are given on a continuous daily basis and are predominately meta-
bolized through CYP enzymes makes them highly prone to DDI. Therefore, in 
chapter 2, literature about DDIs in TKIs therapy was reviewed. The main goal 
of this review was to give the treating clinician a comprehensive overview of 
the most important DDIs during TKI therapy: i)TKIs and acid reducing agents, 
ii) CYP-inhibitors/inducers during TKI therapy and iii) QTc interactions. Acid 
reducing drugs like PPIs can profoundly influence the bioavailability and 
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CYP inhibitors/inducers can significantly affect the exposure of TKIs; clinical 
intervention is often needed. Although rare, QTc-interval prolonging DDIs can 
have fatal consequences and must be accounted for. To improve the safe use 
of TKIs in clinical oncology practice, a profound assessment of co-prescribed 
drugs is needed. In order to achieve this, clinicians should collaborate 
closely with (hospital)pharmacist and general practitioners. In addition, more 
pharmacokinetic and pharmacodynamic research is needed on DDIs in TKI 
therapy to provide a profound basis for medication review. And last but not 
least, in case of a suspected DDI, where pharmacokinetic data are not available, 
physicians and pharmacists must weigh “pros” and “cons” and, if possible, 
extrapolate available pharmacological data to an individual patient.
In chapter 3 and chapter 4, a retrospective study was done to provide an 
overview of the prevalence of potential DDIs in either intravenous and oral 
anticancer therapy, respectively. 
In this analysis, we detected a high prevalence of PDDIs with 46% to 58% of 
all patients being exposed to at least one potential DDI. More importantly, these 
potential DDIs were not just theoretically relevant. 16% to 34% of all patients 
had at least one potential DDI that may have caused harmful side effects and 
would require intervention or intensive monitoring. Coumarines, quinolones, 
anti-epileptics, opoids and hydrochlorothiazide were frequently involved in 
a DDI. The majority of DDIs concerned central nervous system depression 
interactions (risk of falling), DDIs that can cause gastrointestinal toxicity 
(e.g. NSAIDs and corticosteroids) and prolongation of QTc interval. With the 
increasing numbers of new oral anticancer agents that become available, the 
risk for DDIs will consequently increase.
Due to the retrospective design, a major limitation of this study is that it did 
not investigate the clinical impact of the potential DDIs. Although the clinical 
relevance was not established in these two studies, we can still conclude that 
potential DDIs are common in cancer patients and screening for potential 
interactions should take place routinely during anticancer therapy. However, 
the clinical relevance of DDIs remains to be assessed in further research.
In chapter 5, a prospective study was performed to assess the prevalence of 
DDIs leading to actual clinical interventions during cancer therapy. This study 
served as a sequel to chapter 3 and chapter 4 and the clear desire the investigate 
the clinical relevance of DDIs in cancer patients. In this study we included 
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302 patients and resulted in a clinical intervention already executed by the 
(hemato)oncologist in 39 patients (13%), while an additional intervention was 
proposed by a clinical pharmacologist in 42 patients (14%). Coumarins and 
GI-interactions (especially the combination of corticosteroids with NSAIDs) 
were frequently involved in an intervention, as were combinations of drugs that 
are known to cause QTc-interval prolongation and DDIs between TKIs and acid 
reducing agents (e.g. PPIs).
This study shows that clinical interventions on DDIs are frequently required 
among patients using anticancer therapy. The collaboration with a clinical 
pharmacologist almost doubled the number of clinical interventions due to DDIs. 
Structured screening for clinically relevant DDIs, by clinicians (oncologists 
and clinical pharmacologists), should take place before the start and during 
anticancer treatment. To create a solid base for medication review and, by 
this, to identify and prevent potentially harmful DDIs all drugs prescribed by 
oncologists, general practitioners, and other healthcare professionals should be 
documented electronically, including patient’s medical status, in one national! 
computer-based patient record.
Although the DDI between TKIs and PPIs was frequently seen in the prospective 
study addressed in chapter 5, there are still no clear recommendations on how 
to manage DDIs between TKIs and PPIs. Since pH dependent solubility seems 
to be the key factor that influences TKI absorption, we evaluated the impact of 
cola on the exposure of erlotinib (during PPI use) in patients with lung cancer 
in chapter 6. In this randomized cross-over pharmacokinetic trial twenty-eight 
evaluable patients were included in the analysis. In the patients taking erlotinib 
concomitant with a PPI with cola, the mean AUC0-12h increased with 39% (range 
-12% up to +136%; P=.004). Apparently, cola generated a clinically relevant 
and statistically significant increase in the bioavailability of erlotinib during 
PPI treatment. These findings provide a practical solution to manage the DDI 
between erlotinib and PPIs. Potentially, effects of cola on erlotinib exposure 
may be extrapolated to other TKIs.
On the other hand, when all pharmacological characteristics of either TKIs 
and PPIs are considered, a practical advice purely based on pharmacological 
principles can be given to manage this drug combination. In chapter 7, we 
discussed the pharmacological profile of either TKIs and PPIs and provided 
another solid way to manage this DDI in clinical practice. Since the intragastric 
pH is not elevated over the full 24-hour range, a target time-window of 
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low intragastric pH can be used to safely administer the TKI. If the TKI is 
administered in the morning, a couple of hours prior to intake of the PPI, the 
enteric coating of the PPI will provide a target time-window during which TKIs 
with a pH dependent solubility can pass through the stomach with sufficiently 
low pH. By application of this dosing interval, the absorption of the TKI is not 
compromised by the PPI.
Strangely, the effect of a PPI on TKI pharmacokinetics is not investigated for 
all TKIs in the pre-registration phase. The effect of PPIs on TKIs absorption 
should always be investigated in an “in vivo” pharmacokinetic study. More 
research is also needed into the effects of the nighttime duodenogastric reflux 
pH peak (as a result of the supine position during sleep) on TKI bioavailability 
taken “ante noctem”.
Finally, in order to individualize drug therapy, DDIs are to be reckoned with in 
cancer patients. Clinicians should collaborate in order to identify and manage 
DDIs in clinical practice. For this, one national computer-based patient record 
is needed.
In this prospective study only adult cancer patients were included. Paediatric 
cancer patient were beyond the scope of this thesis. However, in childhood 
cancer the currently prescribed drugs have a high DDI potential. On the other 
hand, the number of co-medications used concomitantly with anticancer drugs 
will probably be lower than in adults cancer patients. Further prospective 
research is needed to fully explore the prevalence and clinical relevance of DDIs 
in childhood cancer. In the Erasmus University Medical Centre, a prospective 
clinical trial such as this is currently ongoing.
Evidently, more research is needed on the effects of co-medication on anticancer 
drugs to explore the true interaction potential of anticancer drugs. For instance, 
the interaction potential of drug transporter, such as OCTs and OATPs, and their 
role on increasing or reducing toxicity and pharmacological effect needs to be 
further explored.
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General discussion and summary
This pharmacological research should always lead to a clear and practical 
recommendation that can readily be used in clinical practice. If no 
pharmacological data are available, healthcare professionals should collaborate 
and use common medical and pharmacological principles to extrapolate known 
data, in order to provide practical recommendations to manage a certain DDI to 
individualize and optimize anticancer therapy.
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DISCUSSIE EN SAMENVATTING
Hoewel de nieuwe en innovatieve behandelopties voor de behandeling van 
kanker elkaar in snel tempo opvolgen is kanker nog steeds een van de meest 
voorkomende doodsoorzaken bij zowel mannen en vrouwen wereldwijd. Hierbij 
vormt, ondanks alle nieuwe ontwikkelingen, de behandeling met antikanker 
geneesmiddelen nog altijd de hoeksteen van de antikanker therapie tegen de 
meeste vormen van kanker. De belangrijke vooruitgang in behandelopties 
heeft echter ook zijn keerzijde. Vooral de ontwikkelingen van de nieuwe (meer 
selectieve) antikanker geneesmiddelen worden geassocieerd met vele nieuwe 
uitdagingen en problemen. Deze zijn uitvoerig beschreven in hoofdstuk 1.
Aangezien de meeste antikanker geneesmiddelen een smalle therapeutische 
breedte hebben (ze veroorzaken bij een te hoge blootstelling bijwerkingen, 
terwijl deze middelen bij een te lage blootstelling niet werkzaam zijn) is het van 
groot belang om “de juiste dosis” te verkrijgen. Dit om de blootstelling aan het 
geneesmiddel te optimaliseren en de resistentie en bijwerkingen te beperken. 
Om dit te bereiken is er steeds meer een verschuiving van één identieke dosis 
voor alle patiënten, naar de meer geïndividualiseerde antikanker behandeling 
(de zogenaamde “therapie op maat”).
Samen met een aantal andere factoren (zoals voedsel, genetische- en 
fysiologische factoren) is het gebruik van comedicatie en het daaropvolgende 
risico op geneesmiddelwisselwerkingen één van de belangrijkste factoren die de 
blootstelling aan antikanker geneesmiddel kan beïnvloeden (zie ook figuur 1). 
Geneesmiddel wisselwerkingen kunnen worden onderverdeeld in twee groepen: 
de zogenaamde “farmacokinetische” en de “farmacodynamische” geneesmiddel 
wisselwerkingen.
Wanneer farmacokinetische en/of farmacodynamische parameters worden 
gewijzigd door het gelijktijdig gebruik van comedicatie kan de blootstelling 
aan het antikanker geneesmiddel worden beïnvloed. Dit kan bij de patiënt 
weer leiden tot een verlies van werking dan wel tot meer bijwerkingen. 
In dit proefschrift wordt het voorkomen en de klinische relevantie van 
geneesmiddel wisselwerkingen bij kankerpatiënten onderzocht. Verder worden 
er, waar mogelijk, specifieke aanbevelingen gegeven voor artsen en apothekers 
voor het identificeren en afhandelen van geneesmiddel wisselwerkingen in de 
dagelijkse klinische praktijk.
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In de traditionele antikanker therapie ligt de focus van werkzaamheid vooral 
bij het verstoren van processen in het genetisch materiaal (DNA). Hoewel 
deze antikankergeneesmiddelen zeer effectief zijn, leiden ze door gebrek aan 
selectiviteit doorgaans tot ernstige bijwerkingen (toxiciteit). Deze toxiciteit kan 
zelfs zo ernstig zijn dat ze het gebruik van deze middelen kunnen beperken. 
Om het effect en bijwerkingenprofiel van antikanker geneesmiddelen te 
optimaliseren verschuift de geneesmiddelontwikkeling de laatste decennia 
steeds meer naar geneesmiddelen die (zeer) specifiek de kankercel aanvallen (en 
niet tegelijkertijd andere snel delende cellen zoals traditionele chemotherapie 
dat doet). Deze gerichte anti-kanker behandeling waarbij (in theorie) alleen de 
kankercel wordt aangevallen noemen we “targeted therapie”.
Eén van de meest veelbelovende groepen geneesmiddelen die valt binnen 
de groep van “targeted therapie” zijn de Tyrosine Kinase Inhibitors (TKI’s). 
Het grote voordeel van het gebruik van TKI’s is dat ze in tegenstelling tot 
traditionele chemotherapie oraal (in tabletvorm) ingenomen kunnen worden. 
Dit verbetert het gebruiksgemak en de kwaliteit van leven voor de patiënt 
tijdens de behandeling met antikanker geneesmiddelen. Hoewel TKIs voordelen 
hebben boven traditionele chemotherapie, zijn er ook vele nieuwe uitdagingen. 
De orale route (inname via de mond in plaats van een infuus) en het gebruik op 
continue basis (in plaats van een wekelijkse of 3-wekelijkse toediening) maakt 
dat deze  geneesmiddelen zeer gevoelig zijn voor wisselwerkingen. Daarnaast 
worden TKI’s in de lever omgezet in afbraakprodukten door enzymen genaamd 
‘cytochromen’ (of CYPs). Om deze reden hebben we in hoofdstuk 2 een 
literatuur-onderzoek gedaan om deze wisselwerkingen goed in kaart te kunnen 
brengen. Het belangrijkste doel van dit review-artikel was om de behandelend 
arts een overzicht te geven van de belangrijkste wisselwerkingen en tevens 
praktische adviezen hoe met deze wisselwerkingen om te kunnen gaan. In het 
review lag de focus voornamelijk op de drie belangrijkste wisselwerkingen, 
namelijk: i) TKIs en maagzuurremmers, ii) CYP-remmers / inductoren 
(= aanjagers) tijdens TKI therapie en iii) een combinatie van geneesmiddelen 
die tot een levensbedreigende vertraging van het hartritme kunnen leiden 
(het zogenaamde QTc-interval).
Maagzuurremmers zoals proton pomp remmers (bijvoorbeeld omeprazol en 
pantoprazol) kunnen een belangrijke negatieve invloed hebben op de opname 
van TKIs vanuit de darm, terwijl door het remmen van (CYP) enzymen in de 
lever (door CYP-remmers en CYP- inductoren) de  TKI spiegel in het bloed 
aanzienlijk omhoog of naar beneden kan gaan. Bij bovenstaande geneesmiddel 
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wisselwerkingen is een klinische interventie (bijvoorbeeld dosis aanpassing, 
stoppen van geneesmiddel e.d.) door een arts of apotheker vaak nodig. Hoewel 
zeldzaam, kunnen wisselwerkingen betreffende het (teveel) vertragen van het 
hartritme fatale gevolgen hebben. Omdat de gevolgen van deze wisselwerking 
zo ernstig kunnen zijn moeten clinici hiermee rekening mee houden. Om het 
veilig gebruik van TKIs te borgen in de klinische praktijk, moet een actueel 
medicatieoverzicht met alle medicatie die de patiënt op dat moment gebruikt 
beoordeeld worden (inclusief kruiden geneesmiddelen e.d.). Om dit te bereiken 
moeten clinici nauw samenwerken met (ziekenhuis) apothekers en huisartsen. 
Ook moet er meer onderzoek gedaan worden naar andere wisselwerkingen 
die mogelijk van invloed kunnen zijn op de bloedspiegel van TKIs. En “last 
but not least”, als er een vermoeden is van een geneesmiddel wisselwerking 
en er zijn geen farmacologische gegevens beschikbaar, dan moeten artsen en 
apothekers de krachten bundelen en ‘voors’ en ‘tegens’ tegen elkaar afwegen. 
Indien mogelijk, moeten ze bestaande gegevens extrapoleren om tot een goed 
advies te komen voor die individuele patiënt op dat moment.
Figuur 1: De belangrijkste factoren die de bloedspiegel (blootstelling) van 
antikanker geneesmiddelen kunnen beinvloeden
Lifestyle
(bv. roken en voedsel)
Genetische factoren
Patiënt
karakteristieken
(bv. leeftijd geslacht)
Overige
factoren
Ziekte gerelateerd
(bv. algemene gesteldheid)
Lichaamsoppervlakte
(bv. BMI)
Co-medicatie
Orgaan functie
(bv. nier- en leverfunctie)
Blootstelling
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In hoofdstuk 3 en hoofdstuk 4, zijn retrospectieve studies uitgevoerd om een 
overzicht te krijgen van de prevalentie van geneesmiddel wisselwerkingen 
in zowel intraveneuze en orale anti-kanker therapie, respectievelijk. Een 
retrospectieve studies (of terugkijkend onderzoek) betekent dat je in de tijd terug 
kijkt en in dit geval nagaat hoeveel geneesmiddel wisselwerkingen er reeds hebben 
plaatsgevonden door middel van onderzoek in de medische status van de patiënt 
(oftewel: de blik is terug in de tijd gericht).
In deze analyse hebben we een hoge prevalentie van wisselwerkingen gezien, 
met 46% tot 58% van alle patiënten die werden blootgesteld aan ten minste één 
geneesmiddel wisselwerking. Wat van belang was, was dat deze wisselwerkingen 
niet alleen theoretisch van aard waren. In 16% tot 34% van alle patiënten zagen we 
tenminste één wisselwerking die mogelijk schadelijke bijwerkingen zou kunnen 
veroorzaken. Hierbij zou een klinische interventie of intensieve monitoring op 
zijn plaats zijn. Bloedverdunners, sommige antibiotica , anti-epileptica, opiaten 
en een middel tegen hoge bloedruk waren vaak betrokken bij een wisselwerking. 
De meerderheid van de betrokken wisselwerkingen had betrekking op een 
verhoogd dempend effect (van de combinatie van geneesmiddelen) op het centrale 
zenuwstelsel (met sufheid en het gevaar van vallen en (heup)fracturen tot gevolg). 
Verder werden veel wisselwerkingen gezien die een extra kans op maagschade 
(bv pijnstillers uit de groep van de NSAID’s) en een mogelijk levensbedreigende 
vertraging van het hartritme (het zogenaamde QTc-interval) tot gevolg hebben. 
Met het toenemende aantal nieuwe orale antikanker middelen dat beschikbaar 
komt, zoals de bovengenoemde TKIs, die ook in toenemende mate in combinatie 
worden gegeven, wordt het risico op wisselwerkingen steeds groter.
Door het retrospectieve karakter van de studie, waarbij wordt teruggekeken naar 
reeds gedocumenteerde gegevens, is een belangrijke beperking van deze twee 
studies dat de klinische gevolgen (bijvoorbeeld bijwerkingen of ineffectiviteit 
van een bepaald antikanker geneesmiddel) niet onderzocht zijn. Hoewel er niet 
gekeken is naar de klinische relevantie in deze twee studies, kunnen we toch 
concluderen dat geneesmiddel combinaties die mogelijk kunnen leiden tot een 
wisselwerking vaak voorkomen bij patiënten met kanker. Routinematige screening 
voor mogelijke wisselwerkingen moet dus plaatsvinden tijdens de behandeling 
van kanker. De klinische relevantie van geneesmiddel wisselwerkingen moet 
echter worden onderzocht in toekomstig onderzoek.
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In hoofdstuk 5 is een prospectieve studie uitgevoerd, waarbij juist nieuwe gegevens 
worden verzameld, om het vóórkomen van geneesmiddel wisselwerkingen die 
leiden tot een daadwerkelijke klinische interventie tijdens de behandeling van 
kanker te beoordelen. 
Studie patiënten worden bij een prospectieve studie gevolgd in de toekomst 
(oftewel: de blik is in de tijd vooruit gericht).
Deze studie diende als een vervolg op de onderzoeken beschreven in 
hoofdstuk 3 en hoofdstuk 4 en de daar omschreven specifieke wens om de 
klinische relevantie van wisselwerkingen bij patiënten met kanker te onderzoeken. 
In deze studie, waarin 302 patiënten werden geïncludeerd, bleek dat een 
klinische interventie door de behandelend (hemato)oncoloog werd uitgevoerd 
bij 39 patiënten (13%), terwijl een additionele interventie werd gedaan door 
een klinisch farmacoloog bij nog eens 42 patiënten (14%). Bloedverdunners 
en de combinatie van corticosteroïden met NSAIDs (door een verhoogde kans 
op maagschade) waren vaak betrokken bij een wisselwerking die leidde tot een 
interventie. Verder werden wisselwerkingen die een additionele verlenging van 
het QTc-interval gaven en wisselwerking waarbij TKIs en maagzuurremmers 
(proton pomp remmers) betrokken waren frequent gezien.
Deze studie toont aan dat er vrij vaak een klinische interventie op basis van 
een geneesmiddel wisselwerking vereist is bij patiënten die antikanker therapie 
ondergaan. Verder heeft de samenwerking tussen clinici en een klinisch 
farmacoloog geleid tot een verdubbeling van het aantal klinische interventies 
als gevolg van een geneesmiddel wisselwerking. Gestructureerde screening 
voor klinisch relevante geneesmiddel wisselwerkingen, door clinici (oncologen 
en klinisch farmacologen), zou routinematig moeten plaatsvinden vóór aanvang 
en tijdens de antikanker behandeling. Om tot een effectieve medicatiebewaking 
te komen, moet er eerst een solide basis zijn waarin een actueel overzicht van 
alle medicijnen (inclusief kruiden en zelfzorg geneesmiddelen) voorhanden is. 
Oncologen, huisartsen en andere beroepsbeoefenaren in de gezondheidszorg 
zouden, idealiter, alle medische gegevens en voorgeschreven geneesmiddel 
moeten vastleggen in één landelijk elektronisch medicatie dossier.
Daar de wisselwerking tussen TKIs en maagzuurremmers vaak werd waar-
genomen in de studie beschreven in hoofdstuk 5, zijn er nog geen duidelijke 
aanbevelingen voor de omgang met deze wisselwerking in de klinische praktijk. 
Aangezien zuurgraad (pH)-afhankelijke oplosbaarheid de “achilleshiel” lijkt bij 
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de opname van TKI’s in het bloed, onderzochten we de invloed van de inname 
van erlotinib met cola (ten opzichte van water) op de blootstelling van erlotinib, 
met en zonder maagzuurremmer, bij longkanker patienten in hoofdstuk 6. In deze 
gerandomiseerde farmacokinetische cross-over studie werden 28 evalueerbare 
patiënten geïncludeerd in de analyse. Bij de patiënten die hun erlotinib 
gelijktijdig met een maagzuurremmer namen met cola lag de bloedspiegel 
gemiddeld 39% hoger ten opzichte van de inname met water. Hiermee heeft 
de inname met cola geleid tot een klinisch relevante verhoging van de opname 
van erlotinib tijdens het gebruik van maagzuurremmers. Deze bevindingen 
bieden een praktische oplossing voor het omzeilen van de wisselwerking tussen 
erlotinib en maagzuurremmers. Mogelijk kan het “cola-effect” op erlotinib 
worden doorgetrokken naar andere TKI’s of andere zure dranken.
Anderzijds, wanneer alle farmacologische eigenschappen van zowel TKIs en 
maagzuurremmers worden beschouwd, dan kan een praktisch advies louter 
gebaseerd op farmacologische principes toereikend zijn om deze geneesmiddel 
wisselwerking af te handelen. In hoofdstuk 7, hebben we het farmacologisch 
profiel van zowel TKI’s als de maagzuurremmers uitvoerig beschouwd en 
hebben we op basis van deze gegevens getracht een praktische manier te 
vinden om deze geneesmiddel wisselwerking af te handelen in de klinische 
praktijk. Aangezien bij éénmaal daags gebruik van maagzuurremmers de maag 
pH niet gedurende de volledige 24-uur verhoogd is, is het mogelijk om  het 
tijdsvenster van (relatieve) lage pH in de maag te gebruiken om de TKI veilig in 
te nemen. Als men de TKI in de ochtend een paar uur voor de maagzuurremmer 
inneemt, zal de maagsap resistente coating (een coating die het geneesmiddel 
beschermt tegen de negatieve invloed van maagzuur) van de maagzuuremmer 
een tijdvenster creëren (maagzuurremmers werken pas na een paar uur) waarin 
de TKI bij voldoende lage pH op kan lossen en op normale wijze opgenomen 
kan worden in het bloed. Bij toepassing van deze gespreide inname, wordt de 
absorptie van de TKI niet negatief beïnvloed door de maagzuurremmer.
Vreemd genoeg wordt het effect van maagzuurremmers op TKI absorptie en 
blootstelling lang niet altijd onderzocht tijdens de ontwikkelingsfase van het 
geneesmiddel. Aangezien maagzuurremmers een klinisch relevant effect kunnen 
hebben op TKI absorptie en blootstelling zou deze wisselwerking naar onze 
mening altijd onderzocht moeten worden in een farmacokinetische onderzoek 
“in proefpersonen”. Tevens is er meer onderzoek nodig naar de effecten van 
de nachtelijke reflux van darmsappen in de maag (mede als gevolg van de 
rugligging tijdens de slaap), de hiermee verhoogde pH in de maag en het effect 
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op de absorptie van TKI’s wanneer deze ingenomen worden voor de slaap.
Tot slot, wanneer men de medicamenteuze behandeling van kanker wil 
individualiseren, dan zijn geneesmiddel wisselwerkingen een zeer belangrijke 
factor om rekening mee te houden. Artsen en andere zorgverleners moeten 
samenwerken om wisselwerkingen te identificeren en af te handelen in de 
klinische praktijk. Eén nationaal elektronisch patiëntendossier zou hier bij 
kunnen helpen.
In de onderzoeken beschreven in dit proefschrift zijn alleen volwassen 
kankerpatiënten geïncludeerd. Kinderen met kanker vielen buiten het bestek 
van dit proefschrift. Echter, de antikanker geneesmiddelen die bij kinderen 
worden voorgeschreven geven ook een hoge kans op wisselwerkingen met 
andere geneesmiddelen. Meer onderzoek is nodig om de prevalentie en klinische 
relevantie van wisselwerkingen bij kinderkanker volledig in kaart te brengen.
Ondanks het vele onderzoek dat reeds is gedaan is nog altijd meer onderzoek 
naar de effecten van gelijktijdig gebruik van comedicatie op antikanker 
geneesmiddelen noodzakelijk om het ware interactie potentieel van 
geneesmiddelen tegen kanker in kaart te brengen.
Deze farmacologisch onderzoeken naar wisselwerkingen moeten altijd leiden 
tot een duidelijk en praktisch advies dat gemakkelijk in de klinische praktijk 
uitgevoerd kan worden. Als er geen farmacologische gegevens beschikbaar zijn 
aangaande een bepaalde wisselwerking, dan moeten beroepsbeoefenaren in de 
gezondheidszorg samenwerken en gebruik maken van elkaars kennis. Als er 
geen gegevens beschikbaar zijn in de literatuur dan moeten artsen en apothekers 
in staat kunnen zijn hun kennis van farmacokinetiek en -dynamiek te gebruiken 
om bestaande gegevens te extrapoleren alvorens tot een praktische aanbeveling 
voor het afhandelen van een bepaalde wisselwerking te komen. Uiteindelijk 
moet dit leiden tot een meer geïndividualiseerde antikanker therapie met 
optimaal effect en zo min mogelijk bijwerkingen.
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Gezien het feit dat het dankwoord in een proefschrift meestal als eerste gelezen 
wordt maak ik van deze gelegenheid dankbaar gebruik om een aantal mensen 
die mij dierbaar zijn en die mij hebben geholpen bij het tot stand komen van dit 
proefschrift te bedanken.
Lieve Pa en Ma, allereerst wil ik jullie bedanken. Zonder jullie onvoorwaardelijke 
liefde en steun was ik nooit zover gekomen! Nog steeds kan ik altijd op jullie 
rekenen en voelt de Kerkweg als een warm nest. Ik bewonder ook jullie grote 
toewijding als grootouders. Katootje en Roelien boffen maar! Lieve Pa, jij bent 
in 1980 gepromoveerd en ik nu 26 jaar later ook. Het staat me nog goed bij dat ik 
vroeger met je meeging naar het Hersen Instituut. Ik kan me de geïmmuniseerde 
geit Betsie, het coupes snijden met Romeo en Bart, of gewoon met jou door een 
microscoop kijken nog goed herinneren. Wellicht onbedoeld en onbewust is 
daar mijn eerste interesse voor de wetenschap geboren. Lieve Ma, zonder jouw 
engelen geduld en hulp bij het eindeloze repeteren van SO’s en proefwerken 
Duits en Nederlands had ik wellicht nooit hier gestaan. Ook je goede adviezen 
op “keypoints” in mijn leven hebben mij de goede kant opgestuurd. Ik ben je 
hier heel dankbaar voor.
Prof. Dr. Mathijssen, beste Ron, wat heb ik veel te danken aan jou! Met jouw 
ervaring en grenzeloze energie haal je elke keer weer het maximale uit jouw 
mensen. Altijd kon ik op je bouwen en dat 24/7! Tot laat op de avond, in de 
weekenden en zelfs tijdens de vakantie konden we praten over de leuke maar 
soms ook minder leuke dingen van het onderzoek. Onze eerste ontmoeting 
voelde een beetje als “serendipity”. We kenden elkaar eigenlijk al, ik jou o.a. van 
jouw St. Janskruid paper en jij mij omdat je mijn eerste artikel had gereviewed 
(Ann Oncol. 2011), maar toch hadden we elkaar nog nooit in levende lijve 
ontmoet. Door de jaren heen zijn we ook echt maatjes geworden en ik kijk uit 
naar de komende jaren waar we hopelijk samen nog veel hoogtepunten kunnen 
beleven! Ik zeg; “consolideren en doorpakken”, op naar interactiestudies 2.0!
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Prof. Dr. van Gelder, beste Teun, in 2012 was jij de eerste die potentie in 
mij zag en het mogelijk maakte met mijn promotie te starten. Op belangrijke 
momenten in de afgelopen jaren was je er om mijn promotie in de juiste richting 
bij te stellen. Ook kon ik altijd bij je terecht voor een praatje of advies en een 
goed luisterend oor. Meer dan iedereen, was je ook de stille kracht achter dit 
proefschrift. Altijd wist je de scherpe randjes van bijvoorbeeld een van onze 
artikelen af te halen waardoor het stuk naar een hoger niveau getrokken werd. 
Zichtbaar kon je genieten van de succesjes die we de afgelopen jaren hebben 
behaald, dat kon ik altijd erg waarderen. Ik hoop dat we de komende jaren 
binnen het samenwerkingsverband tussen apotheek en oncologie nog veel 
zullen samenwerken!
Dr. Jansman, beste Frank, ik kende je al vanuit mijn periode in Maastricht waar 
het fundament gelegd werd voor dit proefschrift. Ook al zat je op afstand, met 
al jouw enthousiasme stond jij altijd klaar om mee te denken en dingen op te 
pakken. Zo hebben we samen het voortouw genomen bij het schrijven van het 
review en de eerste studie naar wisselwerkingen in de oncologie. De bezoekjes 
aan het Deventer Ziekenhuis zullen mij bij blijven. Als copromotor was jij altijd 
de manager in ons promotieteam. Hierbij benadrukte je vaak dat promoveren 
ook vooral managen en (soms tegen beter weten in) doorwerken is. Samen 
nemen we nu zitting in de “Werkgroep Interacties Oncologie”; ik hoop dat we 
deze samenwerking in de toekomst verder zullen uitbouwen.
Prof. Dr. Sonneveld, Prof. Dr. Gelderblom en Prof. Dr. Beijnen, bedankt voor 
het zitting nemen in de kleine commissie en voor de snelle beoordeling van het 
manuscript. Het lijkt weinig, maar een goedgekeurd manuscript is de laatste 
stap naar de verdediging. Het heeft meer impact dan sommige denken.
Prof. dr. Aerts, beste Joachim, de afgelopen jaren is de samenwerking tussen 
de afdelingen oncologie en long-oncologie sterk geïntensiveerd. Zeker met de 
Cola-studie hebben we veelvuldig samengewerkt. Ik heb onze samenwerking 
tot nu toe als zeer prettig ervaren en hoop dat we in de toekomst nog veel 
mooie ideeën kunnen uitwerken. Veel dank voor het zitting nemen in mijn grote 
commissie.
Prof. dr. de Wit en Prof. dr. Smit, hartelijk dank voor uw deelname in mijn grote 
commissie.
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Beste Inge, Mei en Peter, bedankt voor alle hulp bij de Cola-studie. Zonder 
jullie zou het lab stuurloos zijn. Dank voor het doormeten van alle samples, 
het maken van figuren, meewerken aan analyses, en “last but not least” alle 
gezelligheid.
Dr. Eechoute, beste Karel, we kennen elkaar nog niet zo heel lang maar ik kan 
je gezelschap en de daarmee gemoeide gitzwarte (Belgische…?) humor zeer 
waarderen, ik hoop dat je in de toekomst kiest voor de academie en dat we 
kunnen blijven samenwerken!
Beste Stijn, vanaf april zijn we beide postdoc op het lab, ik hoop dat we 
samen met Ron het lab de komende jaren kunnen uitbreiden. Consolideren en 
doorpakken toch?
Beste mede OIO genoten, Sander, Jacqueline, Lisette, Annemiek, Femke en 
Bodine, dank voor alle hulp en steun die ik van jullie heb mogen ontvangen. 
We vormen inmiddels een heel hecht en gezellig team waar iedereen hard 
werkt maar ook veel voor elkaar over heeft. Ik heb intens genoten van onze 
OIO besprekingen, journal clubs, vele borrels in Café Arie, de Ballentent en 
de skivakantie in Oberau! Sander, door de jaren heen hebben we vele mooie 
momenten meegemaakt, ik kan je humor en “no stress” houding waarderen. 
Succes met de opleiding tot internist volgend jaar. Jacqueline, altijd recht 
door zee en niet op je mondje gevallen. Ook jij, veel succes met de opleiding 
tot reumatoloog. Lisette, jij was altijd de theoreticus van ons allen, ik heb 
veelvuldig bij je aangeklopt tijdens het opzetten van de Cola-studie. Veel succes 
met je nieuwe baan in Den Haag. Annemiek, ook al hebben we elkaar niet 
vaak getroffen was jij altijd de stille kracht in de OIO kamer, ik heb zeer veel 
respect voor het promotie traject wat je doorloopt. Succes komende jaar met 
promoveren, afstuderen en jouw eventuele nieuwe baan als medicus. Femke, je 
bent er pas net, maar nu al een vaste waarde binnen ons team, je werklust werkt 
aanstekelijk en je gezelligheid ook. De komende jaren zullen we bij de aantal 
studies intensief gaan samenwerken. Ik kijk hier echt naar uit! Beste Bodine, 
welkom in het team, succes de komende jaren!
Beste studenten, Daniel, Femke, Ingeborg, Foad, Koen, Nikki, Emma en Anne, 
ik ben jullie zeer dankbaar voor alle hulp en inzet die jullie hebben getoond. 
Zonder jullie “handjes” op de werkvloer was dit niet gelukt. Daniël, jij was mijn 
eerste student, jouw werklust (en het vroege opstaan….) heeft een diepe indruk 
op mij achter gelaten. Ingeborg en Foad, tijdens de prospectieve studie, hebben 
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jullie vele patiënten geïncludeerd, het gaat jullie goed in de farmacie. Nikki 
en Koen, “het dreamteam”, tegelijkertijd waren jullie mijn steun en toeverlaat 
tijdens de Cola-studie. Emma, jij was de opvolger van het dreamteam, dat heb 
je met verve gedaan en dat heeft mede geleid tot een prachtige JCO paper. 
Anne, ondanks dat ik niet je directe begeleider was hebben we veel contact 
gehad. Dank voor je inzet, gezelligheid en leuk dat je bij ons was, ik hoop je 
in de toekomst nog tegen te komen. Femke, Koen en Emma, wat leuk dat jullie 
hebben gekozen voor een vervolg in de oncologie en verbonden blijven aan 
ons lab.
Beste Nicole, dank voor alle steun tijdens mijn promotie en daarbuiten. Ik kan 
jou motto “alles komt altijd goed” zeer waarderen. Mede door jouw promotie en 
aanvullingen is het laatste opinie artikel tot stand gekomen. Ik hoop de komende 
jaren, als maatje in de kliniek, nog veel met je samen te werken!
Beste Prof. dr. Sleijfer, beste Stefan, dank voor de steun het afgelopen jaar en 
de mogelijkheid om als klinische ziekenhuisapotheker op de afdeling Interne 
Oncologie aan de slag te mogen. Ik kijk echt uit naar de komende jaren!
Beste oud collega’s uit Maastricht UMC en het Radboud MC, dank voor de hulp 
en steun die ik van jullie heb gekregen tijdens de eerste studie. Ellen, David en 
Cees, dank voor de mogelijkheid om onderzoek te doen. Rogier, Thomas, we 
treffen elkaar binnenkort weer op de racefiets!
Beste Leni, Diane, en Bimla, jullie zijn een prachtig stel. Leni, dank voor de 
hulp tijdens mijn promotie. Diane, wat leuk dat je mee was op de skivakantie! 
En Bimla, jouw catering tijdens de kerstborrel is fenomenaal.
Lieve Aris en Sietse, Lia en Annemarie, wat gezellig dat we zo dicht bij elkaar 
wonen. In zware tijden waren jullie er voor mij en Marije. In goede tijden is het 
altijd gezellig! Dank daarvoor!
Clubgenoten, kegelclubgenoten, fietsmannen, familie, buren, andere vrienden 
en kennissen, jullie brengen veel gezelligheid en plezier in mijn leven. Ik kan 
me geen leven voorstellen zonder jullie.
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Beste paranimfen, Nes en Pa, wat leuk dat jullie mijn paranimfen willen 
zijn! Nes, we kennen elkaar al sinds dag één van de KMT. Als clubgenoot, 
huisgenoot, getuige en ceremoniemeester op elkaars huwelijk hebben we al heel 
veel meegemaakt. Prachtig dat jij mij nu bijstaat bij mijn promotie. Pa, 26 jaar 
later promoveer ik, wat fantastisch dat je erbij kan zijn en dat je me bijstaat!
Lieve Marije, toen ik je voor het eerst zag was ik op slag verliefd. Tijdens 
mijn promotie stond je altijd aan mijn zijde! Jij brengt balans in mijn leven en 
dankzij jouw onvoorwaardelijke steun en liefde waren de tegenslagen minder 
zwaar. Jij hebt mij geleerd dat liefde niet zonder elkaar kunnen is, ik hou heel 
veel van je!
Lieve Kato en Roelien, jullie zijn mijn engeltjes. Elke dag als ik thuis kom 
vliegen jullie in mijn armen, wat is dat een groot geluk! Wat ben ik trots op 
jullie en wat doen jullie het goed. Lieve kleine Jet, ik mis je elke dag.
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CURRICULUM VITAE
Roelof van Leeuwen werd op 2 mei 1978 geboren te Maarssen. In 1998 heeft 
hij zijn VWO diploma behaald aan College de Klop te Utrecht. Tijdens zijn 
middelbare schooltijd heeft hij een ‘summer-student’ onderzoeksstage gelopen 
aan de University of Massachusetts, Worcester, VS. Aansluitend is hij gestart 
met de studie Farmacie aan de Universiteit Utrecht. Tijdens zijn studie heeft 
hij een stage van 6 maanden gevolgd aan de Edinburgh University, Clinical 
Pharmacology Unit, Edinburgh, Schotland onder leiding van Prof. David Webb. 
In mei 2004 heeft hij zijn apothekers diploma gehaald. In hetzelfde jaar is hij 
als assistent niet in opleiding gestart in het Westfriesgasthuis te Hoorn waarna 
gestart kon worden met de opleiding tot ziekenhuisapotheker te Zaans Medisch 
Centrum te Zaandam en VU medisch centrum te Amsterdam. Na het behalen 
van de opleiding is hij als ziekenhuisapotheker-onderzoeker gaan werken in de 
apotheek affiliatie Maastricht UMC en Radboud UMC. Onder leiding van prof. 
dr. Cees Neef en prof. dr. David Burger is Roelof tevens met onderzoek gestart.
Januari 2012 is Roelof als ziekenhuisapotheker aangesteld in het Erasmus MC te 
Rotterdam waar hij het promotieonderzoek zoals beschreven in dit proefschrift 
is gestart bij de ziekenhuisapotheek en het laboratorium Translationele 
Farmacologie van de afdeling interne oncologie, onder begeleiding van prof. 
dr. T. van Gelder, prof. dr. A.H.J. Mathijssen en Dr. F.G.A. Jansman. Momenteel 
heeft Roelof een aanstelling bij zowel de ziekenhuisapotheek als de afdeling 
interne oncologie.
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1. PhD training
Year Workload (ECTS)
General courses
BROK course (Erasmus MC)
Integrity in Research
Training Open Clinica
2013
2014
2014
1
1
0,4
Specific courses (e.g. Research school, Medical Training)
Basic Cancer course NVVO, Ellecom
PUOZ Anticoagulation medicine
PUOZ hemato-oncology day
2010
2014
2015
2
1
1
Seminars and workshops
Clinical Pharmacology meeting
PhD- meeting Personalized Medicine
Others
2012-2016
2012-2016
2012-2016
2
2
2
Presentations
ESMO 2012, Vienna, poster presentation
ESMO 2014, Madrid, poster presentation
ESMO 2015, Vienna, poster presentation
NVKF&B Scientific Meeting (oral presentations)
Figon Dutch Medicine Days, poster presentation
Figon Dutch Medicine Days, poster presentation
Research Meeting Medical Oncology, oral presentations
Daniel den Hoed Dag, 2014
PUOZ course Hemato-oncology, oral presentation
Others (eg. Hematology day, Nursing congress)
2012
2014
2015
2013
2014
2015
2014
2014
2015
2012-2016
1
1
1
1
1
1
0,5
0,5
0,5
2
(International) conferences
European Society for Medical Oncology (ESMO), Vienna
European Society for Medical Oncology (ESMO), Madrid
European Society for Medical Oncology (ESMO), Vienna
Figon Dutch Medicine Days
Figon Dutch Medicine Days
ASCO annual meeting 2013, Chicago
ASCO annual meeting 2014, Chicago
ASCO annual meeting 2015, Chicago
2012
2014
2015
2014
2015
2013
2014
2015
1
1
1
0,4
0,4
1
1
1
Other
MOLMED day, Erasmus MC
Research Meeting Medical Oncology 
NVKF&B scientific meeting
2014
2012-2016
2013-2014
0,2
0,4
0,6
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2. Teaching activities
Year Workload (ECTS)
Lecturing
Education medical students 
PhD- meeting Personalized Medicine
Clinical Pharmacology meeting
Clinical Research Meeting (dept Medical Oncology)
Clinical Lessons nurses (hemato-)oncology
ESMO e-learning on Drug-Drug Interactions in oncology
2012-2016
2012-2016
2012-2016
2012-2016
2012-2016
2015
2
1
1
1
1
1
Supervising Master’s thesis
Daniel Brundel
Femke de Man
Ingeborg Vincenten
Foad Piran
Koen Hussaarts
Nikki IJzerman
Emma Kienhuis
2012
2013
2013
2013
2014
2014
2014
1
1
1
1
1
1
1
Committee work
Special Interest Group Hematology, NVZA/KNMP
Management of drug interaction in Oncology Committee, NVZA/KNMP
2013-2016
2015-2016
1
0,5
Notes
